## Scientific Programme

**15th Congress of ECCO - Vienna**

### Thursday, February 13, 2020

*Scientific programme day by day (as of January 15, 2020)*

*Plenary Hall, Hall D, Reed Messe Wien*

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 11:00 - 12:00 | **Industry Sponsored Satellite Symposia**  
**1a (Plenary Hall), 1b (Parallel Hall) & 1c (Lehar 1-3)** |
| 12:15 - 12:20 | **1: Welcome**  
H. Tilg, Innsbruck, Austria |
| 12:20 - 12:30 | **2: Opening**  
S. Danese, Milan, Italy |
| 12:30 - 14:00 | **Scientific Session 1: Hot debates in IBD**  
W. Reinisch, Vienna, Austria  
N. Yassin, Birmingham, United Kingdom |
| 12:30 - 12:50 | **3: Is there still a place for anti-TNF in 2020?**  
T. Ahmad, Exeter, United Kingdom  
J. Lindsay, London, United Kingdom |
| 12:50 - 13:00 | **4: OP01: Higher versus standard adalimumab maintenance regimens in patients with Moderately to Severely Active Ulcerative Colitis: Results from the SERENE-UC maintenance study**  
J. Colombel, New York, United States |
| 13:00 - 13:20 | **5: Early Crohn's: Surgery first and early medicine later?**  
A. Armuzzi, Rome, Italy  
A. D'Hoore, Leuven, Belgium |
D. Ley, Lille, France |
| 13:30 - 13:40 | **7: OP03: Reduced need for surgery and medical therapy after early ileocaecal resection for Crohn's Disease: Long-term follow up of the LIRIC trial**  
T. Stevens, Amsterdam, The Netherlands |
| 13:40 - 14:00 | **8: Monitoring IBD: Can we abandon endoscopy?**  
C. Hedin, Stockholm, Sweden  
E. Louis, Liège, Belgium |
| 14:00 - 14:30 | **Coffee break** |

OP = Oral presentation – Best abstracts
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Presenters/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:30 - 16:00</td>
<td><strong>Scientific Session 2: When location makes the difference</strong>&lt;br&gt;J. Burisch, Hvidovre, Denmark&lt;br&gt;F. Magro Dias, Porto, Portugal</td>
<td></td>
</tr>
<tr>
<td>14:30 - 14:50</td>
<td>9: Colonic versus small bowel CD: Same mechanism – same treatment?&lt;br&gt;B. Siegmund, Berlin, Germany</td>
<td></td>
</tr>
<tr>
<td>14:50 - 15:00</td>
<td>10: OP04: Long-term outcomes after ileocolonic resection in Crohn’s Disease according to severity of early endoscopic recurrence&lt;br&gt;N. Hammoudi, Paris, France</td>
<td></td>
</tr>
<tr>
<td>15:00 - 15:20</td>
<td>11: Proctitis – a lonely disease?&lt;br&gt;T. Raine, Cambridge, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>15:20 - 15:30</td>
<td>12: OP05: Validation of the Lémann Index in Crohn’s Disease&lt;br&gt;B. Pariente, Lille, France</td>
<td></td>
</tr>
<tr>
<td>15:30 - 15:40</td>
<td>13: OP06: Comparison between Crohn and celiac diseases small intestine transcriptomics and microbial data define similarities and divergent pathways linked to pathogenesis&lt;br&gt;Y. Haberman Ziv, Tel Aviv, Israel</td>
<td></td>
</tr>
<tr>
<td>15:40 - 16:00</td>
<td>14: Surgery for enteric IBD – does location matter?&lt;br&gt;C. Buskens, Amsterdam, The Netherlands</td>
<td></td>
</tr>
<tr>
<td>16:00 - 17:20</td>
<td><strong>Scientific Session 3: Reducing the burden of IBD</strong>&lt;br&gt;N. Ding, Fitzroy, Australia&lt;br&gt;J. Gisbert, Madrid, Spain</td>
<td></td>
</tr>
<tr>
<td>16:00 - 16:20</td>
<td>15: Reducing infections with biologics and immune-modulators&lt;br&gt;S. Ben-Horin, Ramat Gan, Israel</td>
<td></td>
</tr>
<tr>
<td>16:20 - 16:40</td>
<td>16: Reducing neoplastic complications of therapy&lt;br&gt;L. Beaugerie, Paris, France</td>
<td></td>
</tr>
<tr>
<td>16:40 - 16:50</td>
<td>17: OP07: The epidemiology of Inflammatory Bowel Diseases among immigrants to Denmark: A population-based cohort study&lt;br&gt;M. Agrawal, New York, United States</td>
<td></td>
</tr>
<tr>
<td>16:50 - 17:00</td>
<td>18: OP08: Inflammatory Bowel Disease and risk of small bowel cancer: A binational population-based cohort study from Denmark and Sweden&lt;br&gt;J. Axelrad, New York, United States</td>
<td></td>
</tr>
<tr>
<td>17:00 - 17:20</td>
<td>19: Reducing postoperative complications&lt;br&gt;K. Gecse, Amsterdam, The Netherlands</td>
<td></td>
</tr>
<tr>
<td>17:30 - 18:30</td>
<td><strong>Digital Oral Presentations (Sessions 1-5)</strong>&lt;br&gt;See pg. 14</td>
<td></td>
</tr>
<tr>
<td>18:45 - 19:45</td>
<td><strong>Industry Sponsored Satellite Symposia</strong>&lt;br&gt;2a (Plenary Hall), 2b (Parallel Hall) &amp; 2c (Lehar 1-3)</td>
<td></td>
</tr>
</tbody>
</table>

**OP** = Oral presentation – Best abstracts
### Friday, February 14, 2020

*Scientific programme day by day (as of January 15, 2020)*

**Plenary Hall, Hall D, Reed Messe Wien**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:15 - 08:15</td>
<td><strong>Industry Sponsored Morning Satellite Symposia</strong>&lt;br&gt;3b (Parallel Hall) &amp; 3c (Lehar 1-3)</td>
</tr>
<tr>
<td>08:30 - 10:30</td>
<td><strong>Scientific Session 4: IBD out of the gut</strong>&lt;br&gt;L. de Ridder, Rotterdam, The Netherlands&lt;br&gt;G. Mantzaris, Athens, Greece</td>
</tr>
<tr>
<td>08:30 - 08:50</td>
<td>20: Orofacial Crohn’s&lt;br&gt;S. Sebastian, Hull, United Kingdom</td>
</tr>
<tr>
<td>08:50 - 09:00</td>
<td>21: OP09: Immunomodulatory mechanisms of faecal microbiota transplantation is associated with clinical response in Ulcerative Colitis – early results from STOP-Colitis&lt;br&gt;M. Quraishi, Birmingham, United Kingdom</td>
</tr>
<tr>
<td>09:00 - 09:10</td>
<td>22: OP10: IgA coating of intestinal microbiota is associated with Inflammatory Bowel Disease in twin pairs discordant for Inflammatory Bowel Disease&lt;br&gt;E. Brand, Utrecht, The Netherlands</td>
</tr>
<tr>
<td>09:10 - 09:20</td>
<td>23: OP11: Exposure to an inflammatory mix re-induces inflammation in organoids of Ulcerative Colitis patients, independent of the inflammatory state of the tissue of origin&lt;br&gt;K. Arnauts, Leuven, Belgium</td>
</tr>
<tr>
<td>09:20 - 09:40</td>
<td>24: Perianal disease or hidradenitis suppurativa – does it matter?&lt;br&gt;W. Reinisch, Vienna, Austria&lt;br&gt;H. Maier, Vienna, Austria</td>
</tr>
<tr>
<td>09:40 - 09:50</td>
<td>25: OP12: The incidence and disease course of Perianal Crohn’s Disease – A Danish nationwide cohort study&lt;br&gt;M. Wewer, Copenhagen, Denmark</td>
</tr>
<tr>
<td>09:50 - 10:00</td>
<td>26: OP13: Glyco-fingerprint as a relevant risk factor on colitis-associated cancer&lt;br&gt;A. Dias, Porto, Portugal</td>
</tr>
<tr>
<td>10:00 - 10:10</td>
<td>27: OP14: Risk of colorectal cancer diagnosis and colorectal cancer mortality in Crohn’s Disease: A Scandinavian population-based cohort study&lt;br&gt;O. Oien, Stockholm, Sweden</td>
</tr>
<tr>
<td>10:10 - 10:30</td>
<td>28: Managing fatigue in IBD&lt;br&gt;A. Dignass, Frankfurt, Germany</td>
</tr>
<tr>
<td>10:30 - 11:00</td>
<td>Coffee break</td>
</tr>
</tbody>
</table>

**OP** = Oral presentation – Best abstracts
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00 - 12:30</td>
<td><strong>Scientific Session 5: Cartels in IBD – Part 1</strong></td>
</tr>
<tr>
<td></td>
<td>I. Dotan, Petah Tikva, Israel</td>
</tr>
<tr>
<td></td>
<td>P. Irving, London, United Kingdom</td>
</tr>
<tr>
<td>11:00 - 11:20</td>
<td>29: IBD genetics consortium</td>
</tr>
<tr>
<td></td>
<td>S. Vermeire, Leuven, Belgium</td>
</tr>
<tr>
<td>11:20 - 11:30</td>
<td>30: OP15: Multi-omic data integration with network analysis reveal</td>
</tr>
<tr>
<td></td>
<td>underlying molecular mechanisms driving Crohn’s Disease heterogeneity</td>
</tr>
<tr>
<td></td>
<td>B. Verstockt, Leuven, Belgium</td>
</tr>
<tr>
<td>11:30 - 11:50</td>
<td>31: Prevention initiatives</td>
</tr>
<tr>
<td></td>
<td>J. Colombel, New York, United States</td>
</tr>
<tr>
<td>11:50 - 12:00</td>
<td>32: OP16: Influence of early life factors on the development of</td>
</tr>
<tr>
<td></td>
<td>intestinal microbiota of infants born to mothers with and without IBD</td>
</tr>
<tr>
<td></td>
<td>J. Guedelha Sabino, Leuven, Belgium</td>
</tr>
<tr>
<td>12:00 - 12:10</td>
<td>33: OP17: Protein intakes and risk of Inflammatory Bowel Disease in</td>
</tr>
<tr>
<td></td>
<td>the European Prospective Investigation into Cancer and Nutrition cohort</td>
</tr>
<tr>
<td></td>
<td>(EPIC-IBD)</td>
</tr>
<tr>
<td></td>
<td>C. Dong, Saint-Mandé, France</td>
</tr>
<tr>
<td>12:10 - 12:20</td>
<td>34: OP18: Surgical prevention of anastomotic recurrence by excluding</td>
</tr>
<tr>
<td></td>
<td>mesentery in Crohn’s Disease: The SuPREMe-CD Study</td>
</tr>
<tr>
<td></td>
<td>G. Luglio, San Prisco, Italy</td>
</tr>
<tr>
<td>12:20 - 12:30</td>
<td>35: OP19: Perinatal factors do not affect paediatric Inflammatory Bowel</td>
</tr>
<tr>
<td></td>
<td>Disease risk: A Scottish nationwide cohort study using administrative</td>
</tr>
<tr>
<td></td>
<td>health data 1981-2017</td>
</tr>
<tr>
<td></td>
<td>C. Burgess, Edinburgh, United Kingdom</td>
</tr>
<tr>
<td>12:30 - 13:30</td>
<td><strong>Break / Guided Poster Session (Hall C)</strong></td>
</tr>
<tr>
<td></td>
<td>See pg. 16</td>
</tr>
<tr>
<td>12:40 - 13:20</td>
<td><strong>Industry Sponsored Lunch Satellite Symposia LS1</strong></td>
</tr>
<tr>
<td></td>
<td>(Plenary Hall), LS2 (Parallel Hall), LS3 (Lehar 1-3) &amp;</td>
</tr>
<tr>
<td></td>
<td>LS4 (Strauss 1-2)</td>
</tr>
</tbody>
</table>

**OP** = Oral presentation – Best abstracts
### Scientific Programme

**Friday, February 14, 2020, cont.**

*Scientific programme day by day (as of January 15, 2020)*

**Plenary Hall, Hall D, Reed Messe Wien**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Presenters</th>
</tr>
</thead>
</table>
| 13:30 - 15:00 | **Scientific Session 6: Cartels in IBD – Part 2** | F. Baert, Roeselare, Belgium  
U. Kopylov, Tel Aviv, Israel |
| 13:30 - 13:50 | **36: Microbiome consortium** | J. Raes, Leuven, Belgium |
| 13:50 - 14:00 | **37: OP20: The gut microbiota during biological therapy for Inflammatory Bowel Disease** | C. Caenepeel, Kessel, Belgium |
| 14:00 - 14:20 | **38: TDM consortium** | K. Papamichail, Boston, United States |
| 14:30 - 14:40 | **40: OP22: Crohn’s Disease exclusion diet reduces bacterial dysbiosis towards healthy controls in paediatric Crohn’s Disease** | J. Van Limbergen, Amsterdam, The Netherlands |
| 14:40 - 15:00 | **41: ECCO Quality Standards of Care** | G. Fiorino, Rozzano, Italy |
| 15:00 - 15:30 | **Coffee break** | |
| **15:30 - 16:10** | **Scientific Session 7: Milestones in clinical care** | J. Halfvarson, Örebro, Sweden  
S. Jäghult, Stockholm, Sweden |
| 15:30 - 15:37 | **42: I-CARE** | L. Peyrin-Biroulet, Vandoeuvre-Lès-Nancy, France |
| 15:47 - 15:54 | **44: UR-CARE** | F. Baert, Roeselare, Belgium |
| 15:54 - 16:04 | **45: OP24: A novel subcutaneous infliximab (CT-P13): 1-year results including switching results from intravenous infliximab (CT-P13) in patients with active Crohn’s Disease and Ulcerative Colitis** | S. Ben-Horin, Ramat Gan, Israel |
| 16:04 - 16:10 | **46: IBD Nurse Education Programme** | K. Kemp, Manchester, United Kingdom |

**OP = Oral presentation – Best abstracts**
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Topic</th>
<th>Details</th>
</tr>
</thead>
</table>
| 16:10 - 17:10 | **Scientific Session 8: IBD Horizons**  
(Plenary Hall, Hall D, Reed Messe Wien)  
G. D’Haens, Amsterdam, The Netherlands  
S. Schreiber, Kiel, Germany | 47: OP25: Biologics before surgery for IBD – Are they associated with post-operative infectious outcomes? Results from the National Surgical Quality Improvement Program Inflammatory Bowel Disease Collaborative | S. Holubar, Cleveland, United States |
| 16:10 - 16:20 | 48: OP26: The first real-life multicentre prospective validation study of the electronic chromoendoscopy score (Paddington International Virtual ChromoendoScopy ScOre) and its outcome in Ulcerative Colitis | M. Iacucci, Birmingham, United Kingdom |
| 16:20 - 16:30 | 49: OP27: Long-term safety and efficacy of risankizumab treatment in patients with Crohn’s Disease: Final results from the Phase 2 open-label extension study | M. Ferrante, Leuven, Belgium |
| 16:30 - 16:40 | 50: OP28: Gene expression (GE) values in a phase 2 trial of mirikizumab in Ulcerative Colitis (UC) correlate better with histopathology (HP) than endoscopy (EN) and Mayo scores | K. Gottlieb, Indianapolis, United States |
| 16:50 - 17:00 | 51: OP29: Tofacitinib in Ulcerative Colitis: Real world evidence from Eneida Registry | M. Chaparro, Madrid, Spain |
| 17:00 - 17:10 | 52: OP30: The interplay of microbiome dysbiosis and immune system deregulation in patients with Crohn’s Disease | N. Seyed Tabib, Leuven, Belgium |

**OP** = Oral presentation – Best abstracts
### Scientific Programme

#### 15th Congress of ECCO - Vienna

**Friday, February 14, 2020, cont.**

*Scientific programme day by day (as of January 15, 2020)*

**Parallel Hall, Hall C, Reed Messe Wien**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>15:30 - 17:10</strong></td>
<td><strong>Scientific Session 9: Basic Science: Big Data research</strong> (Parallel Hall, Hall C, Reed Messe Wien)</td>
<td>S. Zeissig, Dresden, Germany, L. Egan, Galway, Ireland</td>
</tr>
<tr>
<td>15:30 - 15:50</td>
<td><strong>53: Pits and pearls of Big Data in scientific research: Computational analysis, deconvolution, machine learning and more</strong></td>
<td>A. Franke, Kiel, Germany</td>
</tr>
<tr>
<td>15:50 - 16:00</td>
<td><strong>54: OP31: Meta-omics reveals microbiome driven proteolysis as a contributing factor to severity of Ulcerative Colitis disease activity</strong></td>
<td>P. Dulai, San Diego, United States</td>
</tr>
<tr>
<td>16:00 - 16:10</td>
<td><strong>55: OP32: Mincle signaling promotes intestinal mucosal inflammation through induction of macrophage pyroptosis and neutrophil chemotaxis in Crohn’s Disease</strong></td>
<td>W. Gong, Nanjing, China</td>
</tr>
<tr>
<td>16:10 - 16:30</td>
<td><strong>56: Integrating multi-omics in IBD</strong></td>
<td>A. Kaser, Cambridge, United Kingdom</td>
</tr>
<tr>
<td>16:30 - 16:40</td>
<td><strong>57: OP33: Multi-omics analysis reveals specific bio-geographical and functional characteristics in Inflammatory Bowel Disease intestinal mucosa</strong></td>
<td>N. Maimon, Haifa, Israel</td>
</tr>
<tr>
<td>16:40 - 16:50</td>
<td><strong>58: OP34: Whole blood profiling of T-cell derived miRNA allows the development of prognostic models in Inflammatory Bowel Disease</strong></td>
<td>R. Kalla, Edinburgh, United Kingdom</td>
</tr>
<tr>
<td>16:50 - 17:10</td>
<td><strong>59: How Big Data changes medicine: Concrete examples for translating Big Data into daily clinical practice</strong></td>
<td>Y. Chowers, Haifa, Israel</td>
</tr>
<tr>
<td><strong>17:25 - 18:25</strong></td>
<td><strong>Digital Oral Presentations (Sessions 6-10)</strong></td>
<td>See pg. 15</td>
</tr>
<tr>
<td><strong>18:40 - 19:40</strong></td>
<td><strong>Industry Sponsored Satellite Symposia 4b (Parallel Hall), 4c (Lehar 1-3) &amp; 4d (Strauss 1-2)</strong></td>
<td></td>
</tr>
</tbody>
</table>

*OP = Oral presentation – Best abstracts*
### Saturday, February 15, 2020

**Scientific programme day by day (as of January 15, 2020)**

**Plenary Hall, Hall D, Reed Messe Wien**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session/Abstract</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>08:30 - 10:20</strong></td>
<td><strong>Scientific Session 10: Multidisciplinary cases</strong></td>
</tr>
<tr>
<td></td>
<td>D. Turner, Jerusalem, Israel</td>
</tr>
<tr>
<td></td>
<td>M. Ferrante, Leuven, Belgium</td>
</tr>
<tr>
<td></td>
<td>P. Michetti, Lausanne, Switzerland</td>
</tr>
<tr>
<td></td>
<td>Y. Panis, Clichy, France</td>
</tr>
<tr>
<td>08:30 - 08:40</td>
<td><strong>60: GRADE-ing Guidelines: ECCO CD Treatment</strong></td>
</tr>
<tr>
<td></td>
<td>J. Torres, Loures, Portugal</td>
</tr>
<tr>
<td></td>
<td>M. Adamina, Winterthur, Switzerland</td>
</tr>
<tr>
<td>08:40 - 08:50</td>
<td><strong>61: ECCO ESPGHAN Guideline Pitch on Paediatric CD (update)</strong></td>
</tr>
<tr>
<td></td>
<td>F. Ruemmele, Paris, France</td>
</tr>
<tr>
<td></td>
<td>P. Van Rheenen, Groningen, The Netherlands</td>
</tr>
<tr>
<td>08:50 - 09:00</td>
<td><strong>62: OP35: Treatment outcomes of Inflammatory Bowel Disease in the biological era – A nationwide retrospective cohort study in three Nordic countries: Results from the TRINordic study</strong></td>
</tr>
<tr>
<td></td>
<td>M. Zhao, Hvidovre, Denmark</td>
</tr>
<tr>
<td>09:00 - 09:20</td>
<td><strong>63: Clinical Case: Medical CD</strong></td>
</tr>
<tr>
<td></td>
<td>R. Panaccione, Calgary, Canada</td>
</tr>
<tr>
<td>09:20 - 09:30</td>
<td><strong>64: OP36: Investigating the role of bioactives produced by gut bacteria to modulate immune response in Inflammatory Bowel Disease</strong></td>
</tr>
<tr>
<td></td>
<td>R. Giri, Brisbane, Australia</td>
</tr>
<tr>
<td>09:30 - 09:50</td>
<td><strong>65: Clinical Case: Surgical CD</strong></td>
</tr>
<tr>
<td></td>
<td>P. Kotze, Curitiba, Brazil</td>
</tr>
<tr>
<td>09:50 - 10:00</td>
<td><strong>66: OP37: Fibrogenesis in chronic DSS colitis is driven by an innate lymphoid cell-independent innate immune response</strong></td>
</tr>
<tr>
<td></td>
<td>B. Creyns, Leuven, Belgium</td>
</tr>
<tr>
<td>10:00 - 10:20</td>
<td><strong>67: Clinical Case: Paediatric CD</strong></td>
</tr>
<tr>
<td></td>
<td>D. Turner, Jerusalem, Israel</td>
</tr>
<tr>
<td><strong>10:20 - 10:50</strong></td>
<td><strong>Coffee break</strong></td>
</tr>
</tbody>
</table>

**OP = Oral presentation – Best abstracts**
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:50 - 12:20</td>
<td><strong>Scientific Session 11: What have we got outside our box of drugs?</strong></td>
<td>G. Doherty, Dublin, Ireland J. Panes, Barcelona, Spain</td>
</tr>
<tr>
<td>10:50 - 11:10</td>
<td><strong>68: The multi-refractory paediatric patients: Out of the box therapeutic treatments</strong></td>
<td>D. Wilson, Edinburgh, United Kingdom</td>
</tr>
<tr>
<td>11:10 - 11:20</td>
<td><strong>69: OP38: Top-down infliximab superior to step-up in children with Moderate-to-Severe Crohn’s Disease – A multicenter randomized controlled trial</strong></td>
<td>M. Jongsma, Rotterdam, The Netherlands</td>
</tr>
<tr>
<td>11:20 - 11:40</td>
<td><strong>70: Drugs of the future: Update on developmental agents</strong></td>
<td>W. Sandborn, La Jolla, United States</td>
</tr>
<tr>
<td>11:40 - 11:50</td>
<td><strong>71: OP39: Treatment of Ulcerative Colitis with AMT-101, a novel oral Interleukin-10 Immunomodulatory fusion biologic that traffics across intestinal epithelium</strong></td>
<td>R. Mrsny, San Francisco, United States</td>
</tr>
<tr>
<td>11:50 - 12:00</td>
<td><strong>72: OP40: A core transferable microbiota in responders to faecal microbiota transplant for Ulcerative Colitis shape mucosal T-Cell immunity</strong></td>
<td>R. Longman, New York, United States</td>
</tr>
<tr>
<td>12:00 - 12:20</td>
<td><strong>73: Pathology guided surgery</strong></td>
<td>P. Borralho Nunes, Lisbon, Portugal A. Spinelli, Rozzano, Italy</td>
</tr>
<tr>
<td>12:20 - 12:50</td>
<td><strong>Scientific Session 12: ECCO Lecture</strong></td>
<td>S. Danese, Milan, Italy L. Peyrin-Biroulet, Vandoeuvre-lès-Nancy, France J. van der Woude, Rotterdam, The Netherlands</td>
</tr>
<tr>
<td>12:50 - 13:05</td>
<td><strong>75: Awards and Closing remarks</strong></td>
<td>S. Danese, Milan, Italy J. van der Woude, Rotterdam, The Netherlands</td>
</tr>
<tr>
<td>13:05 - 13:15</td>
<td><strong>ECCOFilm</strong></td>
<td></td>
</tr>
</tbody>
</table>

**OP = Oral presentation – Best abstracts**
Thursday, March 7, 2019

Scientific programme day by day (as of February 1, 2019)
Plenary Hall, Hall A, Bella Center

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00 - 12:00</td>
<td>Industry sponsored satellite symposia 1a &amp; 1b &amp; 1c</td>
</tr>
<tr>
<td></td>
<td>See pg. 106</td>
</tr>
<tr>
<td>12:15 - 12:20</td>
<td>1: Welcome</td>
</tr>
<tr>
<td></td>
<td>President of Dansk Selskab for Gastroenterologi og Hepatologi</td>
</tr>
<tr>
<td></td>
<td>Henning Glerup, Silkeborg, Denmark</td>
</tr>
<tr>
<td>12:20 - 12:30</td>
<td>2: Opening</td>
</tr>
<tr>
<td></td>
<td>Silvio Danese, Milan, Italy</td>
</tr>
<tr>
<td>12:30 - 14:00</td>
<td>Scientific Session 1: Silencing IBD</td>
</tr>
<tr>
<td></td>
<td>Peter Irving, London, United Kingdom</td>
</tr>
<tr>
<td></td>
<td>Britta Siegmund, Berlin, Germany</td>
</tr>
<tr>
<td>12:30 - 12:50</td>
<td>3: Can we prevent IBD?</td>
</tr>
<tr>
<td></td>
<td>Jean-Frédéric Colombel, New York, United States</td>
</tr>
<tr>
<td>12:50 - 13:00</td>
<td>4: OP01: In-depth characterisation of host-genetics and gut microbiome</td>
</tr>
<tr>
<td></td>
<td>unravels novel host-microbiome interactions in Inflammatory Bowel Disease</td>
</tr>
<tr>
<td></td>
<td>S. Hu, A. Vich Vila, R. Gacesa, Y. Collij, R. Xavier, C. Stevens, M.</td>
</tr>
<tr>
<td></td>
<td>Daly, C. Wijmenga, H. van Dullemen, G. Dijkstra, M. Visschedijk, E.</td>
</tr>
<tr>
<td></td>
<td>Festen, J. Fu, A. Kurilshikov, A. Zhernakova, R. Weersma</td>
</tr>
<tr>
<td></td>
<td>1Universitair Medisch Centrum Groningen, Gastroenterology &amp; Hepatology,</td>
</tr>
<tr>
<td></td>
<td>Groningen, Netherlands, 2Massachusetts General Hospital, Molecular</td>
</tr>
<tr>
<td></td>
<td>Biology, Boston, United States, 3Broad Institute, Boston, United</td>
</tr>
<tr>
<td></td>
<td>States, 4Universitair Medisch Centrum Groningen, Genetics, Groningen,</td>
</tr>
<tr>
<td></td>
<td>Netherlands, 5Universitair Medisch Centrum Groningen, Pediatrics,</td>
</tr>
<tr>
<td></td>
<td>Groningen, Netherlands</td>
</tr>
<tr>
<td>13:00 - 13:20</td>
<td>5: Can we cure IBD?</td>
</tr>
<tr>
<td></td>
<td>Arthur Kaser, Cambridge, United Kingdom</td>
</tr>
<tr>
<td>13:20 - 13:30</td>
<td>6: OP02: The role of PTPN2 SNP in the pathogenesis of fibrosis in</td>
</tr>
<tr>
<td></td>
<td>Crohn’s Disease</td>
</tr>
<tr>
<td></td>
<td>C. Li, J. Kuemmerle</td>
</tr>
<tr>
<td></td>
<td>Virginia Commonwealth University, Internal Medicine, Richmond, United</td>
</tr>
<tr>
<td></td>
<td>States</td>
</tr>
<tr>
<td>13:30 - 13:40</td>
<td>7: OP03: Inhibition of autophagy exacerbates intestinal fibrosis and</td>
</tr>
<tr>
<td></td>
<td>EMT</td>
</tr>
<tr>
<td></td>
<td>J. Cosin-Roger, D. Ortiz-Masia, F. Canet, A. Trescoli-Garcia, S.</td>
</tr>
<tr>
<td></td>
<td>Calatayud, M. D. Barrachina</td>
</tr>
<tr>
<td></td>
<td>1University of Valencia, Pharmacology, Valencia, Spain, 2Hospital Dr</td>
</tr>
<tr>
<td></td>
<td>Peset, Valencia, Spain, 3University of Valencia, Medicine, Valencia,</td>
</tr>
<tr>
<td></td>
<td>Spain</td>
</tr>
<tr>
<td>13:40 - 14:00</td>
<td>8: Are fibrotic complications reversible?</td>
</tr>
<tr>
<td></td>
<td>Geert D’Haens, Amsterdam, The Netherlands</td>
</tr>
<tr>
<td></td>
<td>Massimo Pinzani, London, United Kingdom</td>
</tr>
</tbody>
</table>

14:00 - 14:30 Coffee break

OP = Oral presentation – Best abstracts
Thursday, March 7, 2019, cont.

Scientific programme day by day (as of February 1, 2019)

Plenary Hall, Hall A, Bella Center

<table>
<thead>
<tr>
<th>14:30 - 16:00</th>
<th>Scientific Session 2: Complementary treatments: The good and the bad</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:30 - 14:50</td>
<td>9: The crazy stuff – what your patients are taking and why? Fernando Gomollón García, Zaragoza, Spain</td>
</tr>
<tr>
<td>14:50 - 15:00</td>
<td>10: OP04: Turning sweet in Inflammatory Bowel Disease: Glycans as novel immunomodulators of T cell-mediated immune response A. Dias¹, M. Pereira¹, A. Correia¹, I. Alves¹, V. Pinto¹, L. Azevedo¹, L. Maia³, R. Marcos-Pinto¹, M. Vilanova¹, P. Lago¹, S. Pinho¹ ¹Institute for Research and Innovation in Health (i3S), Immunology, Cancer &amp; GlycoMedicine, Porto, Portugal, ²Medical Faculty, Department of Community Medicine, Information and Health Decision Sciences, Porto, Portugal, ³Porto Centre Hospital, Gastroenterology, Porto, Portugal</td>
</tr>
<tr>
<td>15:00 - 15:20</td>
<td>11: ECCO Topical Review on complementary medicine Joana Torres, Lisbon, Portugal, Stephan Vavricka, Zurich, Switzerland</td>
</tr>
<tr>
<td>15:20 - 15:30</td>
<td>12: OP05: Crohn’s Disease exclusion diet is equally effective but better tolerated than exclusive enteral nutrition for induction of remission in Mild to Moderate Active Paediatric Crohn’s Disease: A prospective randomised controlled trial J. Van Limbergen¹,², E. Wine³, A. Assa⁴, R. Sigall Boneh⁵, R. Shaoul⁶, M. Kori⁷, S. Cohen⁸, S. Peleg⁹, H. Shamaly¹⁰, A. On¹¹, P. Milman¹², L. Abramas¹³, T. Ziv Baran¹⁴, S. Grant¹⁵, A. Levine¹⁴, ¹³ ¹Dalhousie University, Halifax, Canada, ²IWK Center, Halifax, Canada, ³University Alberta, Edmonton, Canada, ⁴Schneider Medical Center, Petach Tikva, Israel, ⁵Wolfson Medical Center, Holon, Israel, ⁶Meyer Hospital, Haifa, Israel, ⁷Kaplan Hospital, Rehovot, Israel, ⁸Dana childrens Hospital, Tel Aviv, Israel, ⁹HaEmek Hospital, Afula, Israel, ¹⁰French Hospital, Nazareth, Israel, ¹¹Porinah Hospital, Tiberias, Israel, ¹²Hadassah Hospital, Jerusalem, Israel, ¹³Tel Aviv University, Tel Aviv, Israel, ¹⁴Mount Saint Vincent University, Halifax, Canada</td>
</tr>
<tr>
<td>15:30 - 15:40</td>
<td>13: OP06: Gut-brain-axis revisited: Shedding light on the mucosa associated microbial composition in IBD patients with psychological distress, anxiety and depression F. Humbel¹, P. Juillerat², M. Scharl¹, B. Misselwitz², P. Schreiner¹, A. Macpherson¹, G. Rogler¹, R. von Känel², B. Yilmaz³, ⁴, ⁵L. Biedermann¹, ⁴, ⁵ ¹University Hospital Zurich, Department of Gastroenterology &amp; Hepatology, Zurich, Switzerland, ²Bern University Hospital, Department of Visceral Surgery and Medicine, Bern, Switzerland, ³University Hospital Zurich, Consultation-Liaison Psychiatry and Psychosomatic Medicine, Zurich, Switzerland, ⁴University of Bern, Maurice Müller Laboratories, Bern, Switzerland, ⁵Equal, Contribution, Switzerland</td>
</tr>
<tr>
<td>15:40 - 16:00</td>
<td>14: Psychological support in IBD Yoram Inspector, London, United Kingdom</td>
</tr>
</tbody>
</table>

OP = Oral presentation – Best abstracts
Thursday, March 7, 2019, cont.

Scientific programme day by day (as of February 1, 2019)
Plenary Hall, Hall A, Bella Center

| 16:00 - 17:20 | **Scientific Session 3: Precision medicine: Lessons to learn and paths to the future**
|              | Axel Dignass, Frankfurt am Main, Germany
|              | Jesús Rivera-Nieves, San Diego, United States |

**16:00 - 16:20**

15: What is system biology?
Dermot McGovern, Los Angeles, United States

**16:00 - 16:20**

16: Multi-omics profiling of IBD
Jonas Halfvarson, Örebro, Sweden

**16:40 - 16:50**

17: OP07: Analysing intestinal organoids in a multi-omics, systems biology framework to investigate functional processes affected in Crohn’s Disease due to autophagy impairment
L. Gul1, E. Jones1, Z. Matthews1, P. Sudhakar1,2,5, A. Treveil1,2, D. Divekar1,3, J. Buck1, M. Jefferson3, S. Armstrong1, A. Watson2,3, S. Carding2,3, U. Mayer6, P. Powell3, I. Hautefort1, T. Wiléman2,3, T. Korcsmaros1,2
1Earlham Institute, Norwich, United Kingdom, 2Quadram Institute, Norwich, United Kingdom, 3Norwich Medical School, University of East Anglia, Norwich, United Kingdom, 4KU Leuven, Department of Chronic Diseases, Metabolism and Ageing, Translational Research Center for Gastrointestinal Disorders (TÄRGID), Leuven, Belgium, 5University of Liverpool, National Institute of Health Research, Liverpool, United Kingdom, 6School of Biological Sciences, University of East Anglia, Norwich, United Kingdom

**16:50 - 17:00**

18: OP08: Long-term efficacy and pharmacodynamics of the anti-Mucosal Addressin Cell Adhesion Molecule-1 (MAdCAM-1) monoclonal antibody SHP647 in Crohn’s Disease: The OPERA II study
G. D’Haens1, W. Reinisch2, S. D. Lee3, D. Tarabar4, E. Louis5, M. Klopopcka6, J. Klaus1, S. Schreiber5, D. I. Park6, X. Hébuterne6, K. J. Gorelick1, S. W. Martin1, A. Banerjee1, P. Nagy3, Y. Wang8, F. Cataldi14, W. J. Sandborn15
1Academic Medical Centre, Amsterdam, Netherlands, 2Medical University of Vienna, Vienna, Austria, 3University of Washington, Seattle, WA, United States, 4Clinic of Gastroenterology and Hepatology, Military Medical Academy, Belgrade, Serbia, 5University Hospital of Liège, Liège, Belgium, 6Nicolaus Copernicus University, Collegium Medicum in Bydgoszcz, Bydgoszcz, Poland, 7University Hospital Ulm, Ulm, Germany, 8University Hospital Schleswig-Holstein, Christian-Albrechts-University of Kiel, Kiel, Germany, 9Kangbuk Samsung Hospital, Sungkyunkwan University, Seoul, South Korea, 10University of Nice Sophia Antipolis, Hospital l’Archet, Nice, France, 11Zymo Consulting Group, Newtown Square, PA, United States, 12Pfizer, Cambridge, MA, United States, 13Shire, Zug, Switzerland, 14Shire, Lexington, MA, United States, 15University of California San Diego, La Jolla, CA, United States

**17:00 - 17:20**

19: Stratifying by disease biology to choose the right drug for the right patient
Charlie Lees, Edinburgh, United Kingdom

17:30 - 18:30

Digital Oral Presentations (Sessions 1-5)
See pg. 41

18:45 - 19:45

Industry sponsored satellite symposia 2a & 2b & 2c
See pg. 108
### Scientific Programme Day by Day (as of February 1, 2019)

**Plenary Hall, Hall A, Bella Center**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:15 - 08:15</td>
<td><strong>Industry sponsored satellite symposia 3b &amp; 3c</strong></td>
<td>See pg. 109</td>
</tr>
<tr>
<td>08:30 - 10:30</td>
<td><strong>Scientific Session 4: Best practice in UC</strong></td>
<td>Andre D'Hoore, Leuven, Belgium Henit Yanai, Petah Tikva, Israel</td>
</tr>
<tr>
<td>08:30 - 08:50</td>
<td><strong>20: When do you start a biologic?</strong></td>
<td>Simon Travis, Oxford, United Kingdom</td>
</tr>
<tr>
<td>09:00 - 09:10</td>
<td><strong>22: OP10: Systems genomics of Ulcerative Colitis: Combining GWAS and signalling networks for patient stratification and individualised drug targeting in Ulcerative Colitis</strong></td>
<td>J. Brooks1, 2, D. Modos3, P. Sudhakar4, 5, D. Fazekas4, 6, A. Zoufir4, A. Watson1, 7, M. Tremelling1, B. Verstockt3, S. Vermeire3, A. Bender4, S. Carding4, 5, T. Korcsmaros4, 5</td>
</tr>
<tr>
<td>09:20 - 09:40</td>
<td><strong>23: OP11: Organoids derived from inflamed intestinal biopsies of patients with Ulcerative Colitis lose their inflammatory phenotype during ex vivo culture</strong></td>
<td>K. Arnauts2, 3, B. Verstockt1, 3, M. Vancamelbeke1, S. Vermeire1, 3, C. Verfaillie2, M. Ferrante1, 3</td>
</tr>
<tr>
<td>09:40 - 09:50</td>
<td><strong>24: Where is the exit?</strong></td>
<td>Marc Ferrante, Leuven, Belgium</td>
</tr>
</tbody>
</table>

**Friday, March 8, 2019**
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 09:40 - 09:50 | 25: OP12: Targeting inflammation in Ulcerative Colitis by inhibiting glucose uptake  
1Hospital of the Ludwig Maximilian University, General-, Visceral-, Vascular- and Transplantation Surgery, Munich, Germany, 2Hospital of the Ludwig Maximilian University, Laboratory Medicine, Munich, Germany, 3Hospital of the Ludwig Maximilian University, Medicine II, Munich, Germany |
| 09:50 - 10:00 | 26: OP13: Molecular response to ustekinumab in Moderate to Severe Ulcerative Colitis by serum protein and biopsy gene expression analysis: Results from the UNIFI phase 3 induction study  
K. Li, F. Yang, K. Hayden, D. Strawn, E. Wadman, S. Bhagat, C. Marano, J. R. Friedman  
Janssen Research & Development, LLC, Spring House, United States |
| 10:00 - 10:10 | 27: OP14: Improved endoscopic outcomes and mucosal healing of upadacitinib as an induction therapy in adults with Moderately to Severely Active Ulcerative Colitis: Data from the U-ACHIEVE study  
1University of California San Diego, La Jolla, United States, 2University Hospital Schleswig-Holstein, Kiel, Germany, 3University of Washington, Seattle, United States, 4Centre for Immunobiology, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom, 5Service de Gastroentérologie et Nutrition Clinique, Nice, France; Université de Nice-Sophia-Antipolis, Nice, France, 6AbbVie Inc., North Chicago, United States, 7Mayo Clinic, Rochester, United States |
| 10:10 - 10:30 | 28: Precision surgery in UC  
Yves Panis, Clichy, France |

**OP = Oral presentation – Best abstracts**
### Scientific Session 5: IBD around the world

#### 11:00 - 12:30
Toshifumi Hibi, Tokyo, Japan
Giovanni Maconi, Milan, Italy

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00 - 11:20</td>
<td>29: Vaccination and travelling with IBD: An update</td>
</tr>
<tr>
<td></td>
<td>Jean-François Rahier, Yvoir, Belgium</td>
</tr>
<tr>
<td></td>
<td>¹North Zealand University Hospital, Frederikssund, Denmark, ²Ben Gurion University of the Negev, Beer Sheva, Israel, ³Soroka Medical Center and Ben Gurion University of the Negev, Beer Sheva, Israel, ⁴University Hospital Center Zagreb, Zagreb, Croatia, ⁵Semmelweis University, Budapest, Hungary, ⁶Amiens University and Hospital, Amiens, France, ⁷Lithuanian University of Health Sciences, Kaunas, Lithuania, ⁸Hospital de São João, Porto, Portugal, ⁹Moscow Regional Research Clinical Institute, Moscow, Russian Federation, ¹⁰Tampere University Hospital, Tampere, Finland, ¹¹Imperial College London, London, United Kingdom, ¹²Herlev University Hospital, Herlev, Denmark, ¹³State University of Medicine and Pharmacy of the Republic of Moldova, Chisinau, Moldova, Republic of, ¹⁴Azienda Ospedaliera di Padova, Padova, Italy, ¹⁵Complexo Hospitalar Universitário de Vigo, Vigo, Spain, ¹⁶Morgagni Hospital, Forli, Italy, ¹⁷Careggi Regional Referral Center for Inflammatory Bowel Disease, Florence, Italy, ¹⁸University Hospital Ioannina, Greece, ¹⁹Charles University, Prague, Czech Republic, ²⁰National Hospital of the Faroe Islands, Tórshavn, Faroe Islands, ²¹Ehning Hospital, Herning, Denmark, ²²Mater Dei Hospital, Msida, Malta, ²³Tartu University Hospital, Tartu, Estonia, ²⁴University of Medicine ‘Victor Babes’, Timisoara, Romania, ²⁵American Gastroenterology Center, Nicosia, Cyprus, ²⁶Slagelse Hospital, Department of medicine, Denmark, ²⁷Regional Hospital of Viborg, Viborg, Denmark, ²⁸Örebro University, Örebro, Sweden, ²⁹Hull and East Yorkshire NHS Trust, Hull, United Kingdom, ³⁰Aarhus University Hospital, Aarhus, Denmark</td>
</tr>
<tr>
<td>11:30 - 11:50</td>
<td>31: Management of IBD outside of Europe: The example of India</td>
</tr>
<tr>
<td></td>
<td>Rupa Banerjee, Hyderabad, India</td>
</tr>
<tr>
<td>11:50 - 12:00</td>
<td>32: OP16: A randomised, multicentre, double-blind, placebo-controlled study of a targeted release oral cyclosporine formulation in the treatment of Mild to Moderate Ulcerative Colitis: Efficacy results</td>
</tr>
<tr>
<td></td>
<td>S. Bloom¹, T. Iqbal², C. Nwokolo³, M. Smith⁴, D. O'Donoghue⁵, J. Hall⁶, B. Dzyngel⁶</td>
</tr>
<tr>
<td></td>
<td>¹University College London Hospitals, London, United Kingdom, ²Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom, ³University Hospital Coventry &amp; Warwickshire, Coventry, United Kingdom, ⁴Shrewsbury and Telford Hospital, Shrewsbury, United Kingdom, ⁵St Vincent’s University Hospital, Centre for Colorectal Disease, Dublin, Ireland, ⁶Sublimity Therapeutics, Solana Beach, United States</td>
</tr>
</tbody>
</table>
**Friday, March 8, 2019, cont.**

*Scientific programme day by day (as of February 1, 2019)*

*Plenary Hall, Hall A, Bella Center*

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:00 - 12:10</td>
<td><strong>33: OP17: A molecular measure of inflammation in IBD patients based on transcriptional profiles from 2495 intestinal biopsies</strong></td>
</tr>
<tr>
<td></td>
<td>1Icahn School at Mount Sinai, Department of Population, Health Science and Policy, New York, United States, 2University College of London, London, United Kingdom, 3Department of Genetics and Genomic Science, New York, United States, 4Icahn School at Mount Sinai, Department of Medicine, Susan and Leonard Feinstein Inflammatory Bowel Disease Clinical Center, New York City, United States, 5Janssen Research &amp; Development, Janssen Biotech, Johnson &amp; Johnson, Spring House, United States</td>
</tr>
<tr>
<td>12:10 - 12:30</td>
<td><strong>34: East meets West: Epidemiology of IBD</strong></td>
</tr>
<tr>
<td></td>
<td>Johan Burisch, Copenhagen, Denmark</td>
</tr>
<tr>
<td></td>
<td>Siew Ng, Hong Kong, China</td>
</tr>
<tr>
<td>12:30 - 13:30</td>
<td><strong>Guided Poster Session (Hall B)</strong></td>
</tr>
<tr>
<td>13:30 - 14:40</td>
<td><strong>Scientific Session 6: New ways of doing endoscopy and imaging in IBD</strong></td>
</tr>
<tr>
<td></td>
<td>Hankje Escher, Rotterdam, The Netherlands</td>
</tr>
<tr>
<td></td>
<td>Christian Maaser, Lüneburg, Germany</td>
</tr>
<tr>
<td>13:30 - 13:50</td>
<td><strong>35: Assessing bowel damage in CD from adult to childhood</strong></td>
</tr>
<tr>
<td></td>
<td>Anne Griffths, Toronto, Canada</td>
</tr>
<tr>
<td>13:50 - 14:00</td>
<td><strong>36: OP18: Proactive adalimumab trough measurements increase corticosteroid-free clinical remission in paediatric patients with Crohn's Disease: The paediatric Crohn's Disease adalimumab level-based optimisation treatment (PAILOT) trial</strong></td>
</tr>
<tr>
<td></td>
<td>1Schneider Children’s Hospital, Gastroenterology, Nutrition and Liver Diseases, Petach Tikva, Israel, 2Schneider Children’s medical center, Gastroenterology, Nutrition and Liver Diseases, Petach Tikva, Israel, 3Shaare Zedek Medical Center, Gastroenterology, Nutrition and Liver Diseases, Jerusalem, Israel, 4Assaf Harofeh, Pediatric Gastroenterology, Zerifin, Israel, 5Sheba Medical Center, Pediatric Gastroenterology, Ramat Gan, Israel, 6Shaare Zedek Medical Center, Pediatric Gastroenterology, Nutrition and Liver Diseases, Jerusalem, Israel, 7Tel Aviv Medical Center, Pediatric Gastroenterology, Tel-Aviv, Israel, 8Kaplan Medical Center, Pediatric Gastroenterology, Rehovot, Israel, 9Rambam Medical Center, Pediatric Gastroenterology, Haifa, Israel, 10Soroka Medical Center, Pediatric Gastroenterology, Beer Sheva, Israel</td>
</tr>
<tr>
<td>14:00 - 14:20</td>
<td><strong>37: Best practice in screening for dysplasia</strong></td>
</tr>
<tr>
<td></td>
<td>Marietta Iacucci, Birmingham, United Kingdom</td>
</tr>
</tbody>
</table>

**IIS Abstract Award**

**OP = Oral presentation – Best abstracts**
### Scientific programme day by day (as of February 1, 2019)

**Plenary Hall, Hall A, Bella Center (Session 7 & 8)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 14:20 - 14:30 | **38: OP19** Corticosteroid response rectal gene signature and associated microbial variation in treatment naïve Ulcerative Colitis  
1Sheba Medical Center, Tel Hashomer, Israel, 2Cincinnati Children Hospital Medical Center, Cincinnati, United States, 3Broad Institute of MIT and Harvard University, Cambridge, United States, 4Georgia Institute of Technology, Atlanta, United States, 5University of North Carolina, Chapel Hill, United States, 6Emory University, Atlanta, United States, 7Hospital For Sick Children, Toronto, Canada, 8Harvard School of Public Health, Boston, United States, 9Broad Institute of MIT and Harvard University, Boston, United States, 10Connecticut Children’s Medical Center, Hartford, United States |
| 14:30 - 14:40 | **39: OP20** Mucosal microRNA profiles predict response to autologous stem-cell transplantation in Crohn's Disease  
A. Lewis1, R. Jeffrey1, T. Kumagai1, C. J. Hawkey2, M. M. Clark2, M. Allez3, J. Satsangi4, G. Rogler5, A. Silver1, J. O. Lindsay6  
1Blizard Institute, Barts and The London School of Medicine & Dentistry, Centre for Genomics and Child Health, London, United Kingdom, 2Centre for Digestive Diseases, Queens Medical Centre, Nottingham, United Kingdom, 3Department of Gastroenterology, Hôpital Saint Louis, APHP, INSERM UMRS 1160, Paris Diderot, Sorbonne Paris-Cité University, Paris, France, 4Translational Gastroenterology Unit, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom, 5Department of Gastroenterology and Hepatology, University Hospital, Zurich, Switzerland, 6Blizard Institute, Barts and The London School of Medicine & Dentistry, Centre for Immunobiology, London, United Kingdom |
| 14:40 - 15:10 | Coffee break |
| EITHER:       | Scientific Session 7: ECCO Fellowships and Grants  
(Plenary Hall, Hall A, Bella Center)  
Edouard Louis, Liège, Belgium  
Janneke van der Woude, Rotterdam, The Netherlands |
| 15:10 - 15:55 | **40: Outcomes from the ECCO Pioneer Award 2017: Faecal transplantation using a novel conditioning method for donor and recipient in mild to moderate treatment refractory colitis in Inflammatory Bowel Disease**  
Arie Levine, Tel Aviv, Israel |
| 15:10 - 15:17 | **41: Outcomes from the ECCO Fellowship 2018: Role of TNF-inducible gene-6 (TSG-6) in fistulising Crohn's Disease**  
Sudharshan Elangovan, Thuwal, Saudi Arabia |
| 15:17 - 15:24 | **42: Outcomes from the ECCO Fellowship 2018: Monocyte-derived macrophages as crucial players in the resolution of inflammation and tissue repair in Inflammatory Bowel Disease**  
Sales Ibiza, Lisbon, Portugal |
| 15:24 - 15:31 | **43: Outcomes from the ECCO-IOIBD Fellowship 2017: Precision medicine for IBD using advanced machine learning**  
Aria Zand, Los Angeles, United States |
| 15:31 - 15:38 | **44: Outcomes from the ECCO-IOIBD Fellowship 2018: Deciphering the gut-specific B cell response in Inflammatory Bowel Disease**  
Mathieu Uzzan, Clichy, France |
| 15:38 - 15:45 | **45: Announcement of ECCO Fellowships & Grants 2019** |

**OP** = Oral presentation – Best abstracts
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>1University Hospitals Leuven, Leuven, Belgium, 2CHU Nice Hospital Archet, 3Nice, France, 4Piotr Napora Centrum Klinicznych Lekarze Sp., Wroclaw, Poland, 5SANTA FAMILIA, Centrum Badań, 6Profilaktyki i Leczenia, Lodz, Poland, 7Vasútegészségügyi Nonprofit Közhasznú Kft, Debrecen, Hungary, 8CHU Nantes Hotel Dieu, Nantes, France, 9KO-Med, Lublin, Poland, 10Abivax, Paris, France</td>
</tr>
<tr>
<td>16:05 - 16:15</td>
<td>47: OP22</td>
<td>Mesenchymal stromal cell-derived exosomes stimulate epithelial regeneration in vitro and reduce experimental Colitis</td>
<td>M. Barnhoorn, L. Plug, E. Muller - de Jonge, E. Bos, A. van der Meulen-de Jong, H. Verspaget, L. Hawinkels</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>1Leiden University Medical Center, Gastroenterology and Hepatology, Leiden, Netherlands, 2Leiden University Medical Center, Cell and Chemical Biology, Leiden, Netherlands</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>1Research Institute, Chong Kun Dang Pharmaceutical Corporation, Yongin, South Korea, 2Hallym University, Department of Biomedical Science, Chuncheon, South Korea, 3Inje University College of Medicine, Department of Microbiology and Immunology, Gimhae, South Korea, 4Seoul National University College of Medicine, Department of Internal Medicine and Liver Research Institute, Seoul, South Korea, 5Seoul National University Hospital Healthcare System Gangnam Center, Department of Internal Medicine and Healthcare Research Institute, Seoul, South Korea</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>1Amiens University Hospital, Gastroenterology, Amiens, France, 2Nancy University Hospital, Gastroenterology, Nancy, France, 3Lyon University Hospital, Lyon, France, 4Montpellier University Hospital, Gastroenterology, Montpellier, France, 5Saint Etienne University Hospital, Gastroenterology, Saint Etienne, France, 6Rennes University Hospital, Gastroenterology, Rennes, France, 7Caen University Hospital, Gastroenterology, Caen, France, 8Bordeaux University Hospital, Gastroenterology, Bordeaux, France, 9Nice University Hospital, Gastroenterology, Nice, France, 10Clermont-Ferrand, Gastroenterology, Clermont Ferrand, France, 11Hôpital Beaujon, Gastroenterology, Clichy, France, 12Toulouse University Hospital, Gastroenterology, Toulouse, France, 13Amiens University Hospital, Gastroenterology, Amiens, France, 14Lyon University Hospital, Gastroenterology, Lyon, France, 15Saint Etienne University Hospital, Gastroenterology, Saint-Etienne, France</td>
</tr>
</tbody>
</table>

**OP = Oral presentation – Best abstracts**
## Scientific programme day by day (as of February 1, 2019)

### Plenary Hall, Hall A, Bella Center (Session 7 & 8)

#### 16:35 - 16:45

**50: OP25: Targeting endoscopic outcomes through combined pharmacokinetic and pharmacodynamic monitoring of infliximab therapy in patients with Crohn's Disease**

E. Dreesen¹, F. Baert², D. Laharie³, P. Bossuyt⁴, Y. Bouhnik⁵, A. Buisson⁶, G. Lambrecht⁷, E. Louis⁸, B. Oldenburg⁹, B. Pariente¹⁰, M. Pierik¹¹, C. J. van der Woude¹², G. D’Haens¹³, S. Vermeire¹⁴,¹⁵, A. Gils¹

¹University of Leuven, Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium, ²AZ Delta, Department of Gastroenterology, Roeselare, Belgium, ³Hôpital Haut-Lévêque, Service d’Hépato-gastroentérologie et Oncologie Digestive, Bordeaux, France, ⁴Imelda General Hospital, IBD Clinic, Bonheiden, Belgium, ⁵Beaujon Hospital, APHP, Paris Diderot University, Department of Gastroenterology, Clichy, France, ⁶Estaing University Hospital, Department of Gastroenterology, Clermont-Ferrand, France, ⁷AZ Damiaan, Department of Gastroenterology, Oostende, Belgium, ⁸Liège University Hospital, Department of Gastroenterology, Liège, Belgium, ⁹University Medical Centre, Department of Gastroenterology and Hepatology, Utrecht, Netherlands, ¹⁰Hurniez Hospital, Lille, ¹¹University, Department of Gastroenterology and Hepatology, Lille, France, ¹²University Medical Centre, Department of Gastroenterology and Hepatology, Maastricht, Netherlands, ¹³Erasmus Medical Centre, Department of Gastroenterology and Hepatology, Rotterdam, Netherlands, ¹⁴Academic Medical Centre, Department of Gastroenterology, Amsterdam, Netherlands, ¹⁵University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium, ¹⁶University of Leuven, Department of Chronic Diseases, Metabolism and Ageing, Leuven, Belgium

#### 16:45 - 16:55

**51: OP26: Long-term safety of vedolizumab in Ulcerative Colitis and Crohn’s Disease: Final results from the GEMINI LTS study**


¹University Hospitals Leuven, Leuven, Belgium, ²Icahn School of Medicine at Mount Sinai, New York, United States, ³Western University, London, Canada, ⁴University of California San Diego, La Jolla, United States, ⁵Humanitas University, Milan, Italy, ⁶Academic Medical Centre, Amsterdam, Netherlands, ⁷University of Calgary, Calgary, Canada, ⁸University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, United States, ⁹Shafran Gastroenterology Research Center, Winter Park, United States, ¹⁰Takeda Pharmaceuticals, Cambridge, United States, ¹¹Mayo Clinic College of Medicine, Rochester, United States

---

**OP** = Oral presentation – Best abstracts
Friday, March 8, 2019, cont.

Scientific programme day by day (as of February 1, 2019)
C1-M4-5, Hall C, Bella Center (Session 9)

OR:

Scientific Session 9: Basic Science: Immune cells and microbes: A happy marriage?
(C1-M4-5, Hall C, Bella Center)
Tim Raine, Cambridge, United Kingdom
Raja Atreya, Erlangen, Germany

15:10 - 16:50

52: Metabolic profiling – the new player in microbiome research
Stefan Schreiber, Kiel, Germany

53: OP27: High-dimensional mass cytometry reveals the immune cell landscape in Inflammatory Bowel Disease
V. van Unen1, N. Li1, T. Abdelaal1, Y. Kooy-Winkelaar1, L. Ouboter1, G. Beyrend1, T. Höllt5, L. Mearin7, A. Witte8, H. Escher9, B. Lelieveldt10, A. van der Meulen - de Jong9, F. Koning1
1Leiden University Medical Center, Department of Immunohematology and Blood Transfusion, Leiden, Netherlands, 2Delft University of Technology, Delft Bioinformatics Lab, Delft, Netherlands, 3Leiden University Medical Center, Leiden Computational Biology Center, Leiden, Netherlands, 4Leiden University Medical Center, Department of Gastroenterology, Leiden, Netherlands, 5Leiden University Medical Center, Leiden Computational Biology Center, Leiden, Netherlands, 6Leiden University Medical Center, Department of Paediatrics, Leiden, Netherlands, 7Alrijne Hospital, Department of Gastroenterology, Leiden, Netherlands, 8Fondazione Policlinico Universitario A. Gemelli IRCCS – Università Cattolica del Sacro Cuore, UOC Internal Medicine, Gastroenterology and Hepatology, Rome, Italy, 9Case Western Reserve University, Cleveland, United States, 10Delft University of Technology, Pattern Recognition and Bioinformatics Group, Delft, Netherlands, 11Leiden University Medical Center, Department of LKEB Radiology, Leiden, Netherlands

15:30 - 15:40

54: OP28: Host-microbial crosstalk in the pathogenesis of inflammation and cancer in primary sclerosing cholangitis
M. Neyazi1, N. Ilott2, Oxford IBD Cohort study investigators1, S. Travis1, C. Arancibia1, F. Powrie2, A. Geremia1
1University of Oxford, Translational Gastroenterology Unit, Oxford, United Kingdom, 2University of Oxford, Kennedy Institute of Rheumatology, Oxford, United Kingdom

16:10 - 16:20

56: OP29: ST2+/IL-33 responsive cells promote tumorigenesis in colitis-associated colorectal cancer
L. R. Lopetuso1, C. De Salvo2, L. Di Martino3, W. Goodman3, F. Scaldaferrì1, A. Armuzzi4, A. Gasbarri1, T. T. Pizarro2
1Fondazione Policlinico Universitario A. Gemelli IRCCS – Università Cattolica del Sacro Cuore, UOC Internal Medicine, Gastroenterology and Hepatology, Rome, Italy, 2Case Western Reserve University, Cleveland, United States, 3Fondazione Policlinico Universitario A. Gemelli IRCCS – Università Cattolica del Sacro Cuore, UOC Internal Medicine, Gastroenterology and Hepatology, Rome, Italy, 4Fondazione Policlinico Universitario A. Gemelli IRCCS – Università Cattolica del Sacro Cuore, UOC Internal Medicine, Gastroenterology and Hepatology, Rome, Italy, 5Fondazione Policlinico Universitario A. Gemelli IRCCS – Università Cattolica del Sacro Cuore, UOC Internal Medicine, Gastroenterology and Hepatology, Rome, Italy, 6Fondazione Policlinico Universitario A. Gemelli IRCCS – Università Cattolica del Sacro Cuore, UOC Internal Medicine, Gastroenterology and Hepatology, Rome, Italy, 7Fondazione Policlinico Universitario A. Gemelli IRCCS – Università Cattolica del Sacro Cuore, UOC Internal Medicine, Gastroenterology and Hepatology, Rome, Italy, 8Fondazione Policlinico Universitario A. Gemelli IRCCS – Università Cattolica del Sacro Cuore, UOC Internal Medicine, Gastroenterology and Hepatology, Rome, Italy, 9Fondazione Policlinico Universitario A. Gemelli IRCCS – Università Cattolica del Sacro Cuore, UOC Internal Medicine, Gastroenterology and Hepatology, Rome, Italy, 10Fondazione Policlinico Universitario A. Gemelli IRCCS – Università Cattolica del Sacro Cuore, UOC Internal Medicine, Gastroenterology and Hepatology, Rome, Italy, 11Fondazione Policlinico Universitario A. Gemelli IRCCS – Università Cattolica del Sacro Cuore, UOC Internal Medicine, Gastroenterology and Hepatology, Rome, Italy

55: Using mucosal immune pathways to predict disease outcome
Ahmed Hegazy, Berlin, Germany

Y-ECCO Abstract Award
### Scientific Programme

**Friday, March 8, 2019, cont.**

*Scientific programme day by day (as of February 1, 2019)*

**C1-M4-5, Hall C, Bella Center (Session 9)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Presentation</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:20 - 16:30</td>
<td><strong>57: OP30: Serum proteomic profiling predicts and diagnoses pouchitis in Ulcerative Colitis patients undergoing ileal pouch-anal anastomosis</strong>&lt;br&gt;K. Machiels¹,², M. Ferrante¹,², N. Davani¹, A. Wolthuis¹, A. D’Hoore³, S. Vermeire¹,² ¹KU Leuven, Translational Research Center for Gastrointestinal Disorders (TARGID), Leuven, Belgium, ²University Hospitals Leuven, Department of gastroenterology and hepatology, Leuven, Belgium, ³University Hospitals Leuven, Abdominal surgery, Leuven, Belgium</td>
</tr>
<tr>
<td>16:30 - 16:50</td>
<td><strong>58: Resolution pathways: Next frontier to control intestinal inflammation</strong>&lt;br&gt;Silvia D’Alessio, Milan, Italy</td>
</tr>
</tbody>
</table>

**17:05 - 18:05**  
**Digital Oral Presentations (Sessions 6 - 10)**  
See pg. 41

**18:35-19:35**  
**Industry sponsored satellite symposia 4a & 4c & 4d**  
See pg. 112

**OP** = Oral presentation – Best abstracts
### Scientific programme day by day (as of February 1, 2019)

**Plenary Hall, Hall A, Bella Center**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30 - 10:20</td>
<td><strong>Scientific Session 10: The cycle of IBD life in clinical practice</strong></td>
</tr>
<tr>
<td></td>
<td>Glen Doherty, Dublin, Ireland</td>
</tr>
<tr>
<td></td>
<td>Richard Russell, Glasgow, United Kingdom</td>
</tr>
<tr>
<td>08:30 - 08:50</td>
<td>59: Challenges in managing the elderly</td>
</tr>
<tr>
<td></td>
<td>Guillaume Savoye, Rouen, France</td>
</tr>
<tr>
<td>08:50 - 09:00</td>
<td>60: OP31: TP53 mutation in human colonic organoids acquires resistance to in vitro long-term inflammation</td>
</tr>
<tr>
<td></td>
<td>Tokyo Medical and Dental University and Dental University and, Tokyo, Japan</td>
</tr>
<tr>
<td>09:00 - 09:10</td>
<td>61: OP32: A novel mechanism of colonic epithelial-T cell cross-talk is dysregulated in IBD</td>
</tr>
<tr>
<td></td>
<td>R. J. Dart1, 2, 3, P. Vantourout1, 2, P. M. Irving1, A. Hayday1, 2</td>
</tr>
<tr>
<td></td>
<td>1King’s College London, Peter Gorer Dept of Immunobiology, London, United Kingdom, 2Francis Crick Institute, Immunosurveillance Lab, London, United Kingdom, 3Guy’s and St Thomas Hospital, Department of Gastroenterology, London, United Kingdom</td>
</tr>
<tr>
<td>09:10 - 09:30</td>
<td>62: The reproductive phase: Practical recommendations</td>
</tr>
<tr>
<td></td>
<td>Ailsa Hart, London, United Kingdom</td>
</tr>
<tr>
<td>09:30 - 09:40</td>
<td>63: OP33: Late-breaking Abstract</td>
</tr>
<tr>
<td>09:40 - 09:50</td>
<td>64: OP34: Late-breaking abstract</td>
</tr>
</tbody>
</table>

**OP** = Oral presentation – Best abstracts
Saturday, March 9, 2019, cont.

Scientific programme day by day (as of February 1, 2019)

Plenary Hall, Hall A, Bella Center

09:50 - 10:00


1Amiens University Hospital, Amiens, France, 2Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York, United States, 3IBD Clinic, Department of Gastroenterology, Imelda General Hospital, Bonheiden, Belgium, 4AZ Delta Roeselare, Roeselare, Belgium, 52-nd Department of Internal Medicine, University Hospital Hradec Králové, Hradec Králové, Czech Republic, 6Department of Gastroenterology and Hepatology, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands, 7Cumming School of Medicine, University of Calgary, Calgary, Canada, 8Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria, 9Presidio Columbus Fondazione Policlinico A. Gemelli IRCCS - Università Cattolica del Sacro Cuore, Rome, Italy, 10Medical Clinical Investigational Center of Medical Center Health Clinic LLC, Vinnytsia, Ukraine, 11Universityate de Medicina si Farmacie, Timisoara, Romania, 12Translational Gastroenterology Unit, Nuffield Department of Experimental Medicine, University of Oxford, Oxford, United Kingdom, 13Gastro-Entérologie & Nutrition Clinique, Hôpital de l’Arche 4, Nice, France, 14University Hospitals Leuven, Leuven, Belgium, 15Department of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland, 16Humanitas University, Istituto Clinico Humanitas, Milan, Italy, 17Central Clinical Hospital of the Ministry of Interior in Warsaw, Warsaw, Poland, 18Claude Huriez Hospital, Lille University, Lille, France, 19Skane University Hospital, Lund, Sweden, 20Grigore T. Popa University of Medicine and Pharmacy, Iasi, Romania, 21Hepato-Gastroenterology Department, North Hospital, University of Mediterranean, Marseille, France, 22University of Medicine and Pharmacy “Carol Davila”, Bucharest, Romania, 23Hépato-Gastro-Entérologie, Hôpital de Brabois, Nancy, France, 24Hépato-gastroentérologie et d’oncologie digestive, Hôpital Haut-Lévêque, Pessac, France, 25Kingsbury Hospital, Cape Town, South Africa, 26Hospital Clínico de Zaragoza, ILS Aragon, Zaragoza, Spain, 27Military Medical Academy named after S.M.Kirov, Saint-Petersburg, Russian Federation, 28Department of Internal Medicine I, Kiel University, Kiel, Germany, 29IBD Center, Sapporo Kosei General Hospital, Sapporo, Japan, 30Uppsala University Hospital, Uppsala, Sweden, 31Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden

10:00 - 10:20

66: Cancer risk in children with IBD, an under-recognised issue

Arie Levine, Tel Aviv, Israel

10:20 - 10:50 Coffee break
Scientific Programme
14th Congress of ECCO - Copenhagen

Saturday, March 9, 2019, cont.
Scientific programme day by day (as of February 1, 2019)
Plenary Hall, Hall A, Bella Center

<table>
<thead>
<tr>
<th>Time</th>
<th>Scientific Session 11: Towards the future of IBD</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:50 - 11:10</td>
<td>67: Artificial intelligence augmenting medical management</td>
</tr>
<tr>
<td></td>
<td>Vishal Nangalia, London, United Kingdom</td>
</tr>
<tr>
<td>11:10 - 11:20</td>
<td>68: OP36: A colonic gene expression signature predicts non-response to anti-inflammatory therapies in Inflammatory Bowel Disease</td>
</tr>
<tr>
<td></td>
<td>T. Sato¹, K. Li¹, K. Hayden¹, L. Tomsho¹, F. Baribaud¹, C. Brodmerkel¹, L. E. Greenbaum¹, J. R. Friedman¹, M. Curran¹, Y. Ima¹, S. Plevy¹, S. E. Telesco¹</td>
</tr>
<tr>
<td></td>
<td>¹Janssen Research &amp; Development, LLC, Spring House, United States, ¹Janssen Pharmaceutical K.K., Tokyo, Japan</td>
</tr>
<tr>
<td>11:20 - 11:40</td>
<td>69: Robot and surgeon: How will a partnership work?</td>
</tr>
<tr>
<td></td>
<td>Antonino Spinelli, Milan, Italy</td>
</tr>
<tr>
<td>11:40 - 11:50</td>
<td>70: OP37: Efficacy and safety of ustekinumab as maintenance therapy in Ulcerative Colitis: Week 44 results from UNIFI</td>
</tr>
<tr>
<td></td>
<td>W. J. Sandborn¹, B. E. Sands¹, R. Panaccione¹, C. D. O’Brien¹, H. Zhang¹, J. Johanss¹, L. Peyrin-Biroulet¹, G. Van Assche⁶, S. Danese⁷, S. R. Targan¹⁰, M. T. Abreu¹⁰, T. Hisamatsu¹⁰, P. Szapary⁴, C. Marano⁴</td>
</tr>
<tr>
<td></td>
<td>¹University of California San Diego, La Jolla, United States, ²Icahn School of Medicine at Mount Sinai, New York, United States, ³University of Calgary, Calgary, Canada, ⁴Janssen Research &amp; Development, LLC, Spring House, United States, ⁵Nancy University Hospital, Université de Lorraine, Nancy, France, ⁶University of Leuven, Leuven, Belgium, ⁷Humanitas Research Hospital, Milan, Italy, ⁸Cedars-Sinai Medical Center, Los Angeles, United States, ⁹University of Miami Miller School of Medicine, Miami, United States, ¹⁰Kyorin University, Tokyo, Japan</td>
</tr>
<tr>
<td>11:50 - 12:00</td>
<td>71: OP38: Maintenance treatment with mirikizumab, a p19-directed IL-23 antibody: 52-week results in patients with Moderately to Severely Active Ulcerative Colitis</td>
</tr>
<tr>
<td></td>
<td>G. R. D’Haens¹, W. J. Sandborn¹, M. Ferrante¹, B. R. Bhandari³, E. Berliba⁵, T. Hibi⁸, J. Tuttle⁷, J. B. Canavan⁶, S. Friedrich⁶, M. Durante⁶, V. Arora⁸, B. Feagan⁸</td>
</tr>
<tr>
<td></td>
<td>¹Amsterdam University Medical Centers, Amsterdam, Netherlands, ²University California San Diego, La Jolla, California, United States, ³UZ Leuven, KU Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium, ⁴Delta Research Partners, LLC, Bastrop, LA, United States, ⁵Nicolae Testemitanu State University of Medicine and Pharmacy, Chisinau, Moldova, Republic of, ⁶Kita-sato Institute Hospital Center for Advanced IBD Research and Treatment, Minato-ku, Tokyo, Japan, ⁷Eli Lilly and Company, Lilly Biotechnology Center, San Diego, California, United States, ⁸Eli Lilly and Company, Indianapolis, Indiana, United States, ⁹Western University, Robarts Clinical Trials Inc, London, Ontario, Canada</td>
</tr>
<tr>
<td>12:00 - 12:20</td>
<td>72: Big data: Potential for transforming IBD research and care</td>
</tr>
<tr>
<td></td>
<td>Ignacio Hernandez-Medrano, Madrid, Spain</td>
</tr>
</tbody>
</table>

OP = Oral presentation – Best abstracts
Saturday, March 9, 2019, cont.
Scientific programme day by day (as of February 1, 2019)
Plenary Hall, Hall A, Bella Center

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 12:20 - 12:50 | **Scientific Session 12: ECCO Lecture**  
Silvio Danese, Milan, Italy  
Laurent Peyrin-Biroulet, Vandœuvre-Les-Nancy, France |
| 12:20 - 12:50 | 73: **ECCO Lecture: Inflammatory cytokines from discoveries to therapies**  
Charles Dinarello, Denver, United States |
| 12:50 - 12:55 | **Awards and closing remarks**  
Silvio Danese, Milan, Italy |
| 12:55 - 13:00 | **The ECCO Film** |

OP = Oral presentation – Best abstracts
### Scientific Programme

**13th Congress of ECCO - Vienna**

**Thursday, February 15, 2018**

*Scientific programme day by day (as of January 15, 2018)*

**Plenary Hall, Hall D, Messe Wien**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00 - 12:00</td>
<td><strong>Industry sponsored satellite symposia 1a &amp; 1b</strong></td>
<td>Please refer to pages 104-105</td>
</tr>
<tr>
<td>12:15 - 12:20</td>
<td><strong>1: Welcome</strong></td>
<td>Rainer Schöfl, Linz, Austria</td>
</tr>
<tr>
<td>12:20 - 12:30</td>
<td><strong>2: Opening</strong></td>
<td>Julián Panés, Barcelona, Spain</td>
</tr>
<tr>
<td>12:30 - 14:00</td>
<td><strong>Scientific session 1: Exploring IBD over time</strong></td>
<td>Axel Dignass, Frankfurt, Germany</td>
</tr>
<tr>
<td></td>
<td><strong>Axel Dignass</strong>, Frankfurt, Germany</td>
<td>Charlotte Hedin, Stockholm, Sweden</td>
</tr>
<tr>
<td></td>
<td><strong>3: Can we diagnose pre-symptomatic IBD?</strong></td>
<td>Joana Torres, Lisbon, Portugal</td>
</tr>
<tr>
<td>12:30 - 12:50</td>
<td><strong>4: OP001: Gut barrier dysfunction – a primary defect in twins with</strong></td>
<td><strong>Crohn’s Disease predominantly caused by genetic predisposition</strong></td>
</tr>
<tr>
<td></td>
<td><strong>A. V. Keita</strong>, <strong>C.M. Lindqvist</strong>, <strong>A. Öst</strong>, <strong>C. DL Magana</strong>, <strong>I. Schoultz</strong>, <strong>J. Halfvarson</strong></td>
<td>1:linköping University, Department Of Clinical And Experimental Medicine, Linköping, Sweden, 2Örebro University, Department of Medical Sciences, Örebro, Sweden, 3Aleris Medilab, Department of Pathology and Cytology, Täby, Sweden, 4Örebro University, Department of Gastroenterology, Örebro, Sweden</td>
</tr>
<tr>
<td>12:50 - 13:00</td>
<td><strong>5: Targeting early disease - lessons from rheumatoid arthritis</strong></td>
<td>Daniel Aletaha, Vienna, Austria</td>
</tr>
<tr>
<td>13:00 - 13:20</td>
<td><strong>6: OP002: Assessment of disease activity patterns during the first 10</strong></td>
<td><strong>years after diagnosis in a population-based Crohn’s Disease cohort shows a quiescent disease course for a substantial proportion of the population</strong></td>
</tr>
<tr>
<td></td>
<td><strong>D. Wintjens</strong>, <strong>F. Bergey</strong>, <strong>E. Saccenti</strong>, <strong>S. Jeuring</strong>, <strong>M. Romberg-Camps</strong>, <strong>L. Oostenbrug</strong>, <strong>A. Masclée</strong>, <strong>D. Jonkers</strong>, <strong>V. Martins dos Santos</strong>, <strong>M. Pierik</strong></td>
<td>1Maastricht University Medical Center +, Department of Internal Medicine, Division of Gastroenterology and Hepatology, Maastricht, The Netherlands, 2Maastricht University Medical Center +, NUTRIM School for Nutrition and Translational Research in Metabolism, Maastricht, The Netherlands, 3LifeGlimmer GmbH, Berlin, Germany, 4Wageningen University &amp; Research, Laboratory of Systems and Synthetic Biology, Wageningen, The Netherlands, 5Zuyderland Medical Centre, Department of Gastroenterology and Hepatology, Sittard-Geleen/Heerlen, The Netherlands</td>
</tr>
</tbody>
</table>

**OP = Oral presentation – Best abstracts**
### Scientific Programme Day by Day (as of January 15, 2018)

**Plenary Hall, Hall D, Messe Wien**

**Thursday, February 15, 2018, cont.**

#### Scientific Programme

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Description</th>
<th>Presenters/Institutions</th>
</tr>
</thead>
</table>
| 13:30 - 13:40 | 7: OP003: Temporal changes in immune pathways with consecutive biological therapies as measured by serum proteomics | M. de Bruyn<sup>1,2</sup>, V. Ballet<sup>1</sup>, S. Verstockt<sup>1</sup>, B. Verstockt<sup>1,3</sup>, G. Van Assche<sup>1,3</sup>, M. Ferrante<sup>1,4</sup>, K. Machiels<sup>1</sup>, S. Vermeire<sup>1,3</sup>  
<sup>1</sup>Translational Research Center for GastroIntestinal Disorders (TARGID), Chronic Diseases, Metabolism and Ageing (CHROMETA), Leuven, Belgium,  
<sup>2</sup>Rega Institute for Medical Research, Microbiology and Immunology, Leuven, Belgium,  
<sup>3</sup>University Hospitals Leuven, Gastroenterology and Hepatology, Leuven, Belgium,  
<sup>4</sup>Laboratory of Complex Genetics, Human Genetics, Leuven, Belgium |
| 13:40 - 14:00 | 8: Evolution of disease pathways over time in CD – early versus late disease        | Gerhard Rogler, Zurich, Switzerland                                                    |
| 14:00 - 14:30 | **Coffee break**                                                                    |                                                                                        |
| 14:30 - 16:00 | **Scientific session 2: Novel treatment strategies**                                 | Matthieu Allez, Paris, France                                                        |
|               |                                                                                     | Tim Raine, Cambridge, United Kingdom                                                 |
| 14:30 - 14:50 | 9: Combining new drugs with different mechanisms                                    | Shomron Ben-Horin, Ramat Gan, Israel                                                 |
| 14:50 - 15:00 | 10: OP004: The TLR9 agonist cobitolimod induces anti-inflammatory effects and balances the Th17/T-reg cell response in Ulcerative Colitis | H. Schmitt<sup>1</sup>, U. Billmeier<sup>1</sup>, J. Ulmschneider<sup>1</sup>, C. Admyre<sup>1</sup>, T. Knittel<sup>1</sup>, A. Zargari<sup>2</sup>, M.F. Neurath<sup>1</sup>, R. Atreya<sup>1</sup>  
<sup>1</sup>Friedrich-Alexander-University Erlangen-Nürnberg, First Department of Medicine, Erlangen, Germany,  
<sup>2</sup>InDex Pharmaceuticals AB, Stockholm, Sweden |
| 15:00 - 15:20 | 11: Stem cell therapy for perianal CD – multidisciplinary management               | Silvio Danese, Milan, Italy                                                         |
|               |                                                                                     | Damián García-Olmo, Madrid, Spain                                                   |
| 15:20 - 15:30 | 12: OP005: Higher anti-TNF serum levels are associated with perianal fistula closure in Crohn’s Disease patients | A. Strik<sup>1</sup>, M. Löwenberg<sup>1</sup>, C. Ponsioen<sup>1</sup>, K. Gecse<sup>1</sup>, C. Buskens<sup>1</sup>, W. Bemelman<sup>1</sup>, G. D’Haens<sup>1</sup>  
<sup>1</sup>Academic Medical Center, Gastroenterology and Hepatology, Amsterdam, The Netherlands,  
<sup>2</sup>Academic Medical Center (AMC), Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands,  
<sup>3</sup>Academic Medical Center (AMC), Department of Surgery, Amsterdam, The Netherlands |
| 15:30 - 15:40 | 13: OP006: Apremilast for active Ulcerative Colitis: A phase 2, randomised, double-blind, placebo-controlled induction study | S. Danese<sup>1</sup>, M. Neurath<sup>2</sup>, A. Kopon<sup>3</sup>, S. Zakko<sup>4</sup>, T. Simmons<sup>5</sup>, R. Fogel<sup>6</sup>, J. Maccarone<sup>7</sup>, X. Zhan<sup>7</sup>, K. Usiskin<sup>7</sup>, D. Chitkara<sup>7</sup>  
<sup>1</sup>Instituto Clínico Humanitas, Milan, Italy,  
<sup>2</sup>University Erlangen, Nurnberg, Germany,  
<sup>3</sup>Torunskie Centrum Gastrologiczne, Torun, Poland,  
<sup>4</sup>Connecticut Clinical Research Foundation of Bristol Hospital, Bristol, United States,  
<sup>5</sup>West Gastroenterology Medical Group, Los Angeles, United States,  
<sup>6</sup>Clinical Research Institute of Michigan, Chesterfield, United States,  
<sup>7</sup>Celgene Corporation, Summit, United States |
| 15:40 - 16:00 | 14: Small molecules are back                                                         | Laurent Peyrin-Biroulet, Vandeouvre-Les-Nancy, France                                |

**OP = Oral presentation – Best abstracts**
Thursday, February 15, 2018, cont.

Scientific programme day by day (as of January 15, 2018)

Plenary Hall, Hall D, Messe Wien

<table>
<thead>
<tr>
<th>16:00 - 17:20</th>
<th>Scientific session 3: Returning to a normal life with IBD</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:00 - 16:20</td>
<td>15: Sexual dysfunction in IBD patients</td>
</tr>
<tr>
<td></td>
<td>Eugeni Domènech, Badalona, Spain</td>
</tr>
<tr>
<td>16:20 - 16:40</td>
<td>16: How to prevent disability</td>
</tr>
<tr>
<td></td>
<td>Jean-Frédéric Colombel, New York City, United States</td>
</tr>
<tr>
<td>16:40 - 16:50</td>
<td>17: OP007: Detection of mucosal healing with a serum marker panel in adalimumab treated patients with Ulcerative Colitis</td>
</tr>
<tr>
<td></td>
<td>M. de Bruyn1,2, R. Ringold1, E. Martens2, M. Ferrante1,4, G. Van Assche1,4, G. Opdenakker2, A. Dukler1, S. Vermeire1,4</td>
</tr>
<tr>
<td></td>
<td>1Translational Research center for GastroIntestinal Disorders (TARGID), Chronic Diseases, Metabolism and Ageing (CHROMETA), Leuven, Belgium, 2Rega Institute for Medical Research, Microbiology and Immunology, Leuven, Belgium, 3Kepler Diagnostics, Inc., Simi Valley, United States, 4University Hospitals Leuven, Gastroenterology and Hepatology, Leuven, Belgium</td>
</tr>
<tr>
<td>16:50 - 17:00</td>
<td>18: OP008: α4β7 integrin-dependent gut homing of non-classical monocytes is essential for intestinal wound healing mediated by M2 macrophages</td>
</tr>
<tr>
<td></td>
<td>L. Schleier1, M. Wiendl1, M.-T. Binder1, R. Atreya1, A. Watson1, C. Neufert1, I. Atreya1, M.F. Neurath1, S. Zundler1</td>
</tr>
<tr>
<td></td>
<td>1University of Erlangen-Nuremberg, Department of Medicine I, Erlangen, Germany, 2University of East Anglia, Norwich Medical School, Norwich, United Kingdom</td>
</tr>
<tr>
<td>17:00 - 17:20</td>
<td>19: Patient perspective on treatment goals</td>
</tr>
<tr>
<td></td>
<td>Corey Siegel, Lebanon, United States</td>
</tr>
</tbody>
</table>

**Digital Oral Presentations (Sessions 1-5)**

Please refer to page 43

**Industry sponsored satellite symposia 2a & 2b & 2c**

Please refer to pages 105-106

OP = Oral presentation – Best abstracts
07:15 - 08:15 Industry sponsored satellite symposia, 3a & 3b & 3c
Please refer to pages 106-107

08:30 - 10:30 Scientific session 4: The future of IBD diagnosis and disease prediction
Iris Dotan, Petah Tikva, Israel
Jonas Halfvarson, Örebro, Sweden

08:30 - 08:50
20: ECCO-ESGAR Guidelines: Present and future of diagnostic techniques for IBD
Christian Maaser, Lueheburg, Germany
Jaap Stoker, Amsterdam, The Netherlands

08:50 - 09:00
H. Sarter1, G. Savoye1, D. Turck2, F. Vasseur1, G. Marot1, B. Pariente1, S. Singh1, J.F. Colombel1, C. Gower-Rousseau2, M. Fumery1
1 Lille Hospital and University, Public Health, Epidemiology and Economic Health, Epimad registry, Regional house of clinical research, Lille, France, 2 Lille University, Lille Inflammation Research International Center LIRIC-UMR 995 Inserm, Lille, France, 3 Rouen Hospital and University, Gastroenterology Unit, Epimad registry, Rouen, France, 4 Lille University Jeanne de Flandre Children’s Hospital and Faculty of Medicine, Division of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Lille, France, 5 Lille University and Hospital, Biostatistics Unit, EA 2694, Lille, France, 6 Lille University and Hospital, EA 2694 - Santé publique: épidémiologie et qualité des soins, Lille, France, 7 Inria Lille Nord Europe, Modal, Lille, France, 8 Gastroenterology Unit, Epimad registry, Lille Hospital and University, Lille, France, 9 Prometheus Laboratories Inc, San Diego, United States, 10 Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York, United States, 11 Amiens Hospital and University, Gastroenterology Unit, EPIMAD Registry, Amiens, France

09:00 - 09:10
22: OP010: Shallow whole genome sequencing predicts the future cancer risk of low grade dysplastic lesions arising in Ulcerative Colitis
I. Al Bakir1, K. Curtius1, A.-M. Baker1, T.S.O. Clarke1, M. Moorghen1, M. Jansen1, M. Rodriguez-Justo1, S. Leedham1, T. Graham2, A. Hart2
1 Queen Mary University of London, Barts Cancer Institute, London, United Kingdom, 2 St. Mark’s Hospital, Inflammatory Bowel Disease Unit, Harrow, United Kingdom

09:10 - 09:20
23: OP011: Integration of whole exome sequencing and RNA sequencing of intestinal biopsies in Inflammatory Bowel Disease identifies inflammation dependent effects
R. Barbieri1, W. Uniken Venema1, A. Vich Vila1, Y. Li1, L. Franke1, F. van Dijk1, N. De Klein1, M. Swertz1, S. Sanna1, M.D. Voskuil1, M. Rivas2, R. Xavier2, M. Daly2, G. Dijkstra2, E.A. Festen1, R.K. Weersma1
1 UMCG, Groningen, The Netherlands, 2 The Broad Institute of MIT and Harvard, Cambridge, United States

09:20 - 09:40
24: Molecular endoscopy for IBD
Raja Atreya, Erlangen, Germany

OP = Oral presentation – Best abstracts
### Friday, February 16, 2018, cont.

**Scientific programme day by day (as of January 15, 2018)**

**Plenary Hall, Hall D, Messe Wien**

<table>
<thead>
<tr>
<th>Time</th>
<th>Abstract</th>
</tr>
</thead>
</table>
| 09:40 - 09:50 | **25: OP012: IL-23 is centrally involved in mediating molecular resistance to anti-TNF therapy in Crohn’s Disease patients**
|            | **H. Schmitt**\(^1\), U. Billmeier\(^1\), W. Dieterich\(^1\), T. Rath\(^1\), S. Sonnewald\(^1\), S. Reid\(^2\), S. Hirschmann\(^1\), K. Hildner\(^1\), M.J. Waldner\(^1\), J. Mudter\(^1\), A. Hartmann\(^1\), R. Grützmann\(^1\), C. Neufert\(^1\), T. Münster\(^1\), M.F. Neurath\(^1\), R. Atreya\(^1\) |
|            | \(^1\)Friedrich-Alexander-University Erlangen-Nürnberg, First Department of Medicine, Erlangen, Germany, \(^2\)Friedrich-Alexander-University Erlangen-Nürnberg, Department of Biology, Erlangen, Germany, |
| 09:50 - 10:00 | **26: OP013: HLA-DQA1 contributes to the development of antibodies to anti-TNF therapy in Crohn’s Disease**
|            | **A. Sazonovs**\(^1\), N.A. Kennedy\(^2\), C. Bewshe\(^2\), L. Moutsianas\(^1\), G.J. Walker\(^2\), K. De Lange\(^1\), J. Goodhand\(^2\), C. Anderson\(^1\), J. Barrett\(^1\), PANTS Investigator Consortium, T. Ahmad\(^2\) |
|            | \(^1\)Wellcome Trust Sanger Institute, Hinxton, United Kingdom, \(^2\)University of Exeter, IBD Pharmacogenetics, Exeter, United Kingdom |
| 10:00 - 10:10 | **27: OP014: Analysis of 1792 gut metagenomes reveals microbial treatment targets for Inflammatory Bowel Disease and irritable bowel syndrome**
|            | **A. Vich Vila**\(^1\), F. Imhann\(^1\), V. Collij\(^1\), S.A. Jankipersadsing\(^1\), T. Gurry\(^2\), Z. Mujagic\(^1\), A. Kurilshikov\(^1\), M.J. Bonder\(^1\), J. Xiaofang\(^2\), E. Tichelhaar\(^1\), J. Dekens\(^1\), V. Peters\(^1\), M.D. Voskuil\(^1\), M.C. Visschedijk\(^1\), F. Eleonora A.M.\(^1\), G. Dijkstra\(^1\), A.A. Mascal\(^1\), M.H. Hofker\(^1\), R. Xavier\(^1\), E.J. Alm\(^2\), J. Fu\(^1\), C. Wijmenga\(^1\), D.M. Jonkers\(^1\), A. Zhernakova\(^1\), R. Weersma\(^1\) |
|            | \(^1\)University Medical Center Groningen, Groningen, The Netherlands, \(^2\)Massachusetts Institute of Technology, Boston, United States, |
| 10:10 - 10:30 | **28: Integration of “omics” and potential for clinical practice**
|            | **Claudio Fiocchi**, Cleveland, United States |

**10:00 - 12:30**

**Scientific session 5: New opportunities for IBD care and research**

Dominik Bettenworth, Münster, Germany

James Lindsay, London, United Kingdom

#### 11:00 - 12:30

<table>
<thead>
<tr>
<th>Time</th>
<th>Abstract</th>
</tr>
</thead>
</table>
| 11:00 - 11:20 | **29: Remote monitoring**
|            | **Daniel Baumgart**, Berlin, Germany |
| 11:20 - 11:40 | **30: Point of care tests**
|            | **Ann Gils**, Leuven, Belgium |
| 11:40 - 12:00 | **31: Web-based registries**
|            | **Pascal Juillerat**, Bern, Switzerland |

**OP = Oral presentation – Best abstracts**
**Friday, February 16, 2018, cont.**

_Scientific programme day by day (as of January 15, 2018)_

**Plenary Hall, Hall D, Messe Wien**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session/Abstract</th>
</tr>
</thead>
</table>
| 12:00 - 12:10 | **32: OP015:** Biomarker correlation with endoscopic outcomes in patients with Crohn's Disease: Data from CALM  
¹Medical University of Vienna, Vienna, Austria, ²University of Calgary, Calgary, Canada, ³Imelda General Hospital, Bonheiden, Belgium, ⁴AZ Delta Roeselare-Menen, Menen, Belgium, ⁵Presidio Columbus, Fondazione Policlinico Gemelli Università Cattolica, Rome, Italy, ⁶Oxford University Hospitals, Oxford, United Kingdom, ⁷Istituto Clinico Humanitas, Milan, Italy, ⁸University of California San Diego, La Jolla, United States, ⁹Academic Medical Center, Amsterdam, The Netherlands, ¹⁰AbbVie AB, Solna, Sweden, ¹¹AbbVie Inc., North Chicago, United States, ¹²Icahn School of Medicine at Mount Sinai, New York, United States |
| 12:10 - 12:30 | **33:** Can the patient become an investigator?  
Germari Bianchi, Milan, Italy |
| 12:30 - 13:30 | **Break / Guided Poster Session**  
Please refer to page 74 |
Please refer to pages 107-108 |
| 13:30 - 15:00 | **Scientific session 6: Best perioperative management of IBD**  
Yves Panis, Clichy, France  
Walter Reinisch, Vienna, Austria |
| 13:30 - 13:50 | **34:** Get your patient fit for surgery  
Peter Irving, London, United Kingdom  
Paulo Kotze, Curitiba, Brazil; Calgary, Canada |
| 13:50 - 14:00 | **35: OP016:** Need for primary abdominal surgery, but not repeated surgery, has decreased – a nationwide study of temporal trends in Crohn surgery in Sweden 1990-2014  
**D. Kalman**¹, C. Nordenvall², A. Hallqvist Everhov¹, J.F. Ludvigsson¹, M.C. Sachs³, A. Ekbom⁴, O. Olén⁵, P. Myrelid⁶  
¹Division of surgery, Department of Clinical and Experimental Medicine, Faulty of Health Sciences, Linköping University and Department of Surgery, County Council of Östergötland, Linköping, Sweden, ²Dept. of Molecular Medicine and Surgery, Karolinska Institutet; Center for Digestive Disease, Div. of Coloproctology, Karolinska University Hospital, Stockholm, Sweden, ³Department of Clinical Science and Education, Södersjukhuset; Karolinska Institutet; Clinical Epidemiology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden, ⁴Department Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; Department of Pediatrics, Örebro University Hospital, Örebro University, Örebro, Sweden; Division of Epidemiology and Public Health, School of Medicine, University of Nottingham, Nottingham, UK; Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA, Stockholm, Sweden, ⁵Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ⁶Clinical Epidemiology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden, ⁷Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Stockholm, Sweden; Clinical Epidemiology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden; Department of pediatric gastroenterology and nutrition, Sachs’ Children and Youth Hospital, Stockholm, Sweden |

**OP = Oral presentation – Best abstracts**

---

32
### Scientific programme day by day (as of January 15, 2018)

**Plenary Hall, Hall D, Messe Wien (Session 7 & 8)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 14:00 - 14:20 | 36: Enhanced postoperative recovery pathways  
Gionata Fiorino, Milan, Italy  
Antonino Spinelli, Milan, Italy |
| 14:20 - 14:30 | 37: OP017: Transanal minimally-invasive proctectomy with ileal pouch and anastomosis (Ta-IPAA) in patients with Ulcerative Colitis: A cohort study from the TaTME international database  
G. Pellino¹,² K. Sahnan¹,² M. Penna¹,² S. Adegbola¹,² P. Chandrasinghe²,³,⁴, A Spinelli¹,² R. Hompes¹, J. Warusaviærne¹,², on behalf of the International TaTME Registry Collaborative.  
¹Università della Campania, Unit of Colorectal Surgery, Naples, Italy,  
²St Mark’s Hospital, Fistula Research Unit, London, United Kingdom,  
³Imperial College, Department of Surgery and Cancer, London, United Kingdom,  
⁴Oxford University Hospital NHS Trust - Churchill Hospital, Department of Colorectal Surgery, Oxford, United Kingdom,  
⁵Faculty of Medicine, University of Kelaniya, Department of Surgery, Kelaniya, Sri Lanka,  
⁶Humanitas University, Colon and Rectal Surgery Unit, Department of General Surgery, Rozzano, Italy,  
⁷Humanitas University, Humanitas University, Department of Biomedical Sciences, Rozzano, Italy |
| 14:30 - 14:40 | 38: OP018: High-Fat diet and inflammation drive intestinal fibrosis enhancing epithelial-mesenchymal transition through the activation of S1P3 signaling  
C. Mascaraque¹, S. Elangovan², L. Petti¹, A. Piontini², C. Correale¹, V. Arena¹, B. Romano¹, F. Ungaro², V. Garlatti², S. D’Alessio², G. Fiorino¹, A. Spinelli¹,², S. Danese¹,², S. Vetrano²  
¹Humanitas Research Institute, IBD Center Laboratory of Immunology in Gastroenterology, Rozzano, Italy,  
²Humanitas University, Department of Biomedical Sciences, Rozzano, Italy,  
³Catholic University of Rome, Institute of Pathology, Rome, Italy,  
⁴Humanitas Research Institute, Colon and Rectal Surgery, Rozzano, Italy |
| 14:40 - 15:00 | 39: Preventive strategy after resection surgery in CD  
Pierre Michetti, Lausanne, Switzerland |

**OP = Oral presentation – Best abstracts**
**Friday, February 16, 2018, cont.**

*Scientific programme day by day (as of January 15, 2018)*

**Plenary Hall, Hall D, Messe Wien (Session 7 & 8)**

**Parallel Hall, Hall C, Messe Wien (Session 9)**

| 15:30 - 16:10 | **Scientific session 7: ECCO Fellowships and Grants**  
               | (Plenary Hall, Hall D, Messe Wien)  
               | Gerhard Rogler, Zurich, Switzerland  
               | Dino Tarabar, Belgrade, Serbia |
|----------------|--------------------------------------------------------------------------------|
| 15:30 - 15:37 | 40: Outcomes from the ECCO-IOIBD Fellowship 2016  
               | The interleukin-1 pathway as a putative new target in pediatric inflammatory bowel disease  
               | Sharon Veenbergen, Rotterdam, The Netherlands |
| 15:37 - 15:44 | 41: Outcomes from the ECCO-IOIBD Fellowship 2017  
               | Precision Medicine for IBD using advanced machine learning  
               | Aria Zand, Los Angeles, United States |
| 15:44 - 15:50 | 42: Announcement of Fellowships and Grants 2018 |
| 15:50 - 16:00 | 43: OP019: In Faecal Microbiota Transplantation (FMT) for Ulcerative Colitis, fusobacterium is associated with lack of remission, while metabolic shifts to starch degradation and short chain fatty acid production are associated with remission (FOCUS study)  
               | S. Paramsothy\(^1\), M. Kamm\(^1\), S. Nielsen\(^1\), N. Deshpande\(^1\), J. Faith\(^2\), J. Clemente\(^2\), R. Paramsothy\(^2\), A. Walsh\(^6\), J. van den Bogaerde\(^7\), D. Samuel\(^8\), R. Leong\(^8\), S. Connor\(^8\), W. Ng\(^8\), E. Lin\(^9\), M. Wilkins\(^7\), J.-F. Colombel\(^2\), T. Borody\(^7\), H. Mitchell\(^1\), N. Kaakoush\(^1\)  
               | \(^1\)University of New South Wales, Sydney, Australia, \(^2\)Icahn School of Medicine at Mount Sinai, New York, United States, \(^3\)St Vincent’s Hospital, Melbourne, Australia, \(^4\)University of Melbourne, Melbourne, Australia, \(^5\)Liverpool Hospital, Sydney, Australia, \(^6\)St Vincent’s Hospital, Sydney, Australia, \(^7\)Nambour General Hospital, Nambour, Australia, \(^8\)Bankstown-Lidcombe Hospital, Sydney, Australia, \(^9\)Centre for Digestive Diseases, Sydney, Australia |
| 15:50 - 16:00 | 44: OP020: The clinical determinants affect gut microbial profile of Inflammatory Bowel Disease patients  
               | P. Juillerat\(^5\), E. Yilmaz\(^5\), R. Wiest\(^1\), G. Rogler\(^8\), A.J. Macpherson\(^1\)  
               | \(^1\)Clinic for Visceral Surgery and Medicine, Gastroenterology, Bern, Switzerland, \(^2\)University of Bern, Department of Biomedical Research, Bern, Switzerland, \(^3\)University Hospital Zurich, Division of Gastroenterology and Hepatology, Zurich, Switzerland |

**OP** = Oral presentation – Best abstracts
### 16:10 - 17:10

#### Scientific session 8: IBD Horizons
(Plenary Hall, Hall D, Messe Wien)

Filip Baert, Roeselare, Belgium
Gerassimos Mantzaris, Athens, Greece

**45: OP021: Autologous haematopoietic stem cell transplantation for Crohn’s Disease: A retrospective study from the European Society for Blood & Marrow Transplantation (EBMT) Autoimmune Diseases Working Party**


1. Oxford University Hospitals, Department of Haematology, Oxford, United Kingdom
2. Département d’Hématologie Gustave Roussy, Programme de transplantation des cellules souches, Villejuif, France
3. Université Pierre et Marie Curie, Saint Antoine Hospital, EBMT Paris Study Office, Department of Haematology, Paris, France
4. Hospital Clinic of Barcelona, Haematology Department, Barcelona, Spain
5. Hospital Clinic of Barcelona, Gastroenterology Department, Barcelona, Spain
6. University Hospitals Leuven, Department of Haematology, Leuven, Belgium
7. University Hospitals Leuven, Department of Gastroenterology, Leuven, Belgium
8. Medical Faculty and University Hospital Freiburg, Department of Medicine II, Freiburg, Germany
9. University of Freiburg, Department of Gastroenterology, Freiburg, Germany
10. Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, Haematology - BMT Centre, Milan, Spain
11. Luigi Sacco University Hospital, Gastroenterology Unit, Milan, Italy
12. Western General Hospital, University of Edinburgh, Gastro-intestinal Unit, Institute of Genetics and Molecular Medicine, Edinburgh, United Kingdom
13. Guy’s and St Thomas’ NHS Foundation Trust and King’s College Hospital, Department of Haematology, London, United Kingdom
14. Ramon y Cajal Hospital, Gastroenterology and Hepatology Department, Madrid, Spain
15. AP-HP Hôpital Saint-Louis, Centre de Référence des Maladies auto-immunes systémiques Rares d’Ile-de-France (site constitutif), Filière FA12R, Internal Medicine, Autoimmune and Vascular Diseases Unit, UF 04, Paris, France
16. Oxford University Hospitals, Translational Gastroenterology Unit, Oxford, United Kingdom
17. Queen’s Medical Centre, Nottingham Digestive Diseases Centre, School of Clinical Sciences, Nottingham, University of Nottingham
18. Sheffield Teaching Hospitals NHS Foundation Trust, Department of Haematology, Sheffield, United Kingdom

**16:20 - 16:30**

**46: OP022: Rapidity of clinical and laboratory improvements following upadacitinib induction treatment: Data from the CELEST study**


1. University Hospital Schleswig-Holstein, Kiel, Germany
2. University of Lorraine, Nancy, France
3. University of California, San Diego, San Diego, United States
4. University of Michigan, Ann Arbor, United States
5. Presidio Columbus, Fondazione Policlinico Gemelli Università Cattolica, Rome, Italy
6. University of California, San Francisco, Medical Center at Parnassus, San Francisco, United States
7. AbbVie Inc., North Chicago, United States
8. AbbVie Spain S.L.U., Madrid, Spain

---

**OP = Oral presentation – Best abstracts**
Friday, February 16, 2018, cont.

Scientific programme day by day (as of January 15, 2018)

Plenary Hall, Hall D, Messe Wien (Session 7 & 8)
Parallel Hall, Hall C, Messe Wien (Session 9)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:30 - 16:40</td>
<td>OP023</td>
<td>A phase 3b open-label multicentre study (VERSIFY) of the efficacy of vedolizumab on endoscopic healing in Moderately to Severely active Crohn's Disease (CD)</td>
<td>S. Danese, B. Feagan, W. Sandborn, J.-F. Colombel, S. Vermeire, S. Jones, K. Brennan, J. Bornstein</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1Humanities University, IBD Center, Humanitas Clinical and Research Center, Rozzano, Milan, Italy, 2University of Western Ontario, Robarts Clinical Trials, London, Ontario, Canada, 3University of California, Inflammatory Bowel Disease Center, Division of Gastroenterology, San Diego, United States, 4Icahn School of Medicine at Mount Sinai, Department of Gastroenterology, New York, NY, United States, 5University Hospitals Leuven, Département de Gastroenterologie and Hepatologie, Leuven, Belgium, 6Europe Development Centre, Takeda R&amp;D, London, United Kingdom, 7Takeda Pharmaceuticals International Co., Cambridge, MA, United States</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>1Academic Medical Centre, Amsterdam, The Netherlands, 2Medical University of Vienna, Vienna, Austria, 3University of Washington, Seattle, United States, 4Clinic of Gastroenterology and Hepatology, Military Medical Academy, Belgrade, Serbia, 5University Hospital CHU of Liège, Liège, Belgium, 6Nicolaus Copernicus University, Collegium Medicum in Bydgoszcz, Bydgoszcz, Poland, 7Universitätsklinikum Ulm, Ulm, Germany, 8University Hospital Schleswig-Holstein, Christian-Albrechts-University, Kiel, Germany, 9Kangbuk Samsung Hospital, Sungkyunkwan University, Seoul, South Korea, 10Université de Nice Sophia Antipolis, Hôpital de l’Archet, Nice, France, 11Shire, Lexington, United States, 12Pfizer, Cambridge, United States, 13Zymo Consulting Group, Newtown Square, United States, 14University of California San Diego, La Jolla, United States</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>M. Bohm1, S.V. Saqi1, M. Fischer1, S. Kadire1, G. Tran1, M. Rahal1, S. Aniwan1, J. Merves1, A. Weiss1, G. Kochhar1, P. Shashi1, D. Faleck1, A. Winters1, S. Chablaney1, J.L. Kollani-Pace1, B. Bolandi1, S. Singh1, R. Hirten1, E. Shmidt1, K. Lasch1, M. Luo1, D. Hudesman1, S. Chang1, D. Lukin1, K. Sultan1, A. Swaminath1, N. Gupta1, C.A. Siegel1, S. Kane1, E.V. Loftus1, B.E. Sands1, W.J. Sandborn1, J.-F. Colombel1, B. Shen1, P.S. Dulai2</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>1Indiana University, Indianapolis, United States, 2Mayo Clinic, Rochester, United States, 3University of California - San Diego, La Jolla, United States, 4Montefiore Medical Center, New York, United States, 5Cleveland Clinic Foundation, Cleveland, United States, 6Icahn School of Medicine at Mount Sinai, New York, New York, United States, 7Dartmouth-Hitchcock Medical Center, Lebanon, United States, 8Takeda Pharmaceuticals U.S.A., Inc., Deerfield, United States, 9New York University (NYU), New York, United States, 10North Shore University Hospital, Manhasset, United States, 11Lenox Hill Hospital, New York, United States, 12University of Mississippi, Jackson, United States</td>
<td></td>
</tr>
</tbody>
</table>

OP = Oral presentation – Best abstracts
### Scientific Programme

#### 13th Congress of ECCO - Vienna

**Friday, February 16, 2018, cont.**

**Scientific programme day by day (as of January 15, 2018)**

**Plenary Hall, Hall D, Messe Wien (Session 7 & 8)**

**Parallel Hall, Hall C, Messe Wien (Session 9)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
<th>Institutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:00 - 17:10</td>
<td>50: OP026</td>
<td>Comparative effectiveness of vedolizumab and TNF-antagonist therapy in Ulcerative Colitis: A multicentre consortium propensity score-matched analysis</td>
<td>D. Faleck¹, P. Shashi², J. Meserve³, M. Rahal³, S. Kadire³, G. Tran⁴, A. Weiss⁵, A. Winters¹, S. Chablaney¹, S. Aniwan⁶, J.L. Koliangi-Pace⁷, G. Kochhar², B. Boland³, S. Singh¹, R. Hirten¹, E. Shmidt¹, K. Lasch⁴, M. Luo⁸, M. Bohm⁴, S. V. Sagi⁸, M. Fischer⁸, D. Hudesman⁸, S. Chang⁹, D. Lukin¹⁰, K. Sultan¹⁰, A. Swaminathan¹¹, N. Gupta¹², C.A. Siegel¹², B. Shen¹², W.J. Sandborn¹, B.E. Sands¹, J.F. Colombel¹¹, S. Kane⁶, E.V. Loftus⁵, P.S. Dulai³</td>
<td>¹Icahn School of Medicine at Mount Sinai, New York, United States, ²Cleveland Clinic Foundation, Cleveland, United States, ³University of California – San Diego, La Jolla, United States, ⁴Indiana University, Indianapolis, United States, ⁵Montefiore Medical Center, New York, United States, ⁶Mayo Clinic, Rochester, United States, ⁷Dartmouth-Hitchcock Medical Center, Lebanon, United States, ⁸Takeda Pharmaceuticals U.S.A., Inc., Deerfield, United States, ⁹New York University (NYU), New York, United States, ¹⁰North Shore University Hospital, Manhasset, United States, ¹¹Lenox Hill Hospital, New York, United States, ¹²University of Mississippi, Jackson, United States</td>
</tr>
</tbody>
</table>

**OR:**

**Scientific session 9: Basic Science: Evolving concepts of IBD pathogenesis**

(Parallel Hall, Hall C, Messe Wien)

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Authors</th>
<th>Institutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:30 - 16:10</td>
<td>51: Pathogenesis of fistulising IBD</td>
<td>Michael Scharl, Zurich, Switzerland</td>
<td>¹Urinary Medicine Center, Zurich, Switzerland</td>
</tr>
<tr>
<td>15:30 - 15:50</td>
<td>52: OP027: SUCNR1 receptor mediates intestinal fibrosis</td>
<td>J. Cosin-Roger¹², D. Ortiz-Masia¹², D.C. Macias-Ceja¹, L. Gisbert-Ferrandiz², P. Salvador², M. Hausmann³, G. Rogler³, S. Calatayud³, M.D. Barrachina³</td>
<td>¹Fisabio, Hospital Dr Peset, Valencia, Spain, ²University of Valencia, Valencia, Spain, ³University of Zurich, Gastroenterology, Zurich, Switzerland</td>
</tr>
<tr>
<td>15:50 - 16:00</td>
<td>53: OP028: Single cell RNA sequencing of t-cells in Crohn's Disease identifies tissue specific drug targets</td>
<td>E. Festen¹, R. Weersma¹, W.T. Uniken Venema¹, M.D. Voskuil¹, D. Graham²</td>
<td>¹University Medical Center Groningen, Gastroenterology and Hepatology, Groningen, The Netherlands, ²The Broad Institute of MIT and Harvard, Cambridge, United States</td>
</tr>
<tr>
<td>16:00 - 16:10</td>
<td>54: Stress-induced controllers of intestinal inflammatory reactions</td>
<td>Hermona Soreq, Jerusalem, Israel</td>
<td>¹University Medicine Center, Jerusalem, Israel</td>
</tr>
<tr>
<td>16:10 - 16:30</td>
<td>55: OP029: Characterisation of Paneth cell dysfunction in XIAP-deficient mice</td>
<td>M. Yabal¹, A. Wahida¹, B. Popper², K. Steiger³, P. Jost¹</td>
<td>¹Technical University Munich, III. Medizinische Klinik, Munich, Germany, ²Ludwig-Maximilian University of Munich, Department for Cell Biology, Munich, Germany, ³Technical University Munich, Institut for Pathologie, Munich, Germany</td>
</tr>
</tbody>
</table>

**OP** = Oral presentation – Best abstracts
### 56: OP030: Loss of PTPN2 in dendritic cells promotes T cell activation and expression of co-stimulatory molecules

L. Hering¹, C. Gottier¹, S. Lang¹, B. Becher², G. Rogler¹, M. Scharl¹, M. Spalinger¹

¹University Hospital Zurich, Division of Gastroenterology and Hepatology, Zurich, Switzerland, ²University of Zurich, Institute of Experimental Immunology, Zurich, Switzerland

### 57: How the gut speaks to the liver: Novel insights from PSC pathogenesis

Herbert Tilg, Innsbruck, Austria
**Saturday, February 17, 2018**

*Scientific programme day by day (as of January 15, 2018)*

*Plenary Hall, Hall D, Messe Wien*

<table>
<thead>
<tr>
<th>Time</th>
<th>Scientific session 10: Growing up with IBD safely</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30 - 08:50</td>
<td><strong>58: Safe use of drugs in paediatric and elderly populations</strong>&lt;br&gt;Arie Levine, Tel Aviv, Israel&lt;br&gt;Murat Toruner, Ankara, Turkey</td>
</tr>
<tr>
<td>08:50 - 09:00</td>
<td><strong>59: OP031: Clinical effectiveness, safety and immunogenicity of anti-TNF therapy in Crohn’s Disease: 12 month data from the PANTS study</strong>&lt;br&gt;N.A. Kennedy¹, G. Heap¹, B. Hamilton¹, G.J. Walker¹, C. Bewshea¹, S. Bouri¹, J. Goodhand¹, PANTS Investigator Consortium, T. Ahmad¹&lt;br&gt;¹University of Exeter, IBD Pharmacogenetics, Exeter, United Kingdom, ²Abbvie, Chicago, United States, ³St Mark’s Hospital, IBD Unit, London, United Kingdom</td>
</tr>
<tr>
<td>09:00 - 09:10</td>
<td><strong>60: OP032: Outcome of pregnancies in female IBD patients treated with vedolizumab</strong>&lt;br&gt;A. Moens¹, K. van Hoeve¹, E. Humblet², J.-F. Rahier³, P. Bossuyt⁴, S. Dewit⁴, D. Franchimont⁵, E. Macken⁵, J. Nijs⁶, A. Posen⁷, A. Van Hooitgem⁷, W. Van Moerkercke⁷, S. Vermeire¹, M. Ferrante²&lt;br&gt;¹University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium, ²KU Leuven, Department of Chronic Diseases, Metabolism and Ageing, Leuven, Belgium, ³University Hospitals Leuven, Department of Paediatric gastroenterology, Leuven, Belgium, ⁴Ziekenhuis Oost-Limburg-Campus Sint-Jan, Department of Gastroenterology and Hepatology, Genk, Belgium, ⁵CHU UCL Namur, Université catholique de Louvain, Uccle, Belgium, ⁶Imelda ziekenhuis, Department of Gastroenterology and Hepatology, Bonheiden, Belgium, ⁷Mariazienkajus, Department of Gastroenterology and Hepatology, Overpelt, Belgium, ⁸Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium, ⁹University Hospital Antwerp, Department of Gastroenterology and Hepatology, Antwerp, Belgium, ¹⁰Sint-Trudo Ziekenhuis, Department of Gastroenterology and Hematology, Tongeren, Belgium, ¹¹AZ Eversius, Department of Gastroenterology and Hepatology, Tongeren, Belgium, ¹²AZ Kloosterveer, Department of Gastroenterology and Hepatology, Brasschaat, Belgium, ¹³AZ Groeninge, Department of Gastroenterology and Hepatology, Kortrijk, Belgium</td>
</tr>
<tr>
<td>09:10 - 09:30</td>
<td><strong>61: ESPGHAN-ECCO Guidelines: Update on Paediatric UC Treatment</strong>&lt;br&gt;Richard Russell, Glasgow, United Kingdom, Dan Turner, Jerusalem, Israel</td>
</tr>
<tr>
<td>09:30 - 09:40</td>
<td><strong>62: OP033: The effect of tofacitinib on serum lipids and cardiovascular safety in patients with Ulcerative Colitis – results from the tofacitinib Ulcerative Colitis clinical programme</strong>&lt;br&gt;B.E. Sands¹, P.R. Taub², B.G. Feagan³, A. Armuzzi⁴, G.S. Friedman⁵, M. Moscariello⁶, N. Lawendy⁷, R.D. Pedersen⁷, G. Chan⁸, C.I. Nduaka⁹, D. Quirk¹⁰, L. Salese¹¹, C. Su¹²&lt;br&gt;¹Icahn School of Medicine at Mount Sinai, Dr. Henry D. Janowitz Division of Gastroenterology, New York, NY, United States, ²UC San Diego School of Medicine, Division of Cardiovascular Medicine, La Jolla, CA, United States, ³Western University, Robarts Clinical Trials, London, ON, Canada, ⁴Presidio Columbus Fondazione Policlinico Gemelli Università Cattolica, IBD Unit, Rome, Italy, ⁵Phizer Inc, Collegeville, PA, United States</td>
</tr>
</tbody>
</table>

**OP = Oral presentation – Best abstracts**
63: OP034: The initiation of thiopurines in elderly patients with Inflammatory Bowel Disease is associated with an increased risk of adverse effects: A case-control study of the eneida registry


1Hospital Son Llàtzer, Palma, Spain, 2Universitat Autònoma de Barcelona, Barcelona, Spain, 3Hospital Universitari Germans Trías i Pujol, Badalona, Spain, 4CIBERehd Institut de Salud Carlos III, Madrid, Spain, 5Hospital Clínic, Barcelona, Spain, 6Hospital Reina Sofia, Córdoba, Spain, 7Hospital Puerta de Hierro, Majadahonda, Spain, 8Hospital Bellvitge, L’Hospitalet, 9Hospital de Llobregat, Spain, 10Hospital Clínico San Carlos, Madrid, Spain, 11Hospital La Fe, Valencia, Spain, 12Hospital Ramón y Cajal, Madrid, Spain, 13Hospital La Paz, Madrid, Spain, 14Hospital Clínico de Valencia, Valencia, Spain, 15Hospital Universitario Miguel Servet, Zaragoza, Spain, 16Hospital Universitario Central de Asturias, Oviedo, Spain, 17Hospital Clínico Lozano Blesa, Zaragoza, Spain, 18Hospital Parc Taulí, Sabadell, Spain, 19Hospital Santa Creu i Sant Pau, Barcelona, Spain, 20Hospital Universitario Marqués de Valdecilla, Santander, Spain, 21Complejo Hospitalario de Vigo, Vigo, Spain, 22Hospital Virgen de la Macarena, Sevilla, Spain, 23Hospital Universitario de Burgos, Burgos, Spain, 24Hospital Río Hortega, Valladolid, Spain, 25Hospital Mutua de Terrassa, Terrassa, Spain, 26Hospital del mar, Barcelona, Spain, 27Hospital General Universitario de Alicante, Alicante, Spain, 28Hospital Clínico de Málaga, Málaga, Spain, 29Hospital de octubre, Madrid, Spain, 30Hospital Universitario Fundación Alcorcón, Alcorcón, Spain, 31Hospital Dr Josep Trueta, Girona, Spain, 32Hospital General Universitario de Elche, Elche, Spain, 33Hospital General de Ciudad Real, Ciudad Real, Spain, 34Hospital Universitario Fuenlabrada, Fuenlabrada, Spain, 35Hospital Manises, Manises, Spain, 36Consorti sanitari de Terrassa, Terrassa, Spain, 37Hospital Santa Lucía, Cartagena, Spain, 38Hospital Clínico Universitario Valladolid, Valladolid, Spain, 39CH de Navarra, Pamplona, Spain, 40Hospital Universitario de Salamanca, Salamanca, Spain, 41Hospital de Cruces, Barakaldo, Spain, 42Hospital Galdakao, Galdakao, Spain, 43Instituto Biodonostia UPV/EHU, Donostia, Spain, 44Hospital San Jorge, Huesca, Spain, 45Hospital Nuestra Sra Candelaria, Stá Cruz Tenerife, Spain, 46Hospital Mancha Centro, Alcazar de San Juan, Spain, 47Hospital General Universitario de Valencia, Valencia, Spain, 48Hospital Moisés Brogi, St Joan Despi, Spain, 49CH Santiago, Santiago de Compostela, Spain, 50CH de Palencia, Palencia, Spain, 51Hospital Universitario de Canarias, La Laguna, Spain, 52Hospital Torrejón, Torrejón, Spain, 53HG de Castello, Castello, Spain, 54Hospital Sant Joan de Déu-Althaia, Manresa, Spain, 55Hospital General de Tomelloso, Tomelloso, Spain, 56Hospital Basurto, Bilbao, Spain, 57Hospital Viladecans, Viladecans, Spain, 58Hospital Royo Vilanova, Zaragoza, Spain, 59Hospital General, Segovia, Spain, 60Hospital Son Espases, Palma, Spain, 61Hospital Arnau de Vilanova, Lleida, Spain, 62Complejo Hospitalario de Jaén, Jaén, Spain

OP = Oral presentation – Best abstracts
64: **OP035: NUDT15 variants contribute to thiopurine-induced myelosuppression in European populations**

**G. Walker**¹,², J. Harrison³, M. Voskuil⁴, G. Heap¹,², N. Heerasing¹,², P. Hendy¹,², J. Koskela¹⁶, M. Daly¹⁶, H. Sokol¹, D. McGovern⁵, R. Weersma⁶, C. Bewshea¹, M. Weedon³, J. Goodhand¹,², N. Kennedy¹,², T. Ahmad¹,², IBD Pharmacogenetics Study Group

¹University of Exeter, IBD Pharmacogenetics, Exeter, United Kingdom, ²Royal Devon & Exeter NHS Foundation Trust, Department of Gastroenterology, Exeter, United Kingdom, ³University of Exeter, Exeter Medical School Bioinformatics Team, Exeter, United Kingdom, ⁴University Medical Center Groningen, Department of Gastroenterology and Hepatology, Groningen, The Netherlands, ⁵The Broad Institute of MIT and Harvard, Cambridge, United States, ⁶Massachusetts General Hospital, Analytical and Translational Genetics Unit, Boston, United States, ⁷Hôpital Saint-Antoine, Service de Gastroentérologie et Nutrition, Paris, France, ⁸Cedars-Sinai Medical Center, Inflammatory Bowel Disease Center, Division of Gastroenterology, Los Angeles, United States

09:50 - 10:00

65: **Monitoring and improving safety of new agents**

Miguel Regueiro, Pittsburgh, United States

10:00 - 10:20 Coffee break

10:50 - 12:20 Scientific session 11: Colorectal Cancer in IBD

Jessica de Bruyn, Amsterdam, The Netherlands

Mircea Diculescu, Bucharest, Romania

10:50 - 11:10

**66: Molecular basis of dysplasia in IBD – clues for cancer prevention therapies?**

Laurence Egan, Galway, Ireland

11:10 - 11:20

**67: OP036: Long-term risk of advanced neoplasia after colonic low-grade dysplasia in patients with Inflammatory Bowel Disease: A nationwide cohort study**

**M. de Jong**¹, S. van Tilburg¹,², L. Nissen², W. Kievit¹, I. Nagtegaal³, F. Hoentjen¹, L. Derikx²

¹Radboud University Nijmegen Medical Centre, Gastroenterology and Hepatology, Nijmegen, The Netherlands, ²Jeroen Bosch Hospital, Gastroenterology and Hepatology, S Hertogenbosch, The Netherlands, ³Radboud University Nijmegen Medical Centre, Pathology, Nijmegen, The Netherlands

11:20 - 11:40

**68: Serrated lesions in IBD**

Roger Feakins, London, United Kingdom

Maria Pellise, Barcelona, Spain

11:40 - 11:50

**69: OP037: Risk of cancer in Inflammatory Bowel Disease patients is associated with age and recent use of immunomodulators, while biologics and aminosalicylates are protective factors – a cross-sectional and follow-up analysis of the Swiss IBD cohort Study**

**T. Greuter**⁴, S. Scharl⁴, C. Barthel⁴, J.-B. Rossel⁵, L. Biedermann⁴, B. Misselwitz⁵, S. Vavrnicka¹, G. Rogler¹, M. Scharl¹, on behalf of the Swiss IBD Cohort Study Group

¹University Hospital Zurich, Division of Gastroenterology and Hepatology, Zurich, Switzerland, ²University Hospital Lausanne - CHUV, Institute of Social and Preventive Medicine, Lausanne, Switzerland

11:40 - 11:50

**OP = Oral presentation – Best abstracts**
Saturday, February 17, 2018, cont.

Scientific programme day by day (as of January 15, 2018)
Plenary Hall, Hall D, Messe Wien

11:50 - 12:00
70: OP038: Hobit- and Blimp1-driven tissue resident memory T cells critically control chronic intestinal inflammation
S. Zundler\textsuperscript{1}, E. Becker\textsuperscript{1}, M. Spocinska\textsuperscript{1}, L. Parga-Vidal\textsuperscript{2}, R. Stark\textsuperscript{2}, R. Atreya\textsuperscript{1}, T. Rath\textsuperscript{1}, M. Leppkes\textsuperscript{1}, C. Neufert\textsuperscript{1}, I. Atreya\textsuperscript{1}, K. van Gisbergen\textsuperscript{2}, M.F. Neurath\textsuperscript{1}
\textsuperscript{1}University of Erlangen-Nuremberg, Department of Medicine I, Erlangen, Germany, \textsuperscript{2}Academic Medical Center, Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory, Amsterdam, The Netherlands

12:00 - 12:20
71: Endoscopic resection of dysplasia – mucosal and submucosal resection
Raf Bisschops, Leuven, Belgium

12:20 - 12:50
Scientific session 12: ECCO Lecture
Silvio Danese, Milan, Italy
Julían Panés, Barcelona, Spain

12:20 - 12:50
72: Is translation the way to treatment personalisation?
Yehuda Chowers, Haifa, Israel

12:50 - 12:55
73: Awards and closing remarks
Julían Panés, Barcelona, Spain

12:55 - 13:00
74: The ECCO Film

\textbf{OP = Oral presentation – Best abstracts}
Thursday, February 16, 2017
Scientific programme day by day (as of January 16, 2017)
Plenary Hall, Ground level, CCIB

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:45 - 11:15</td>
<td>Top Tips for chairs (closed session)</td>
<td>Laurence Egan, Galway, Ireland</td>
</tr>
<tr>
<td>11:30 - 12:30</td>
<td>Industry sponsored satellite symposia 1a &amp; 1b</td>
<td>Please refer to pages 186-187</td>
</tr>
<tr>
<td>12:45 - 12:50</td>
<td>1: Welcome</td>
<td>Javier Gisbert, Madrid, Spain</td>
</tr>
<tr>
<td>12:50 - 13:00</td>
<td>2: Opening</td>
<td>Julián Panès, Barcelona, Spain</td>
</tr>
<tr>
<td>13:00 - 14:30</td>
<td>Scientific session 1: Pathways of environmental and genetic factors in IBD</td>
<td>Stephan Vavricka, Zurich, Switzerland, Nynne Nyboe Andersen, Copenhagen, Denmark</td>
</tr>
<tr>
<td>13:00 - 13:20</td>
<td>3: Nutrition and food additives</td>
<td>Charlie Lees, Edinburgh, United Kingdom</td>
</tr>
</tbody>
</table>
| 13:20 - 13:30   | 4: OP001: Whole genome sequencing and imputation in Inflammatory Bowel Disease identifies 26 novel loci and offers therapeutically-relevant mechanistic insights | L. Moutsianas1, K. De Lange2, Y. Luo3,4, J. Lee5, L. Jostins6, C. Lamb6, N. Kennedy7, J. Mansfield8, M. Parkes8, J. Barrett9, C. Anderson9, UK Inflammatory Bowel Disease Genetics Consortium9
1 Wellcome Trust Sanger Institute, Human Genetics, Hinxton, Cambridge, United Kingdom, 2 Broad Institute of Harvard and MIT, Program in Medical and Population Genetics, Cambridge, United States, 3 Harvard Medical School, Division of Genetics and Rheumatology, Boston, United States, 4 Addenbrooke’s Hospital, Inflammatory Bowel Disease Research Group, Cambridge, United Kingdom, 5 Wellcome Trust Centre for Human Genetics, Oxford, United Kingdom, 6 Newcastle University, Newcastle upon Tyne, United Kingdom, 7 University of Exeter, Precision Medicine Exeter, Exeter, United Kingdom, 8 University of Newcastle, Human Genetics, Newcastle upon Tyne, United Kingdom, 9 UK IBD Genetics Consortium, Various, United Kingdom |
| 13:30 - 13:50   | 5: Everyday poisons: Smoking, pollution, stress, sedentary lifestyle  | Stephan Vavricka, Zurich, Switzerland           |
| 13:50 - 14:00   | 6: OP002: Epigenetic biomarkers to detect UC associated neoplasia: Results from phase I of the ENDCAP-C study | T. Iqbal1, A. Beggs1, P. Taniere2, Y. Wallis3, S. Mehta4, L. Magill5, J. Deeks6, G. Matthews6, D. Morton1, EndCAP-C Consortium |
1 University of Birmingham, Institute of Cancer & Genomic Sciences, Birmingham, United Kingdom, 2 University Hospital Birmingham NHS Foundation Trust, Birmingham, United Kingdom, 3 West Midlands Regional Genomics Centre, Birmingham, United Kingdom, 4 University of Birmingham, Birmingham Clinical Trials Unit, Birmingham, United Kingdom |

OP = Oral presentation – Best abstracts
### Scientific programme day by day (as of January 16, 2017)

**Plenary Hall, Ground level, CCIB**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 14:00 - 14:10 | **7: OP003: Increased risk of acute arterial events in young patients with severely active Inflammatory Bowel Disease: A nationwide French cohort study**  
J. Kirchgesner, L. Beaugerie, F. Carrat, N. Nyboe Andersen, T. Jess, M. Schwarzinger, For the BERENICE Study Group  
1St. Antoine Hospital, AP-HP, Gastroenterology, Paris, France,  
2INSERM, University Paris 06, UMR S 1136, Paris, France,  
3Hôpital Saint Antoine, Department of Public Health, Paris, France,  
4INSERM, University Paris 06, UMR S 1136, Paris, France,  
5Statens Serum Institute, Department of Epidemiology Research, Copenhagen, Denmark,  
6Frederiksberg Hospital, Institute of Preventive Medicine, Frederiksberg, Denmark,  
7INSERM, UMR 1137, Paris, France,  
8THEN, Translational Health Economics Network, Paris, France |
| 14:10 - 14:30 | **8: Environmental factors as therapy (diet modification, EEN feeding)**  
Pierre Ellul, Sliema, Malta  
Arie Levine, Tel Aviv, Israel |
| 14:30 - 15:00 | Coffee break |
| 15:00 - 16:30 | **Scientific session 2: Evolving therapeutic algorithms in 2017**  
Jane Andrews, Adelaide, Australia  
Jarosław Kierkus, Warsaw, Poland |
| 15:00 - 15:20 | **9: Placing new molecules in the treatment pathway**  
Gerhard Rogler, Zurich, Switzerland |
| 15:20 - 15:30 | **10: OP004: Resetting of the mucosal T cell repertoire after hematopoietic stem cell transplantation in refractory Crohn’s Disease**  
1Hôpital Saint-Louis INSERM, U1160 - Intestinal Immunity in Inflammation and Cancer, Paris, France,  
2IDIBAPS, Hospital Clinic, Gastroenterology, Barcelona, Spain,  
3University of Nottingham, Gastroenterology, Nottingham, United Kingdom,  
4Barts and The London, Queen Mary University of London, Centre for Immunology, The Blizard Institute, London, United Kingdom,  
5University Hospital Zurich, Department of Gastroenterology and Hepatology, Zurich, Swaziland,  
6Western General Hospital, Gastrointestinal Unit, Centre for Genomic and Experimental Medicine, Edinburgh, United Kingdom,  
7Technical University Munich, Department of Nutrition and Immunology, Freising, Germany |
| 15:30 - 15:50 | **11: Maximising the bang for your buck: How to manage IBD on a minimum budget**  
Peter Irving, London, United Kingdom |

**OP = Oral presentation – Best abstracts**

---

**Thursday, February 16, 2017, cont.**

*Scientific programme day by day (as of January 16, 2017)*

*Plenary Hall, Ground level, CCIB*
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Content</th>
</tr>
</thead>
</table>
| 15:50 - 16:00 | 12: **OP005: The PROSIT cohort of infliximab biosimilar in IBD: A prolonged follow-up on the efficacy and safety across Italy**  
1 Complesso Integrato Columbus, Fondazione Policlinico Gemelli Universita' Cattolica, Internal Medicine and Gastroenterology, Rome, Italy  
2 Humanitas Research Hospital and University, Gastroenterology and IBD Center, Rozzano, Italy  
3 Sacro Cuore Don Calabria Hospital, Gastroenterology and Hepatology, Negrar, Italy  
4 AOU Careggi, DEA, Gastroenterology, Florence, Italy  
5 University of Messina, Clinical Unit for Chronic Bowel Disorders, Messina, Italy  
6 Riuniti Villa Sofia - Cervello Hospital, Internal Medicine  
7 University Hospital, Gastroenterology, Palermo, Italy  
8 University Hospital, Gastroenterology, Rome, Italy  
9 Tor Vergata, Gastroenterology, Roma, Italy  
10 University of Padova, Gastroenterology, Padova, Italy  
11 S. Camillo-Forlanini Hospital, Gastroenterology, Rome, Italy  
12 Federico II University, Gastroenterology, Naples, Italy  
13 University Bari, Gastroenterology, Bari, Italy  
14 IRCCS Policlinico, Gastroenterology & Digestive Endoscopy Unit, San Donato, Milano, Italy  
15 University Hospital, Gastroenterology, Modena, Italy  
16 AO Hospital, Gastroenterology and Endoscopy, Legnano, Italy  
17 AUO di Circolo Fondazione Macchi, Gastroenterology, Varese, Italy  
18 AOU Maggiore, Gastroenterology, Novara, Italy  
19 Ospedale Valduce, Gastroenterology, Como, Italy  
20 S. Matteo Hospital Foundation, University of Pavia, First Department of Medicine, Pavia, Italy  
21 ASST Rhodense, Gastroenterology Unit, Rho, Italy  
22 S. Giuseppe Hospital, Gastroenterology, Milan, Italy  
23 Policlinico Lecco, Gastroenterology and Digestive Endoscopy, Brescia, Italy  
24 AUO Maggiore, Gastroenterology, Novara, Italy  
25 Pellegrino Hospital, Gastroenterology, Trani, Italy  
26 Complesso Integrato Columbus - Catholic University, Internal Medicine and Gastroenterology, Rome, Italy  
27 Valiant Clinic, Gastroenterology, Dubai, United Arab Emirates |
| 16:00 - 16:10 | 13: **OP006: Correlation of durability of response, serum trough concentrations and outcome parameters: Long-term follow-up of the Trough Concentration Adapted Infliximab Treatment (TAXIT) trial**  
L. Pouillon, M. Ferrante, G. Van Assche, P. Rutgeerts, M. Noman, N. Vande Casteele, A. Gils, S. Vermeire  
1 University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium  
2 University of California San Diego, Department of Medicine, La Jolla, CA, United States  
3 University of Leuven, Department of Pharmaceutical Sciences, Leuven, Belgium |
| 16:10 - 16:30 | 14: **Personalised medicine: Dream or reality?**  
Iris Dotan, Tel Aviv, Israel |
| 16:30 - 17:30 | 15: **The child with IBD: Should anti-TNF be used as a mono-therapy in children (safety risk)? Who should (be allowed to) operate on the children in IBD?**  
Dan Turner, Jerusalem, Israel |

OP = Oral presentation – Best abstracts
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 16:42 - 16:54 | **16:** Treating the pregnant woman with IBD: Should anti-TNF be stopped during pregnancy? Should vedolizumab be stopped during pregnancy?  
Janneke van der Woude, Rotterdam, The Netherlands |
| 16:54 - 17:06 | **17:** The elderly patient with IBD: Should azathioprine ever be used in the elderly? Should the type of surgery be different in an elderly patient?  
Jean-Frédéric Colombel, New York, United States |
| 17:06 - 17:18 | **18:** The use of IBD medicine in patients with cancer: Which treatment should be stopped when cancer is diagnosed? Which treatment to use in a patient with a prior diagnosis with cancer?  
Laurent Beaugerie, Paris, France |
| 17:18 - 17:30 | **19:** The patient with psychological comorbidities: How to wean off opiates in these patients? Is there any preference in drugs?  
Jane Andrews, Adelaide, Australia |
| 17:45 - 18:45 | **Industry sponsored satellite symposia 2a & 2b**  
Please refer to pages 187 |
| 17:45 - 18:45 | **Digital oral presentations**  
Please refer to page 43-67 |
### Scientific programme day by day (as of January 16, 2017)

**Plenary Hall, Ground level, CCIB**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 07:15 - 08:15 | Industry sponsored satellite symposia 3a & 3b  
Please refer to page 188 |
| 08:30 - 10:30 | **Scientific session 4: Clinical trials versus real life**  
Janneke van der Woude, Rotterdam, The Netherlands  
Pascal Juillerat, Bern, Switzerland |
| 08:30 - 08:50 | 20: **Trial endpoints vs. therapeutic objectives**  
Filip Baert, Roeselare, Belgium |
| 08:50 - 09:00 | 21: **OP007 A multi-centre double blind randomised placebo-controlled study of the use of rectal tacrolimus in the treatment of resistant ulcerative proctitis**  
I.C. Lawrance\(^1\), A. Baird\(^1\), D. Lightowler\(^1\), G. Radford-Smith\(^1\), J.M. Andrews\(^2\), S. Connor\(^2\)  
\(^1\)University of Western Australia, Medicine and Pharmacology, Perth, Australia, \(^2\)Saint John of God Hospital, Centre for Inflammatory Bowel Diseases, Subiaco, Australia |
| 09:00 - 09:10 | 22: **OP008: An innovative treatment for refractory perianal fistulas in Crohn's Disease: Local micro reinjection of autologous fat and adipose derived stromal vascular fraction (ClinicalTrials.gov NCT02520843, Eudract: 2013-002602-31)**  
M. Serrero\(^1\), C. Philandrianos\(^2\), C. Visee\(^3\), J. Veran\(^2\), P. Orsoni\(^3\), F. Sabatier\(^3\), J.C. Grimaud\(^1\)  
\(^1\)Hopital Nord, Gastroenterology, Marseille, France, \(^2\)Aix-Marseille, Marseille, France, \(^3\)Hopital Nord, Visceral Surgery, Marseille, France |
| 09:10 - 09:20 | 23: **OP009: Long-term efficacy and safety of Cx601, allogeneic expanded adipose-derived mesenchymal stem cells, for complex perianal fistulas in Crohn's Disease: 52-week results of a phase III randomised controlled trial**  
J. Panes\(^1\), D. García-Olmo\(^1\), G. Van Assche\(^1\), J.F. Colombel\(^1\), W. Reinisch\(^1\), D.C. Baumgart\(^1\), M. Nachury\(^1\), M. Ferrante\(^1\), L. Kazemi-Shirazi\(^1\), J.C. Grimaud\(^1\), F. de la Portilla\(^1\), É. Goldin\(^1\), M.P. Richard\(^1\), M.C. Diez\(^1\), S. Danese\(^1\)  
\(^1\)Hospital Clinic de Barcelona, Dept of Gastroenterology, Barcelona, Spain, \(^2\)Hospital U. Fundación Jiménez-Díaz, Madrid, Spain, \(^3\)University Hospitals Leuven, KU Leuven, Leuven, Belgium, \(^4\)Icahn School of Medicine at Mount Sinai, New York, United States, \(^5\)Medical University of Vienna, Vienna, Austria, \(^6\)Charité Medical School - Humboldt-University of Berlin, Berlin, Germany, \(^7\)CHU Lille, Lille, France, \(^8\)Hopital Nord, Marseille, France, \(^9\)Hospital Virgen del Rocío, Sevilla, Spain, \(^10\)Sharée Zedek, MC, Jerusalem, Israel, \(^11\)TiGenix, Madrid, Spain, \(^12\)Istituto Clinico Humanitas, Milano, Italy |
| 09:20 - 09:40 | 24: **The long-term efficacy outside clinical trials**  
Stefan Schreiber, Kiel, Germany |

**OP** = Oral presentation – Best abstracts
**Scientific programme day by day (as of January 16, 2017)**

**Plenary Hall, Ground level, CCIB**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:40 - 09:50</td>
<td>25: OP010</td>
<td>Long term efficacy and safety of Ustekinumab for Crohn’s Disease: Results from IM-UNITI long-term extension through 2 years</td>
<td>W. Sandborn¹, P. Rutgeerts², C. Gasink³, D. Jacobstein¹, L-L. Gao⁴, J. Johanns¹, B. Sands⁵, S.B. Hanauer⁶, S. Targan⁶, S. Ghosh⁷, D.V. Willem J.S.⁸, J-F. Colombel¹ B.G. Feagan⁹ ¹University of California San Diego, La Jolla, United States, ²University Hospital, Gasthuisberg, Leuven, Belgium, ³Janssen Research &amp; Development, LLC, Spring House, United States, ⁴Icahn School of Medicine at Mt Sinai, New York, United States, ⁵Northwestern University Feinberg School of Medicine, Chicago, United States, ⁶Cedars-Sinai Medical Center, Los Angeles, United States, ⁷University of Birmingham, Birmingham, United Kingdom, ⁸University of Stellenbosch, Stellenbosch, South Africa, ⁹Robarts Clinical Trials, Robarts Research Institute, Western University, London, Ontario, Canada</td>
</tr>
<tr>
<td>09:50 - 10:00</td>
<td>26: OP011</td>
<td>Etrolizumab treatment leads to early improvement in symptoms and inflammatory biomarkers in anti-TNF-refractory patients in the open-label induction cohort of the phase 3 HICKORY study</td>
<td>L. Peyrin-Biroulet¹, B.G. Feagan², J. Mansfield³, D.T. Rubin⁴, U. Arulmani⁵, R. Maciuca⁶, H. Tyrrell⁶, J. Thommes⁷, S. Tole⁷ ¹Université de Lorraine, Vandœuvre-lès-Nancy, France, ²University of Western Ontario, London, Canada, ³Newcastle University, Newcastle upon Tyne, United Kingdom, ⁴University of Chicago Medicine, Chicago, United States, ⁵Genentech, South San Francisco, United States, ⁶Roche, Welwyn Garden City, United Kingdom</td>
</tr>
<tr>
<td>10:00 - 10:10</td>
<td>27: OP012</td>
<td>Perioperative use of vedolizumab is not associated with short-term postoperative infectious complications in patients with Ulcerative Colitis undergoing (procto)colectomy with ileal pouch-anal anastomosis</td>
<td>M. Ferrante¹, N. Schils¹, A. de Buck van Overstraeten¹, S. Vermeire¹, G. Van Assche¹, A. Wolthuis¹, A. D’Hoore¹ ¹University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium, ²University Hospitals Leuven, Department of Abdominal Surgery, Leuven, Belgium</td>
</tr>
<tr>
<td>10:10 - 10:30</td>
<td>28: The long-term safety outside clinical trials</td>
<td>Gert van Assche, Leuven, Belgium</td>
<td></td>
</tr>
<tr>
<td>10:30 - 11:00</td>
<td>科学休息</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00 - 12:30</td>
<td>Scientific session 5: Managing bowel damage in IBD: Surgical or medical treatment?</td>
<td>Antonio Spinelli, Milan, Italy Edyta Zagórowicz, Warsaw, Poland</td>
<td></td>
</tr>
<tr>
<td>11:00 - 11:20</td>
<td>29: Are we truly changing disease course with current strategies?</td>
<td>Yves Panis, Clichy, France</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td></td>
<td></td>
</tr>
<tr>
<td>--------------</td>
<td>--------------------------------------------------------------------------</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| 11:20 - 11:30| **30:** OP013: Disease management and outcomes of patients with Crohn’s Disease at high risk of recurrence. Results from PRACTICROHN study  
M. Iborra⁴, M.D. Martín Arranz⁵, E. Domènech⁶, V. García⁶, A. Gutiérrez⁶,  
M. Barreiro-de Acosta⁶, L. Cea-Calvo⁶, C. Romero⁶, B. Juliá⁶  
¹Servicio de Gastroenterología, Hospital La Fe, Valencia, Spain,  
²Hospital Universitario La Paz, Gastroenterology Unit, Madrid, Spain,  
³Hospital Universitario Germans Trias i Pujol and CIBERehd, Gastroenterology Unit, Badalona, Spain,  
⁴Hospital Universitari Germans Trias de Pujol and CIBERehd, Digestive Surgery Unit, Badalona, Spain,  
⁵Hospital General Universitario Alicante, Gastroenterology unit, Alicante, Spain,  
⁶Complejo Hospitalario Universitario de Santiago, Gastroenterology Unit, Santiago de Compostela, Spain,  
⁷MSD Spain, Medical Department, Madrid, Spain |
| 11:30 - 11:50| **31:** Combined approach for intestinal sparing in CD?  
Paulo Kotze, Curitiba, Brazil |
| 11:50 - 12:00| **32:** OP014: Histological remission is predictive of improved clinical outcomes in patients with Ulcerative Colitis: Results from the TOUCHSTONE OLE  
W. Sandborn¹, B. Feagan², G. D’Haens³, B. Levesque³, R. Pai³, S. Hanauer³,  
D. Wolf³, S. Vermeire³, S. Ghosh³, C. Li³, D. Penenberg³, R. Aranda³, A. Olson³  
¹University of California San Diego, San Diego, United States,  
²Robarts Research, London, Canada,  
³Academic Medical Center, Amsterdam, Netherlands,  
⁴Mayo Clinic, Department of Laboratory Medicine and Pathology, Scottsdale, United States,  
⁵Feinberg School of Medicine, Chicago, United States,  
⁶Atlanta Gastroenterology Associates, Atlanta, United States,  
⁷University of Leuven, Leuven, Belgium,  
⁸University of Calgary, Calgary, Canada,  
⁹Receptos, a wholly owned subsidiary of Celgene, San Diego, United States |
| 12:00 - 12:10| **33:** OP015: Cost-effectiveness of laparoscopic ileocecal resection versus infliximab treatment of terminal ileitis in Crohn’s Disease: THE LIRIC TRIAL  
J. de Groof¹,², W. Bemelman¹, E. Eshuis¹, T. Gardenbroek¹, P. Bossuyt¹, J. Bosmans¹, H. van Dongen¹, B. van Wagensveld¹, M. Brink¹, E. Consten¹,  
C. Buskens¹, G. D’Haens³, P. Stokkers³, P. Ponsioen³, LIRIC study group  
¹Academic Medical Center, Surgery, Amsterdam, Netherlands,  
²Academic Medical Center, Gastroenterology, Amsterdam, Netherlands,  
³Academic Medical Center, Epidemiology, Amsterdam, Netherlands,  
⁴VU, Health Sciences, Amsterdam, Netherlands,  
⁵OLVG West, Surgery, Amsterdam, Netherlands,  
⁶Meander Medical Center, Gastroenterology, Amersfoort, Netherlands,  
⁷Meander Medical Center, Surgery, Amersfoort, Netherlands,  
⁸OLVG West, Gastroenterology, Amsterdam, Netherlands |
| 12:10 - 12:30| **34:** The ileorectal anastomosis in UC: Time for a comeback?  
Oded Zmora, Tel Aviv, Israel |
| **12:30 - 13:00** | **Lunch & Guided Poster Session**  
Please refer to page 40 |
| **12:40 - 13:20** | **Educational Lunchtime Satellite Symposia**  
Please refer to pages 188-189 |

**OP = Oral presentation – Best abstracts**
**Friday, February 17, 2017, cont.**

*Scientific programme day by day (as of January 16, 2017)*

**Plenary Hall, Ground level, CCIB**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 13:30 - 15:00 | **Scientific session 6: Intestinal inflammation - not always IBD**  
Chairs: Eugeni Domènech, Badalona, Spain  
Dror Shouval, Tel Aviv, Israel  
Epidemiologist – Vito Annese, Florence, Italy  
Basic Science – Britta Siegmund, Berlin, Germany  
Pathologist – Roger Feakins, London, United Kingdom  
Physician – James Lindsay, London, United Kingdom  

13:30 - 13:50  
**35: Microscopic colitis**  
Carousel  

13:50 - 14:00  
**36: OP016: Potential role of bile acid receptor FXR in microscopic colitis**  
_C. Palmela_¹, J. Torres¹, P. Gomes de Sena², M.P. Costa Santos¹, C. Gouveia¹, M.H. Oliveira², C. M. P. Rodrigues¹, M. Cravo¹, P. Borracho²  
¹Hospital Beatriz Ângelo, Gastroenterology Department, Loures, Portugal  
²Hospital Beatriz Ângelo, Pathology Department, Loures, Portugal  
³Faculty of Pharmacy, Universidade de Lisboa, Research Institute for Medicines, Lisboa, Portugal  
⁴Hospital Cuf Descobertas, Pathology Department, Lisboa, Portugal  
⁵Universidade de Lisboa, Faculty of Medicine, Lisboa, Portugal  

14:00 - 14:20  
**37: IBDU**  
Carousel  

14:20 - 14:30  
**38: OP017: Telemedicine enables a safe shift from examination room based care to personalised care for Inflammatory Bowel Disease: A pragmatic randomised multicenter trial with myIBDcoach**  
_M. de Jong_¹,², A. van der Meulen-de Jong¹, M. Romberg-Camps³, M. Becx⁴, M. Cilissen¹, J. Maljaars¹, A. van Bodegraven⁵, N. Mahmood⁶, T. Markus⁶, W. Hameeteman¹, G. Dijkstra¹, A. Masclée¹,², A. Boonen⁶,⁷, D. Jonkers¹,², A. van Tubergen⁶,⁷, M. Pierik¹,²  
¹Maastricht University Medical Center (MUMC), Department of Internal Medicine, Division of Gastroenterology and Hepatology, Maastricht, Netherlands  
²Maastricht University Medical Center (MUMC), NUTRIM – School for Nutrition and Translational Research in Metabolism, Maastricht, Netherlands  
³Leiden University Medical Centre, Department of Gastroenterology and Hepatology, Leiden, Netherlands  
⁴Zeuyderland Medical Centre, Department of Gastroenterology and Hepatology, Sittard-Geleen, Netherlands  
⁵St. Antonius Hospital, Department of Gastroenterology and Hepatology, Nieuwegein, Netherlands  
⁶CCUVN, Woerden, Netherlands  
⁷St. Antonius Hospital, Department of Gastroenterology and Hepatology, Groningen, Netherlands  
⁸Maastricht University Medical Center (MUMC), Department of Internal Medicine, Division of Rheumatology, Maastricht, Netherlands  
⁹Maastricht University Medical Center (MUMC), CAPHRI - School for Public Health and Primary Care, Maastricht, Netherlands  

14:30 - 14:40  
**39: OP018: Optimal anti-TNF stop week during pregnancy depends on anti-TNF type**  
_S. Kanis_, A. de Lima, C. van der Woude  
Erasmus University Medical Center, Gastroenterology and Hepatology, Rotterdam, Netherlands  

14:40 - 15:00  
**40: Eosinophilic enteritis**  
Carousel

**OP** = Oral presentation – Best abstracts
**Scientific programme day by day (as of January 16, 2017)**

**Plenary Hall, Ground level, CCIB (Scientific sessions 7 & 8)**

**Room 111, Level 1, CCIB (Scientific session 9)**

**Either:**

**Scientific session 7: ECCO Fellowships and Grants**

Britta Siegmund, Berlin, Germany
Gionata Florino, Milan, Italy
Plenary Hall, Ground level, CCIB

<table>
<thead>
<tr>
<th>15:00 - 15:40</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>41:</strong> Outcomes from the 2015-2016 Fellowships: Post-genomic application in general, and the establishment of computational approaches relevant to translational medicine</td>
</tr>
<tr>
<td>Ferdinando Bonfiglio, Stockholm, Sweden</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>15:00 - 15:07</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>42:</strong> Outcomes from the 2015-2016 Fellowships: Hypoxia, autophagy and inflammasome</td>
</tr>
<tr>
<td>Jesús Cosín, Valencia, Spain</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>15:14 - 15:20</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>43:</strong> Announcement of ECCO Fellowships &amp; Grants 2017</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>15:20 - 15:30</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>44:</strong> OP019: Correlation of clinical and endoscopic outcomes in patients with active Crohn's Disease treated with mongersen (GED-0301)</td>
</tr>
<tr>
<td>B. Feagan(^1), J.-F. Colombel(^2), G. Rossiter(^3), X. Li(^4), K. Usiskin(^5), X. Zhan(^5), B. Sands(^2)</td>
</tr>
<tr>
<td>(^1)Robarts Clinical Trials and University of Western Ontario, London, Canada, (^2)Icahn School of Medicine at Mount Sinai, New York, United States, (^3)Celgene Corporation, Summit, United States</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>15:30 - 15:40</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>45:</strong> OP020: Recent anti-TNF exposure predicts lower vedolizumab trough concentrations in patients with Crohn Disease</td>
</tr>
<tr>
<td>A. Gils(^1), E. Dreesen(^1), G. Compernolle(^1), M. Peeters(^1), E. Brouwers(^1), S. Tops(^1), V. Ballet(^2), M. Noman(^2), M. Ferrante(^2), G. Van Assche(^2), S. Vermeire(^2)</td>
</tr>
<tr>
<td>(^1)KU Leuven, P.O. Box 820 Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium, (^2)UZ Leuven, Campus Gasthuisberg, Department of Gastroenterology and Hepatology, Leuven, Belgium</td>
</tr>
</tbody>
</table>

**Scientific session 8: IBD Horizons**

Bruce Sands, New York, United States
Herbert Tilg, Innsbruck, Austria
Plenary Hall, Ground level, CCIB

<table>
<thead>
<tr>
<th>16:10 - 17:10</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>46:</strong> OP021: Hyperbaric oxygen therapy is safe and effective for hospitalised Ulcerative Colitis patients suffering from moderate-severe flares: A multi-center, randomised, double-blind, sham-controlled trial</td>
</tr>
<tr>
<td>P. Dulai(^1,2), J. Buckey Jr.(^3), L. Raffals(^3), J. Swoger(^3), P. Claus(^1), K. O'Toole(^4), J. Ptak(^2), M. Gleeson(^2), C. Widjaja(^1), J. Adler(^2), N. Patel(^2), L. Skinner(^2), S. Haren(^2), K. Goldby-Reffner(^2), K. Thompson(^2), R. Knight(^1), J. Chang(^1), C. Siegel(^2)</td>
</tr>
<tr>
<td>(^1)University of California San Diego, La Jolla, CA, United States, (^2)Dartmouth Hitchcock Medical Center, Lebanon, NH, United States, (^3)Mayo Clinic, Rochester, MN, United States, (^4)University of Pittsburgh Medical Center, Pittsburgh, PA, United States</td>
</tr>
</tbody>
</table>

OP = Oral presentation – Best abstracts
### OP022: Proximity extension assay based proteins show immune cell specificity and can diagnose and predict outcomes in Inflammatory Bowel Diseases: IBD Character study


1. University of Edinburgh, Gastroenterology, Edinburgh, United Kingdom
2. Akershus University Hospital, Department of Gastroenterology, Faculty of Medicine and Health, Akershus, Norway
3. Örebro University, Department of Gastroenterology, Linköping, Sweden
4. University of Oslo, Institute of clinical Medicine, Oslo, Norway
5. Uppsala University, Department of Gastroenterology and Hepatology, Uppsala, Sweden
6. IBD Character Consortium, Edinburgh, United Kingdom
7. Linköping University, Gastroenterology, Linköping, Sweden
8. Maastricht University Medical Center (MUMC), Department of Gastroenterology and Hepatology, Maastricht, Netherlands
9. Karolinska Institutet, Department of Clinical Science, Intervention and Technology, Karolinska, Sweden
10. HCU “Lozano Blesa”, IIS Aragon, CIBEREHD, Zaragoza, Spain

### OP023: Maintenance of clinical effect in patients with Moderate-to-Severe Crohn’s Disease treated with filgotinib, a selective JAK1 inhibitor: Exploratory 20-week data analysis of the Phase 2 FITZROY study


1. University Hospitals Leuven, Department of Gastroenterology, Leuven, Belgium
2. University Medical Center Schleswig-Holstein Kiel, Department of Internal Medicine, Kiel, Germany
3. Vivamed, Warsaw, Poland
4. Asklepios Hospital West Hamburg, Department of Gastroenterology, Hamburg, Germany
5. CHU Nice Hospital I’Archet, Department of Gastroenterology and Nutrition, Nice Cedex 3, France
6. North Hospital, Department of Gastroenterology, Saint Priez en Jarez, France
7. NC University in Torun, Collegium Medicum, Bydgoszcz, Poland
8. Dr. Goldis Center for Gastroenterology, Timisoara, Romania
9. Santa LLC, Santa Familia Research, Prevention and Treatment Centre, Lodz, Poland
10. City Clinical Hospital #31, St. Petersburg, Russian Federation
11. Szent Margit Hospital, Budapest, Hungary
12. PSI Pharma Support EOUD, Sofia, Bulgaria
13. Galapagos NV, Mechelen, Belgium

### OP024: Childhood-Onset Inflammatory Bowel Disease and risk of cancer – a Swedish nationwide cohort study 1964-2014


1. Karolinska Institutet, Department of Medicine Solna, Clinical Epidemiology Unit, Stockholm, Sweden
2. Sachs’ Children’s Hospital, Department of Pediatric Gastroenterology and Nutrition, Stockholm, Sweden
3. Karolinska Institutet, Institute of Environmental Medicine, Stockholm, Sweden
4. Karolinska Institutet, Department of Medical Epidemiology and Biostatistics, Stockholm, Sweden
5. Orebro University Hospital, Department of pediatrics, Orebro, Sweden
6. University of Nottingham, Division of Epidemiology and Public Health, School of Medicine, Nottingham, United Kingdom
7. Columbia University College of Physicians and Surgeons, Department of Medicine, New York, Sweden

**OP = Oral presentation – Best abstracts**
### Scientific session 9: Basic Science meets the clinic

**Arthur Kaser**, Cambridge, United Kingdom  
**Azucena Salas**, Barcelona, Spain

**Room 111, Level 1, CCIB**

<table>
<thead>
<tr>
<th>Time</th>
<th>Presentation</th>
</tr>
</thead>
</table>
| 15:00 - 15:20 | **52: IL-23 and beyond**  
Fiona Powrie, Oxford, United Kingdom                                                                 |
| 15:20 - 15:30 | **53: OP027: IL-33/ST2 axis sustains gut mucosal wound healing and cancerogenesis in Colitis-associated colorectal cancer**  
L.R. Lopetuso\(^1,2\), C. De Salvo\(^3\), L. Di Martino\(^3\), W. Goodman\(^4\), F. Scaldaferr\(i\)\(^4\), A. Gasbarrini\(^5\), T.T. Pizarro\(^6\)  
\(^1\)Catholic University of the Sacred Heart, Internal Medicine, Gastroenterology Division, Rome, Italy,  
\(^2\)Case Western Reserve University, Pathology, Cleveland, United States,  
\(^3\)Case Western Reserve University, Pathology, Cleveland, United States,  
\(^4\)Catholic University of Sacred Heart, Internal Medicine Department, Gastroenterology Division, Rome, Italy |
| 15:30 - 15:40 | **54: OP028: Gut specific regulatory T cells – a new frontier for Crohn’s Disease therapy**  
R. Goldberg\(^1,2,3,4\), C. Scotta\(^4,5\), D. Cooper\(^6\), E. Eliraz\(^7\), E. Nir\(^7\), P. Irving\(^1,8\), J. Sanderson\(^1,4\), N. Shipigel\(^7\), F. Marelli-Berg\(^7\), G. Lombardi\(^12,3,4\), G. Lord\(^12,3,4\)  
\(^1\)Guy’s and St Thomas’ NHS Trust, Gastroenterology, London, United Kingdom,  
\(^2\)King’s College London, Experimental Immunobiology, London, United Kingdom,  
\(^3\)King’s College London, Medical Research Council Centre for Transplantation, London, United Kingdom,  
\(^4\)Guy’s and St Thomas’ NHS Trust, National Institute for Health Research Biomedical Research Centre, London, United Kingdom,  
\(^5\)King’s College London, Immunoregulation and Immune Intervention, London, United Kingdom,  
\(^6\)Barts and the London Queen Mary School of Medicine and Dentistry, William Harvey Research Institute, London, United Kingdom,  
\(^7\)Hebrew University of Jerusalem, Koret School of Veterinary Medicine, Rehovot, Israel,  
\(^8\)King’s College London, Diabetes and Nutritional Sciences, London, United Kingdom |
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:40 - 16:10</td>
<td>Coffee break</td>
<td></td>
</tr>
<tr>
<td>16:10 - 16:30</td>
<td><strong>55: Genetics and function in IBD: The missing link?</strong></td>
<td>Sebastian Zeissig, Dresden, Germany</td>
</tr>
<tr>
<td></td>
<td><strong>56: OP029: Hypoacetylation of histone-3 is a hallmark of intestinal fibrosis in Crohn’s Disease</strong></td>
<td>A. Lewis¹, C. Felice¹, A. Nihjuis¹, S. Iqbal¹, S. Mehta¹, R. Feakins¹, A. Armuzzi¹, A. Silver¹, J. Lindsay¹</td>
</tr>
<tr>
<td>16:30 - 16:40</td>
<td>¹Queen Mary’s University London, Centre for Genomics and Child Health, Blizard Institute, London, United Kingdom, ²Gemelli Hospital Catholic University Foundation, IBD Unit, Presídio Columbus, Rome, Italy, ³The Royal London Hospital, Department of pathology, London, United Kingdom, ⁴Queen Mary’s University</td>
<td></td>
</tr>
<tr>
<td>16:40 - 16:50</td>
<td><strong>57: OP030: Identification of disease-relevant bacterial signatures in gnotobiotic IL-10 deficient mice using fecal samples from IBD patients undergoing hematopoietic stem cell transplantation</strong></td>
<td>A. Metwaly¹, L. F. Buttó¹, N. Waldschmitt¹, I. Lagkouvardos², A.M. Corraliza³, A. Mayorgas³, M. Martinez-Medina³, M. Állez³, J. Panes³, A. Salas³, D. Haller¹²</td>
</tr>
<tr>
<td>16:50 - 17:10</td>
<td><strong>58: Epigenetics in complex diseases</strong></td>
<td>Manel Esteller, Barcelona, Spain</td>
</tr>
</tbody>
</table>

**OP** = Oral presentation – Best abstracts
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:15 - 08:15</td>
<td>Industry sponsored satellite symposia 5a &amp; 5b</td>
</tr>
<tr>
<td>08:30 - 10:20</td>
<td>Scientific session 10: New compounds in the treatment of IBD</td>
</tr>
</tbody>
</table>

**59: JAK-inhibitors**
Séverine Vermeire, Leuven, Belgium

**60: OP031: Long-term safety and tolerability of oral tofacitinib in patients with Crohn's Disease: Results from a phase 2 open-label 48-week extension study**
1Hospital Clinic de Barcelona, IDIBAPS, CIBERheD, Barcelona, Spain,
2Department of Gastroenterology, Academic Medical Centre, Amsterdam, Netherlands, 3University of Michigan, Ann Arbor, MI, United States, 4Pfizer Inc, Collegeville, PA, United States

**61: OP032: Efficacy and safety of oral tofacitinib as maintenance therapy in patients with Moderate to Severe Ulcerative Colitis: Results from a phase 3 randomised controlled trial**

**62: OP033: Reduction of tissue pSTAT3 in Crohn's Disease patients treated with filgotinib (GLPG0634, GS-6034), a JAK1-selective inhibitor**

**63: S1P modulators**
Arthur Kaser, Cambridge, United Kingdom
### Scientific programme day by day (as of January 16, 2017)

**Plenary Hall, Ground level, CCIB**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00 - 10:20</td>
<td>66: Anti IL12/IL23 compounds</td>
<td>Bruce Sands, New York, United States</td>
</tr>
<tr>
<td>10:20 - 10:50</td>
<td>Coffee break</td>
<td>Bruce Sands, New York, United States</td>
</tr>
<tr>
<td>10:50 - 12:20</td>
<td>Scientific session 11: Gut luminal content – more than just bacteria</td>
<td>Isabelle Cleynen, Leuven, Belgium, Miquel Gassull, Barcelona, Spain</td>
</tr>
<tr>
<td>10:50 - 11:10</td>
<td>67: The forgotten populations in the gut</td>
<td>Patricia Lepage, Jouy-En-Josas, France</td>
</tr>
<tr>
<td>11:20 - 11:40</td>
<td>69: Metabolic activity</td>
<td>Dirk Haller, Freising, Germany</td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td>Details</td>
</tr>
<tr>
<td>--------</td>
<td>--------------------------------------------</td>
<td>-------------------------------------------------------------------------</td>
</tr>
<tr>
<td>11:40</td>
<td>70: OP037: Infants born to mothers with Inflammatory Bowel Disease exhibit distinct microbiome features that persist up to 3 months of life</td>
<td><strong>J. Torres</strong>, J. Hu, C. Eisele, N. Nair, H. Panchal, X. Bao, X. Niu, J. Coté-Daigneault, B. Jharap, E. Maser, A. Kornbluth, P. Legnani, J. George, M. Dubinsky, J. Stone, C.-L. Chen, J. Clemente, J.-F. Colombel, I. Peter. Icahn School of Medicine at Mount Sinai, Gastroenterology, New York, United States, Icahn School of Medicine at Mount Sinai, Genetics and Genomic Sciences, New York, United States, Icahn School of Medicine at Mount Sinai, Department of Pediatrics, New York, United States, Icahn School of Medicine at Mount Sinai, Obstetrics, Gynecology and Reproductive Science, New York, United States, Icahn School of Medicine at Mount Sinai, Immunology, New York, United States.</td>
</tr>
<tr>
<td>12:00</td>
<td>72: Microbiome reality check – looking beyond the hype</td>
<td>Jeroen Raes, Ghent, Belgium.</td>
</tr>
<tr>
<td>12:20</td>
<td>Scientific session 12: ECCO Lecture</td>
<td><strong>Julián Panés</strong>, Barcelona, Spain, <strong>Silvio Danese</strong>, Milan, Italy.</td>
</tr>
<tr>
<td>12:20</td>
<td>73: Best individualised IBD care – optimising drugs, psychology, diet and microbes</td>
<td>Michael Kamm, Melbourne, Australia.</td>
</tr>
<tr>
<td>12:55</td>
<td>75: The ECCO Film</td>
<td></td>
</tr>
</tbody>
</table>
**Thursday, March 17, 2016**

*Scientific programme day by day (as of February 15, 2016)*

**Plenary Hall (Hall 11), Level 1, RAI Amsterdam**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:45 - 11:15</td>
<td><strong>Top tips for chairs (closed session)</strong> &lt;br&gt; Laurence Egan, Galway, Ireland</td>
</tr>
<tr>
<td>11:30 - 12:30</td>
<td><strong>Industry sponsored satellite symposia 1a &amp; 1b</strong>&lt;br&gt;Please refer to pages 188-189</td>
</tr>
<tr>
<td>12:45 - 12:50</td>
<td>1: <strong>Welcome</strong> &lt;br&gt; Janneke van der Woude, Rotterdam, The Netherlands &lt;br&gt; Bas Oldenburg, Utrecht, The Netherlands</td>
</tr>
<tr>
<td>12:50 - 13:00</td>
<td>2: <strong>Opening</strong> &lt;br&gt; Séverine Vermeire, Leuven, Belgium</td>
</tr>
<tr>
<td>13:00 - 14:30</td>
<td><strong>Scientific session 1: Cell therapy: Ready for clinical practice?</strong> &lt;br&gt; Pierre Desreumaux, Lille, France &lt;br&gt; Dominik Bettenworth, Munster, Germany</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:00 - 13:20</td>
<td>3: <strong>Haematopoietic stem cell transplantation</strong> &lt;br&gt; Azucena Salas, Barcelona, Spain &lt;br&gt; Elena Ricart, Barcelona, Spain</td>
</tr>
<tr>
<td>13:30 - 13:50</td>
<td>5: <strong>Immune cell manipulation</strong> &lt;br&gt; Graham Lord, London, United Kingdom &lt;br&gt; Matthieu Allez, Paris, France</td>
</tr>
</tbody>
</table>

¹Hospital Clinic Barcelona, Barcelona, Spain, ²Hospital U. Fundación Jiménez-Díaz, Madrid, Spain, ³University Hospitals Leuven, KU Leuven, Leuven, Belgium, ⁴Icahn School of Medicine at Mount Sinai, New York, United States, ⁵Medical University of Vienna, Vienna, Austria, ⁶Charité Medical School - Humboldt-University of Berlin, Berlin, Germany, ⁷CHU Lille, Lille, France, ⁸Hôpital Nord, Marseille, France, ⁹Hospital Virgen del Rocio, Sevilla, Spain, ¹⁰Sharee Zedek MC, Jerusalem, Israel, ¹¹TiGenix, Madrid, Spain, ¹²Istituto Clinico Humanitas, Milano, Italy, ¹³University of Erlangen-Nuernberg, Department of Medicine 1, Erlangen, Germany, ¹⁴Aleris Medilab, Department of Pathology and Cytology, Täby, Sweden, ¹⁵Index Pharmaceuticals, Stockholm, Sweden, ¹⁶Catholic University of Rome, Internal Medicine Department, Gastroenterology Division, Rome, Italy, ¹⁷Nottingham University Hospitals, Department of Gastroenterology, Nottingham, United Kingdom

---

"IBD innovations driving clinical decisions"
### Thursday, March 17, 2016, cont.

**Scientific programme day by day (as of February 15, 2016)**

**Plenary Hall (Hall 11), Level 1, RAI Amsterdam**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 14:00 - 14:20 | **7: Mesenchymal stem cells**  
Tandem talk:  
Stefania Vetrano, Milan, Italy  
Laurence Egan, Galway, Ireland |
| 14:20 - 14:30 | **8: Best abstract: Predicting short and medium-term efficacy of the biosimilar infliximab: Trough levels/ADAs or clinical/biochemical markers play a more important role?**  
P.A. Golovics¹, Z. Vegh¹, M. Rutka², K. Gecse³, A. Balint², K. Farkas², J. Banai¹, L. Bene⁴, B. Gasztonyi⁵, T. Kristof⁶, L. Lakatos⁷, P. Miheller⁸, K. Palatka¹, A. Patai⁴, A. Salamon⁴, T. Szamosi⁴, Z. Szepes¹², G.T. Toth¹³, A. Vincze¹⁴, E. Biro¹⁵, B. Lovasz¹, Z. Kurti³, F. Nagy¹², T. Molnar¹⁵, P. Lakatos¹³  
¹Semmelweis University, 1st Department of Medicine, Budapest, Hungary, ²University of Szeged, ³Military Hospital, State Health Centre, Department of Gastroenterology, Budapest, Hungary, ⁴Peterfy Hospital, ⁵Department of Medicine, Budapest, Hungary, ⁶Zala County Hospital, ⁷Department of Medicine, Zalaegerszeg, Hungary, ⁸B-A-Z County and University Teaching Hospital, ⁹Department of Medicine, Miskolc, Hungary, ¹⁰Csolnoky F. Province Hospital, ¹¹Department of Medicine, Veszprem, Hungary, ¹²Semmelweis University, ¹³University of Debrecen, ¹⁴Institute of Medicine, Department of Gastroenterology, Debrecen, Hungary, ¹⁵Markusovszky Hospital, ¹⁶Department of Medicine and Gastroenterology, Szombathely, Hungary, ¹⁷Tolna County Teaching Hospital, ¹⁸Department of Gastroenterology, Szekszard, Hungary, ¹⁹University of Szeged, First Department of Internal Medicine, Szeged, Hungary, ²⁰Janos Hospital, Department of Gastroenterology, Budapest, Hungary, ²¹University of Pecs, ²²Department of Medicine, Pecs, Hungary, ²³Semmelweis University, Department of Laboratory Medicine, Budapest, Hungary |
| 14:30 - 15:00 | **Coffee break** |
### Thursday, March 17, 2016, cont.

**Scientific programme day by day (as of February 15, 2016)**

**Plenary Hall (Hall 11), Level 1, RAI Amsterdam**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session / Abstract</th>
</tr>
</thead>
</table>
| 15:00  | **Scientific session 2: Application of genetic testing in understanding and managing IBD**  
**Andre Franke, Kiel, Germany**  
**Thomas Billiet, Heverlee, Belgium** |
| 15:00 - 15:20 | **9: Very early onset IBD – from research to bedside**  
Holm Uhlig, Oxford, United Kingdom |
| 15:20 - 15:30 | **10: Best abstract: Gene expression profiling indicates similar molecular pathways are active in adult and paediatric Crohn's Disease**  
**A. Stojmirovic,** R. Dobrin, R. Strauss, D. Chan, K. Li, J. Friedman  
Janssen R & D, LLC, Spring House, United States |
| 15:30 - 15:50 | **11: Genetics in predicting drug response**  
Tariq Ahmad, Exeter, United Kingdom |
| 15:50 - 16:00 | **12: Best abstract: A variable number of tandem repeat polymorphism in the promoter region of the neonatal Fc receptor affects anti-TNF serum levels in IBD**  
**T. Billiet,** I. Cleynen, M. Ferrante, G. van Assche, A. Gils, S. Vermeire  
1Department of Clinical and Experimental Medicine, KU Leuven,  
Translational Research in GastroIntestinal Disorders (TARGID), Leuven, Belgium,  
2University Hospitals Leuven, Gastroenterology - Translational Research Center for Gastrointestinal Disorders (TARGID), Leuven, Belgium,  
3KU Leuven, Laboratory for Therapeutic and Diagnostic Antibodies, Leuven, Belgium |
| 16:00 - 16:10 | **13: Best abstract: Autophagy regulates dendritic cell migration through Rac1 – implications for thiopurine therapy**  
1Academic Medical Center, Gastroenterology and Hepatology, Amsterdam, Netherlands,  
2Academic Medical Center, Tytgat Institute, Amsterdam, Netherlands,  
3Erasmus Medical Center, Department of Gastroenterology and Hepatology, Rotterdam, Netherlands,  
4Beatson Institute for Cancer Research, Glasgow, United Kingdom |
| 16:10 - 16:30 | **14: The future of genetics in clinical medicine**  
Rinse Weersma, Groningen, The Netherlands |
| 16:30 - 16:40 | **15: Best abstract: Comprehensive epigenome-wide DNA methylation profiling in Inflammatory Bowel Disease**  
1University of Edinburgh, CGEM, Edinburgh, United Kingdom,  
2Centro Nacional de Análisis Genómico, Barcelona, Spain,  
3University Of Edinburgh, Department of Child Life and Health, Edinburgh, United Kingdom |
16: Best abstract: Genotype-phenotype analysis across 130,422 genetic variants identifies RSPO3 as the first genome-wide significant modifier gene in primary sclerosing cholangitis


¹University of Groningen and University Medical Centre Groningen, Department of Gastroenterology and Hepatology, Groningen, Netherlands, ²Academic Medical Center, Department of Gastroenterology and Hepatology, Amsterdam, Netherlands, ³University of Cambridge, Department of Medicine, Division of Hepatology, Cambridge, United Kingdom, ⁴Sapienza University of Rome, Department of Clinical Medicine, Division of Gastroenterology, Rome, Italy, ⁵Karolinska University Hospital Huddinge, Karolinska Institutet, Department of Gastroenterology and Hepatology, Stockholm, Sweden, ⁶Landspitali University Hospital, Department of Internal Medicine, Division of Gastroenterology and Hepatology, Reykjavik, Iceland, ⁷Oslo University Hospital, Rikshospitalet, Norwegian PSC Research Center, Division of Cancer Medicine, Surgery and Transplantation, Oslo, Norway, ⁸University of California Davis, Division of Gastroenterology and Hepatology, Davis, United States, ⁹John Radcliffe University Hospitals NHS Trust, Department of Hepatology, Oxford, United Kingdom, ¹⁰Hôpital Saint Antoine and U.P.M.C. Univ Paris 06, AP-HP and Department of Hepatology, Paris, France, ¹¹University Health Network - Toronto General Hospital, Gen. Internal Medicine, Toronto, Canada, ¹²Medical School, University of Thessaly, Department of Medicine and Research Laboratory of Internal Medicine, Larissa, Greece, ¹³University of Calgary, Snyder Institute of Chronic Diseases, Department of Medicine, Calgary, Canada, ¹⁴Christian-Albrechts-University of Kiel, Institute of Clinical Molecular Biology, Kiel, Germany, ¹⁵Helsinki University Hospital, Division of Gastroenterology, Department of Medicine, Helsinki, Finland, ¹⁶University of Padova, Department of Surgical, Oncological and Gastroenterological Sciences, Padova, Italy, ¹⁷Norfolk and Norwich University Hospital, Department of Gastroenterology, Norwich, United Kingdom, ¹⁸University Hospital of Heidelberg, Department of Medicine, Heidelberg, Germany, ¹⁹University of Toronto, Division of Gastroenterology, Department of Medicine, Toronto, Canada, ²⁰Leiden University Medical Centre, Department of Gastroenterology and Hepatology, Leiden, Netherlands, ²¹University of Munich, Department of Medicine II, Munich, Germany, ²²Humanitas Clinical and Research Center, Center for Autoimmune Liver Diseases, Rozzano, Italy, ²³Mayo Clinic, Division of Gastroenterology and Hepatology, Rochester, United States, ²⁴Mayo Clinic, College of Medicine, Center for Basic Research in Digestive Diseases, Division of Gastroenterology and Hepatology, Rochester, United States,
Thursday, March 17, 2016, cont.
Scientific programme day by day (as of February 15, 2016)
Plenary Hall (Hall 11), Level 1, RAI Amsterdam

16:40 - 16:50 cont.

25Institute for Molecular Medicine Finland F.I.M.M., University of Helsinki and National Institute for Health and Welfare, Public Health Genomics Unit, Helsinki, Finland, 26Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, United Kingdom, 27Karolinska Institute, Stockholm, Sweden, 28Hannover Medical School, Department of Gastroenterology, Hepatology and Endocrinology, Hannover, Germany, 29Institute of Medicine, Sahlgrenska Academy and University Hospital, Department of Internal Medicine, Gothenburg, Sweden, 30Università Politecnica delle Marche, Ospedali Riuniti University Hospital, Department of Gastroenterology, Ancona, Italy, 31University of Alberta, Division of Gastroenterology and Hepatology, Edmonton, Canada, 32Medical University of Warsaw, Liver and Internal Medicine Unit, Warsaw, Poland, 33Charité Universitätsmedizin Berlin, Department of Internal Medicine, Hepatology and Gastroenterology, Berlin, Germany, 34University of Barcelona, Liver Unit, Hospital Clinic, I.D.I.B.A.P.S., C.I.B.E.Reh, Barcelona, Spain, 35University Hospital of Heidelberg, Department of Internal Medicine IV, Heidelberg, Germany, 36University Hospitals NHS Trust, Department of Gastroenterology and Hepatology, Norfolk and Norwich, Norwich, United Kingdom, 37University of Munich, Department of Medicine 2, Grosshadern, Munich, Germany, 38Wellcome Trust-Medical Research Council Stem Cell Institute, Anne McLaren Laboratory, Cambridge, United Kingdom, 39University of Cambridge, Academic Department of Medical Genetics, Cambridge, United Kingdom, 40University Medical Center Hamburg-Eppendorf, 41Mount Sinai Hospital Toronto, Inflammatory Bowel Disease (IBD) Group, Zane Cohen Centre for Digestive Diseases, Toronto, Canada, 42University Medical Center Hamburg-Eppendorf, Department of Hepatobiliary Surgery and Transplantation, Hamburg, Germany, 43University of Mainz, 4th Department of Medicine, Mainz, Germany, 44Christian-Albrechts-University of Kiel, Institute for Epidemiology, Kiel, Germany, 45University of Groningen and University Medical Centre Groningen, Department of Genetics, Groningen, Netherlands, 46University of Thessaly, Department of Internal Medicine, Larissa, Greece

16:50 - 17:00

17: Best abstract: Gene-microbiome interactions underlying the onset and the clinical phenotypes of Inflammatory Bowel Disease F. Imhann1, A. Vich Vila1, M.J. Bonder1, D. Gevers1, J. Fu2, M.C. Visschedijk1, L.M. Spekhorst1, L. Franke1, H. van Dullemen1, R.W.F. Ter Steege1, C. Huttenhower2, G. Dijkstra1, R.J. Xavier1, C. Wijmenga3, E.A.M. Festen1, A. Zhernakova2, R.K. Weersma1

1University of Groningen and University Medical Center Groningen, Department of Gastroenterology and Hepatology, Groningen, Netherlands, 2University of Groningen and University Medical Center Groningen, Department of Genetics, Groningen, Netherlands, 1The Broad Institute of MIT and Harvard, Cambridge, United States, 4Harvard School of Public Health, Biostatistics Department, Boston, United States

17:15 - 18:15 Digital oral presentations (Sessions 1-5)
Please refer to pages 42-54

17:15 - 18:15 Industry sponsored satellite symposia 2a & 2b
Please refer to pages 189-190
### Scientific programme day by day (as of February 15, 2016)

**Plenary Hall (Hall 11), Level 1, RAI Amsterdam**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 07:15 - 08:15 | **Industry sponsored satellite symposia 3a & 3b**
|             | Please refer to pages 190-191                                        |
| 08:30 - 09:30 | **Scientific session 3: Resolution of inflammation**
|             | Javier Gisbert, Madrid, Spain                                         |
|             | Giovanni Monteleone, Rome, Italy                                      |
| 08:30 - 08:50 | **18: Mechanisms by which inflammation resolves**
|             | Silvio Danese, Milan, Italy                                           |
| 08:50 - 09:10 | **19: Stopping drugs**
|             | Charlie Lees, Edinburgh, United Kingdom                               |
| 09:10 - 09:20 | **20: Best abstract: Azathioprine dose reduction in Inflammatory Bowel Disease patients on combination therapy: A prospective study**
|             | E. Del Tedesco¹, S. Paul¹, H. Marotte¹, C. Jarlot¹, N. Williet¹, J.M. Phelip⁴, L. Peyrin-Biroulet⁶, J.F. Colombel⁶, **X. Roblin**⁶
|             | ¹University Hospital, Gastroenterology, Saint Etienne, France,        |
|             | ²University of Saint Etienne, Immunology, Saint Etienne, France,      |
|             | ³University Hospital, Rheumatology, Saint Etienne, France, ⁴CHU Saint Etienne, Saint Etienne, France, ⁵CHU de Nancy, Department of Gastroenterology, Vandoeuvre-Lès-Nancy, France, ⁶Mount Sinai Hospital, New York, United States |
| 09:20 - 09:30 | **21: Best abstract: Comparison of adalimumab monotherapy and a combination with azathioprine for patients with Crohn’s Disease: A prospective, multicentre, open-labeled clinical trial (DIAMOND study)**
|             | **T. Matsumoto**¹, S. Motoya², K. Watanabe³, T. Hisamatsu³, H. Nakase³, N. Yoshimura³, T. Ishida³, S. Kato³, T. Nakagawa³, M. Esaki⁴, M. Nagahori⁵, T. Matsui⁶, Y. Naito⁶, K. Kanai⁶, Y. Suzuki⁶, M. Nojima⁶, M. Watanabe⁶, T. Hibi⁶
|             | ¹Iwate Medical University, Division of Gastroenterology, Department of Medicine, Morioka, Japan, ²Sapporo Kosei General Hospital, Inflammatory Bowel Disease Center, Sapporo, Japan, ³Osaka City General Hospital, Division of Gastroenterology, Osaka, Japan, ⁴Kyorin University School of Medicine, The Third Department of Internal Medicine, Tokyo, Japan, ⁵Kyoto University, Department of Gastroenterology and Hepatology, Endoscopic Medicine, Kyoto, Japan, ⁶Tokyo Yamate Medical Center, Department of Medicine, Division of Gastroenterology, Tokyo, Japan, ⁷Oita Red Cross Hospital, Department of Gastroenterology, Oita, Japan, ⁸Saitama Medical Center, Saitama Medical University, Department of Gastroenterology and Hepatology, Kawagoe, Japan, ⁹Chiba University, Department of Gastroenterology and Nephrology (K1), Graduate School of Medicine, Chiba, Japan, ¹⁰Kyushu University, Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Fukuoka, Japan, ¹¹Tokyo Medical and Dental University, Department of Gastroenterology and Hepatology, Tokyo, Japan, ¹²Fukuoka University Chikushi Hospital, Department of Gastroenterology, Chikushino, Japan, ¹³Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Department of Molecular Gastroenterology and Hepatology, Kyoto, Japan, ¹⁴Keio University, Department of Internal Medicine, School of Medicine, Tokyo, Japan, ¹⁵Toho University Sakura Medical Center, Department of Internal Medicine, Sakura, Japan, ¹⁶The Institute of Medical Science Hospital, The University of Tokyo, Center for Translational Research, Tokyo, Japan, ¹⁷Kitsato University Kitsato Institute Hospital, Center for Advanced IBD Research and Treatment, Tokyo, Japan |
Friday, March 18, 2016, cont.

Scientific programme day by day (as of February 15, 2016)
Plenary Hall (Hall 11), Level 1, RAI Amsterdam

<table>
<thead>
<tr>
<th>09:30 - 10:30</th>
<th>Scientific session 4: Viruses and IBD</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Laurent Beaugerie, Paris, France</td>
</tr>
<tr>
<td></td>
<td>Marina Shapina, Moscow, Russia</td>
</tr>
</tbody>
</table>

09:30 - 09:50

22: Should we treat CMV in patients with UC?
Britta Siegmund, Berlin, Germany

09:50 - 10:00

23: Best abstract: Risk factors for colorectal neoplasia in Ulcerative Colitis: Results from the largest and longest-running colonoscopic surveillance programme
*C.H.R. Choi*¹,², I. Al Bakir¹, N.S.J. Ding¹, M. Moorghen¹, S. Thomas-Gibson¹, J. Warusavitarne³, B. Saunders¹, M. Rutter¹, T. Graham², A. Hart¹

¹St. Mark's Hospital, London, United Kingdom, ²Barts Cancer Institute, Tumour Biology, London, United Kingdom, ³University Hospital of North Tees, Department of Gastroenterology, Stockton-on-Tees, Teesside, United Kingdom

10:00 - 10:10

24: Best abstract: Evolution of corticosteroid use in Crohn's Disease patients between 1991 and 2014: Results from the Dutch population-based IBDSL cohort
*S. Jeuring*¹,², V. Biemans¹, L. Liu¹, T. van den Heuvel¹,², M. Zeegers³,⁴, W. Hameeteman¹, M. Romberg-Camps³, L. Oostenbrug³, A. Masclee¹,², D. Jonkers¹,², M. Pierik¹,²

¹Maastricht University Medical Centre, Internal Medicine - Division of Gastroenterology and Hepatology, Maastricht, Netherlands, ²Maastricht University Medical Centre, NUTRIM - School for Nutrition and Translational Research in Metabolism, Maastricht, Netherlands, ³Maastricht University Medical Centre, Complex Genetics - School for Nutrition and Translational Research in Metabolism (NUTRIM), Maastricht, Netherlands, ⁴Maastricht University Medical Centre, Internal Medicine and Gastroenterology-Hepatology, Sittard-Geleen, Netherlands, ⁵Zuyderland Medical Centre, Internal Medicine and Gastroenterology-Hepatology, Heerlen, Netherlands

10:10 - 10:30

25: Other viral complications in clinical practice
Jonas Halfvarsson, Örebro, Sweden

10:30 - 11:00  Coffee break
Friday, March 18, 2016, cont.
Scientific programme day by day (as of February 15, 2016)
Plenary Hall (Hall 11), Level 1, RAI Amsterdam

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Presenter(s)</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00 - 12:20</td>
<td>Scientific session 5: Challenging dogmas – from clinical trials to clinical practice</td>
<td>Torsten Kucharzik, Lüneburg, Germany Maria Chaparro, Madrid, Spain</td>
<td></td>
</tr>
<tr>
<td>11:00 - 11:20</td>
<td>26: Mucosal healing – Is it the holy grail?</td>
<td>Geert D’Haens, Amsterdam, The Netherlands</td>
<td></td>
</tr>
<tr>
<td>11:40 - 12:00</td>
<td>29: Patient-reported outcomes</td>
<td>William Sandborn, San Diego, United States</td>
<td></td>
</tr>
<tr>
<td>12:00 - 12:20</td>
<td>30: Should clinical trials in children be different?</td>
<td>Dan Turner, Jerusalem, Israel</td>
<td></td>
</tr>
</tbody>
</table>

12:20 - 13:20 Lunch break and guided poster session in the exhibition hall
Please refer to pages 38-39

12:30 - 13:10 Industry sponsored educational lunchtime satellite symposia LS1-4
Please refer to pages 191-192
### Scientific Programme

**Friday, March 18, 2016, cont.**

**Scientific programme day by day (as of February 15, 2016)**

**Plenary Hall (Hall 11), Level 1, RAI Amsterdam**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speakers and Institutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:20 - 14:50</td>
<td>6</td>
<td><strong>Scientific session 6: Bugs and drugs in IBD</strong></td>
<td>Philippe Seksik, Paris, France, Barry Hall, Dublin, Ireland</td>
</tr>
<tr>
<td>13:20 - 13:40</td>
<td>31</td>
<td><strong>The microbiome and geographical spread of IBD</strong></td>
<td>Philip Rosenstiel, Kiel, Germany</td>
</tr>
<tr>
<td>13:40 - 14:20</td>
<td>32</td>
<td><strong>Best abstract: Development and validation of diagnostic criteria for IBD-Unclassified (IBDU) in children: A multicentre longitudinal study from the Paediatric IBD Porto group of ESPGHAN</strong></td>
<td>L. Birimberg Schwartz², D. Zucker², A. Akriv³, C. Salvatore³, F. Cameron⁴, I. Lazowska⁵, L. Yianni⁶, P. Siba⁷, S. Kolacek⁷, C. Romano⁷, S. Buderus¹⁰, A. Pirenne²¹, J. C. Escher¹¹, D. Turner¹,²,³</td>
</tr>
<tr>
<td>13:50 - 14:10</td>
<td>33</td>
<td><strong>Manipulating the microbiota in everyday practice</strong></td>
<td>Francisco Guarner, Barcelona, Spain</td>
</tr>
<tr>
<td>14:10 - 14:20</td>
<td>34</td>
<td><strong>Best abstract: Multi donor intense faecal microbiota transplantation is an effective treatment for resistant Ulcerative Colitis: A randomised placebo-controlled trial</strong></td>
<td>S. Paramsothy¹, M. Kamm³, A. Walsh⁴, J. van den Bogaerde⁵, D. Samuel⁶, R. Leon³, S. Connor⁵, W. Ng⁵, R. Paramsothy⁶, N. Kaakoush⁶, H. Mitchell⁶, W. Xuan⁶, E. Lin⁴, T. Borody¹⁰</td>
</tr>
<tr>
<td>14:30 - 14:50</td>
<td>35</td>
<td><strong>Best abstract: The impact of “Crohn’s Disease-TReatment-with-EATing” diet (CD-TREAT diet) and exclusive enteral nutrition on healthy gut bacteria metabolism</strong></td>
<td>V. Svolos¹, R. Hansen², K. Hughes³, U.Z. Ijaz⁴, C. Quince⁴, D. Gaya⁶, R. Russell⁵, K. Gerasimidis¹</td>
</tr>
<tr>
<td>14:50 - 15:20</td>
<td></td>
<td><strong>Coffee break</strong></td>
<td></td>
</tr>
</tbody>
</table>
**Friday, March 18, 2016, cont.**

**Scientific programme day by day (as of February 15, 2016)**

**Plenary Hall (Hall 11), Level 1, RAI Amsterdam**

| 15:20 - 16:00 | Scientific session 7: ECCO Fellowships & Grants | Gerhard Rogler, Zürich, Switzerland  
Noortje Festen, Groningen, The Netherlands |
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>15:20 - 15:27</td>
<td>37: Outcomes from the 2015 Fellowships – Part 1</td>
<td>Carla Felice, Rome, Italy</td>
</tr>
<tr>
<td></td>
<td>Selective histone deacetylase inhibitors: A potential new treatment of Inflammatory Bowel Diseases</td>
<td></td>
</tr>
<tr>
<td>15:27 - 15:34</td>
<td>38: Outcomes from the 2015 Fellowships – Part 2</td>
<td>Cristina Mascaraque, Granada, Spain</td>
</tr>
<tr>
<td></td>
<td>Sphingosine 1-phosphate (S1P)/S1PR3 axis a novel therapeutic target for intestinal fibrosis in Crohn's Disease</td>
<td></td>
</tr>
<tr>
<td>15:34 - 15:40</td>
<td>39: Announcement of ECCO Fellowships &amp; Grants 2016</td>
<td>Gerhard Rogler, Zürich, Switzerland</td>
</tr>
<tr>
<td></td>
<td>¹Division of Gastroenterology, University of California, San Diego, United States, ²Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, United States, ³Academic Medical Centre, University of Amsterdam, Amsterdam, Netherlands, ⁴Department of Gastroenterology, University Hospitals Leuven, Leuven, Belgium, ⁵Klinik für Innere Medizin I, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany, ⁶IBD Center, Department of Gastroenterology, Humanitas Research Hospital, Milan, Italy, ⁷Hospital Clinicas de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain, ⁸Robarts Research Institute, London, Canada, ⁹McMaster University, Hamilton, Canada, ¹⁰Pfizer Inc, Collegeville, United States, ¹¹Pfizer Inc, Groton, United States</td>
<td></td>
</tr>
<tr>
<td>15:50 - 16:00</td>
<td>41: Best abstract: Filgotinib, a selective JAK1 inhibitor, induces clinical remission in patients with moderate-to-severe Crohn’s Disease: Interim analysis from the phase 2 FITZROY study</td>
<td>S. Vermeire¹, S. Schreiber², R. Petryka³, T. Kuehbacher³, X. Hübterne³, X. Roblin⁴, M. Kloppoka⁵, E. Goldis⁶, M. Wisniewska-Jarosinska⁷, A. Baranovsky⁸, R. Sike⁹, C. Tasset¹⁰, A. van der Aa¹¹, P. Harrison¹²</td>
</tr>
<tr>
<td></td>
<td>¹UZ Leuven, Campus Gasthuisberg, Leuven, Belgium, ²University Medical Center Schleswig-Holstein Kiel, Department of Internal Medicine I, Kiel, Germany, ³Vivamed, Warsaw, Poland, ⁴Asklepios Hospital West Hamburg, Department of Internal Medicine, Gastroenterology, Hamburg, Germany, ⁵Archev 2 Hospital, Department of Gastroenterology, Nice, France, ⁶Saint Etienne Hospital, Department of Gastroenterology, Saint Priest en Jarez, France, ⁷University Hospital Nr. 2 im. Biziela, Department of Gastroenterology, Bydgoszcz, Poland, ⁸Policlinica Algomed, Department of Gastroenterology, Timisoara, Romania, ⁹Saint Family Hospital Medical Center, Department of Gastroenterology and Endoscopy, Lodz, Poland, ¹⁰City Clinical Hospital #31, St Petersburg, Russian Federation, ¹¹Szent Margit Hospital, Department of Internal Medicine and Gastroenterology III, Budapest, Hungary, ¹²Galapagos NV, Department of Development, Mechelen, Belgium</td>
<td></td>
</tr>
</tbody>
</table>
### Scientific Programme 8: Challenging Cases

**Date:** Friday, March 18, 2016, cont.

**Venue:** Plenary Hall (Hall 11), Level 1, RAI Amsterdam

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:00</td>
<td><strong>Scientific session 8: Challenging Cases</strong></td>
<td>Peter Irving, London, United Kingdom, Laurent Peyrin-Biroulet, Vandoeuvre-lès-Nancy, France</td>
</tr>
<tr>
<td>16:00 - 16:20</td>
<td><strong>Case 1: Challenges during pregnancy: Anti-TNF treatment during pregnancy</strong></td>
<td>Shannon Kanis, Rotterdam, The Netherlands</td>
</tr>
<tr>
<td>16:20 - 16:40</td>
<td><strong>Case 2: Refractory upper gut Crohn’s Disease: Refractory upper gut Crohn’s Disease with fatal outcome</strong></td>
<td>Miquel Cusachs, Barcelona, Spain</td>
</tr>
<tr>
<td>16:40 - 17:00</td>
<td><strong>Case 3: When extra-intestinal symptoms dominate: Severe arthralgia in Crohn’s Disease – disease or drug-related?</strong></td>
<td>Donata Lissner, Berlin, Germany</td>
</tr>
</tbody>
</table>

### Scientific session 9: What’s new on the Guidelines front?

**Date:** Friday, March 18, 2016, cont.

**Venue:** Plenary Hall (Hall 11), Level 1, RAI Amsterdam

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:00</td>
<td><strong>Scientific session 9: What’s new on the Guidelines front?</strong></td>
<td>Oded Zmora, Tel Aviv, Israel, Loris Lopetuso, Rome, Italy</td>
</tr>
<tr>
<td>17:00 - 17:10</td>
<td><strong>ECCO Guidelines: Surgical CD</strong></td>
<td>Willem Bemelman, Amsterdam, The Netherlands</td>
</tr>
<tr>
<td>17:10 - 17:20</td>
<td><strong>Best abstract: Efficacy and safety of oral tofacitinib for maintenance therapy in patients with moderate to severe Crohn’s Disease: Results of a Phase 2b randomised placebo-controlled trial</strong></td>
<td>G. D’Haens¹, R. Pannaccione², P.D.R. Higgins³, J.-F. Colombel³, B.G. Feagan⁴, M. Moscariello⁴, G. Chan⁴, P. Healey⁴, W. Niezychowski⁴, W. Wang⁴, A. Marren⁵, E. Maller⁵ ¹Academic Medical Centre, University of Amsterdam, Amsterdam, Netherlands, ²University of Calgary, Calgary, Canada, ³University of Michigan, Ann Arbor, United States, ⁴Robarts Research Institute, London, Canada, ⁵Pfizer Inc, Collegeville, United States, ⁶Pfizer Inc, Groton, United States</td>
</tr>
<tr>
<td>17:20 - 17:30</td>
<td><strong>Best abstract: Efficacy and safety of oral tofacitinib for induction therapy in patients with moderate to severe Crohn’s Disease: Results of a Phase 2b randomised placebo-controlled trial</strong></td>
<td>J. Panés¹, W.J. Sandborn², S. Schreiber¹, B.E. Sands³, S. Vermeire³, G. Chan³, M. Moscariello³, W. Wang³, W. Niezychowski³, A. Marren³, P. Healey³, E. Maller³ ¹Hospital Clinicas de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain, ²Division of Gastroenterology, University of California, San Diego, United States, ³Klinik für Innere Medizin I, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany, ⁴Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, United States, ⁵Department of Gastroenterology, University Hospitals Leuven, Leuven, Belgium, ⁶Pfizer Inc, Collegeville, United States, ⁷Pfizer Inc, Groton, United States</td>
</tr>
<tr>
<td>17:30 - 17:40</td>
<td><strong>ECCO Guidelines: UC Update</strong></td>
<td>Rami Eliakim, Tel Hashomer, Israel, Marcus Harbord, London, United Kingdom</td>
</tr>
<tr>
<td>17:40 - 17:45</td>
<td><strong>ECCO Topical Review: Fibrosis</strong></td>
<td>Florian Rieder, Cleveland, United States</td>
</tr>
<tr>
<td>17:45 - 17:50</td>
<td><strong>ECCO Topical Review: Elderly in IBD</strong></td>
<td>Paolo Gionchetti, Bologna, Italy</td>
</tr>
</tbody>
</table>

### Digital oral presentations (Sessions 6-10)

Please refer to pages 56-66

### Industry sponsored satellite symposia 4a & 4b

Please refer to page 193

### ECCO Interaction: Hearts & Minds

**Date:** Friday, March 18, 2016, cont.

**Venue:** Beurs van Berlage, Damrak 243, 1012 ZJ Amsterdam (Please refer to page 207)
### Scientific programme day by day (as of February 15, 2016)

**Plenary Hall (Hall 11), Level 1, RAI Amsterdam**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 07:15 - 08:15 | Industry sponsored satellite symposia 5a & 5b  
Please refer to page 194 |
| 08:30 - 10:20 | **Scientific session 10: Surgical and endoscopic FAQs in IBD**  
André D’Hoore, Leuven, Belgium  
Zuzana Serclova, Prague, Czech Republic |
| 08:30 - 08:50 | 51: Case 1 – Preparing your patient for optimal surgery  
Richard Fedorak, Edmonton, Canada |
| 08:50 - 09:00 | 52: Best abstract: Comparison between newly-developed NBI and panchromoendoscopy for surveillance colonoscopy in patients with Ulcerative Colitis: A prospective multicentre randomised controlled trial, Navigator Study  
1Osaka City General Hospital, Gastroenterology, Osaka, Japan  
2Nishishita Gastrointestinal Hospital, Osaka, Japan  
3Faculty of Human Culture and Science Prefectural University of Hiroshima, Hiroshima, Japan  
4Osakafu Saiseikai Nakatsu Hospital, Gastroenterology and Hepatology, Osaka, Japan  
5Graduate School of Medical Sciences, Kyushu University, Department of Medicine and Clinical Science, Fukuoka, Japan  
6Hiroshima University Hospital, Department of Endoscopy, Hiroshima, Japan  
7Kyoto Katsura Hospital, Digestive Disease Centre, Department of Gastroenterology, Kyoto, Japan  
8Fukuoka University Chikushi Hospital, Department of Gastroenterology, Fukuoka, Japan  
9Osaka Medical College, Second Department of Internal Medicine, Osaka, Japan  
10Hyogo College of Medicine, Department of Inflammatory Bowel Disease, Hyogo, Japan  
11Takano Hospital, Division of Gastroenterology, Coloproctology Center, Kumamoto, Japan  
12Kinki University, Department of Gastroenterology, Osaka, Japan  
13Toho University Sakura Medical Center, Department of Internal Medicine, Chiba, Japan  
14The Jikei University School of Medicine, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Tokyo, Japan  
15The Jikei University School of Medicine, Department of Endoscopy, Tokyo, Japan  
16National Cancer Center Hospital, Endoscopy Division, Tokyo, Japan  
17School of Medicine, Fujita Health University, Department of Gastroenterology, Aichi, Japan  
18Graduate School of Medical and Dental Sciences, Niigata University, Division of Molecular and Diagnostic Pathology, Niigata, Japan  
19The Jikei University School of Medicine, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Department of Endoscopy, Tokyo, Japan |
| 08:50 - 09:00 | 53: Best abstract: Mucosal healing and dysplasia surveillance in a large referral centre cohort of patients with Crohn’s Disease and Ulcerative Colitis treated with vedolizumab  
M. Noman, M. Ferrante, R. Bisschops, G. De Hertogh, K. van den Broeck, K. Rans, P. Rutgeerts, S. Vermeire, **G. van Assche**  
1UZ Leuven, Gastroenterology, Leuven, Belgium  
2UZ Leuven, Campus Gasthuisberg, Pathology, Leuven, Belgium |
### Scientific Programme day by day (as of February 15, 2016)

#### Plenary Hall (Hall 11), Level 1, RAI Amsterdam

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 09:10 - 09:20 | **54: Best abstract: Escalation of medical therapy decreases need for repeat dilatation in Crohn’s anastomotic strictures**  
1St Mark’s Hospital, IBD, London, United Kingdom, 2Imperial College London, Department of Surgery and Cancer, London, United Kingdom, 3St Mark’s Hospital, Wolfson Unit For Endoscopy, Department of Gastroenterology, Harrow, United Kingdom |
| 09:20 - 09:40 | **55: Case 2 – Post-surgery prevention**  
Marc Ferrante, Leuven, Belgium |
| 09:40 - 09:50 | **56: Best abstract: The TOPPIC trial: A randomised, double-blind parallel group trial of mercaptopurine vs placebo to prevent recurrence of Crohn’s Disease following surgical resection in 240 patients**  
**I. Arnott**, C. Mowat, C. Keerie, S. Lewis, N. Kennedy, A. Cahill, M. Dunlop, S. Bloom, J. Lindsay, S. Subramanian,  
J. Satosangi, on behalf of the Toppic Trial Study Group  
1NHS Lothian, Gastroenterology, Edinburgh, United Kingdom, 2NHS Tayside, Gastroenterology, Dundee, United Kingdom, 3University of Edinburgh, Edinburgh Clinical Trials Unit, Edinburgh, United Kingdom, 4University of Edinburgh, Gastroenterology, Edinburgh, United Kingdom, 5NHS Greater Glasgow and Clyde, Gastroenterology, Glasgow, United Kingdom, 6University of Edinburgh, Institute of Genetics and Molecular Medicine, Edinburgh, United Kingdom, 7University College Hospital, Department of Gastroenterology, London, United Kingdom, 8Bart’s Health NHS Trust, Newham University Hospital, Department of Gastroenterology, London, United Kingdom, 9Royal Liverpool University Hospital, Gastroenterology, Liverpool, United Kingdom, 10Toppic Trial Study Group, UK, United Kingdom |
| 09:50 - 10:00 | **57: Best abstract: Anti-TNF therapy is associated with increased risk of postoperative morbidity after surgery for ileocolonic Crohn’s Disease: Outcome analysis in a prospective nationwide cohort of 592 patients conducted by the GETAID chirurgie group**  
1Bicêtre Hospital - Université Paris Sud, Oncologic and Digestive Surgery, Le Kremlin Bicêtre, France, 2Beajon Hospital, Colorectal Surgery, Clichy, France, 3CHU Lille, Digestive Surgery, Lille, France, 4Saint Antoine Hospital, Digestive Surgery, Paris, France, 5CHU Bordeaux, Digestive Surgery, Bordeaux, France, 6CHU Nancy, Digestive Surgery, Nancy, France, 7CHU Lyon-Sud, Digestive Surgery, Lyon, France, 8CHU Marseille, Digestive Surgery, Marseille, France, 9Saint Louis Hospital, Digestive Surgery, Paris, France, 10CHU Rennes, Digestive Surgery, Rennes, France, 11CHU Nice, Digestive Surgery, Nice, France, 12CHU Toulouse, Digestive Surgery, Toulouse, France, 13 Lariboisière Hospital, Digestive Surgery, Paris, France, 14Montsouris Institute, Digestive Surgery, Paris, France, 15CHU Rouen, Digestive Surgery, Rouen, France, 16CHU Nantes, Digestive Surgery, Nantes, France, 17CHU Grenoble, Digestive Surgery, Grenoble, France, 18Saint-Joseph Hospital, Digestive Surgery, Paris, France, 19CHU Montpellier, Digestive Surgery, Montpellier, France, 20Fernand Widal Hospital, Clinical Research, Paris, France |
Saturday, March 19, 2016, cont.

Scientific programme day by day (as of February 15, 2016)

Plenary Hall (Hall 11), Level 1, RAI Amsterdam

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00 - 10:20</td>
<td><strong>58: Case 3 – Dealing with a problematic pouch</strong>&lt;br&gt;Michael Kamm, Melbourne, Australia</td>
</tr>
<tr>
<td>10:20 - 10:50</td>
<td>Coffee break</td>
</tr>
<tr>
<td>10:50 - 12:20</td>
<td><strong>Scientific session 11: Right time, right drug, right strategy</strong>&lt;br&gt;Marijke Pierik, Maastricht, The Netherlands&lt;br&gt;Nik Ding, London, United Kingdom</td>
</tr>
<tr>
<td>10:50 - 11:10</td>
<td><strong>59: Molecular stratification of the patient</strong>&lt;br&gt;Miles Parkes, Cambridge, United Kingdom</td>
</tr>
<tr>
<td>11:10 - 11:20</td>
<td><strong>60: Best abstract: Pharmacokinetics and exposure-response relationships of intravenously administered ustekinumab during induction treatment in patients with Crohn’s Disease: Results from the UNITI-1 and UNITI-2 studies</strong>&lt;br&gt;O.J. Adedokun, 1 Z. Xu1, C. Gasink1, J. Friedman1, P. Szapary1, Y. Lang1, J. Janssens1, L.-L. Gao1, Y. Miao1, H. Davis1, S. Hanauer1, B. Feagan1, W. Sandborn4&lt;br&gt;1Janssen R &amp; D, LLC, Spring House, United States, 2Northwestern University Feinberg School of Medicine, Chicago, United States, 3Robarts Clinical Trials Inc., Robarts Research Institute, University of Western Ontario, London, Canada, 4UCSD, Medicine, La Jolla, United States</td>
</tr>
<tr>
<td>11:20 - 11:40</td>
<td><strong>61: Choosing the right drug</strong>&lt;br&gt;Iris Dotan, Tel Aviv, Israel</td>
</tr>
<tr>
<td>11:40 - 11:50</td>
<td><strong>62: Best abstract: Drug-concentration versus symptom-driven dose adaptation of infliximab in patients with active Crohn’s Disease: A prospective, randomised, multicentre trial (Tailorix)</strong>&lt;br&gt;G. D’haens5, S. Vermeire6, G. Lambrechts7, P. Baert8, P. Bossuyt9, M. Nachury8, A. Buissin9, Y. Bouhnik9, J. Filippi9, J. van der Woude10, P. van Hootegem11, J. Moreau12, E. Louis13, D. Franchimont14, M. De Vos15, F. Maná16, L. Peyrin-Biroulet17, H. Brixi18, M. Allez19, P. Caenepeel20, A. Aubourg21, B. Oldenburg22, M. Pierik23, A. Gils24, S. Chevret25, D. Laharie26&lt;br&gt;5Academic Medical Centre, Gastroenterology, Amsterdam, Netherlands, 6University Hospitals Gasthuisberg, Gastroenterology, Leuven, Belgium, 7AZ Damiaan, Oostende, Belgium, 8AZ Delta, Roeselare, Belgium, 9Imelda GI Clinical Research Centre, Bonheiden, Belgium, 10Hospital Claude Huriez, Lille, France, 11Hospital Estaing, Clermont-Ferrand, France, 12Hospital Beaujon, Clichy, France, 13Hospital Archet, Nice, France, 14Erasmus Medical Centre, Rotterdam, Netherlands, 15St Lukas Hospital, Bruges, Belgium, 16Hospital Rangueil, Toulouse, France, 17Hospital Sart Tilman, Liège, Belgium, 18Hospital Erasme, Brussels, Belgium, 19University of Ghent, Ghent, Belgium, 20Free University of Brussels, Brussels, Belgium, 21Hopital Brabois, Nancy, France, 22Hopital Robert Debre, Reims, France, 23Hopital St Louis, Paris, France, 24Ziekenhuis Oost Limburg, Genk, Belgium, 25Hopital Trousseau, Tours, France, 26University of Utrecht, Utrecht, Netherlands, 27University Hospital Maastricht, Maastricht, Netherlands, 28University of Leuven, Leuven, Belgium, 29Department Biostatistiek St Louis, Paris, France, 30Haut-Leveque, Pessac, France</td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
</tr>
<tr>
<td>--------------</td>
<td>--------------------------------------------------------------------------</td>
</tr>
<tr>
<td>11:50 - 12:00</td>
<td><strong>63: Best abstract: Factors associated with the first trough level of infliximab at week 2 that predicts short- and long-term outcomes in Ulcerative Colitis</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Plenary Hall (Hall 11), Level 1, RAI Amsterdam</strong></td>
</tr>
<tr>
<td>12:00 - 12:20</td>
<td><strong>64: Care or action plans for patients</strong></td>
</tr>
<tr>
<td>12:20 - 12:50</td>
<td><strong>Scientific session 12: ECCO Lecture</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Future of IBD healthcare in Europe</strong></td>
</tr>
<tr>
<td>12:50 - 12:55</td>
<td><strong>66: Awards and closing remarks</strong></td>
</tr>
<tr>
<td>12:55 - 13:00</td>
<td><strong>The ECCO Film 2016</strong></td>
</tr>
</tbody>
</table>
“Bringing science, therapy & quality to patients”

February 18-21, 2015, Barcelona, Spain

Opening & welcome: 12:45 – 13:00
Eugeni Domènech (ES) and Séverine Vermeire (BE)

Scientific session 1: The exposome in the pathogenesis of IBD 13:00 – 14:30
Arie Levine (IL) and Isabelle Cleynen (BE)
- How food triggers inflammation: Marc Velchoen (UK)
- Best abstract: Transmissible Crohn’s disease-like ileitis is caused by functional dysbiosis in the intestinal microbiota independent of inflammation-driven Paneth cell failure: Monika Schambach (DE)
- Impact of lifestyle changes on disease course: Gerhard Rogler (CH)
- Best abstract: UK IBD twin and multiplex registry: Concordance and environmental risk factors of twins with IBD: Hannah Gordon (UK)
- Best abstract: Faecal microbiota transplantation in Ulcerative Colitis: A randomised controlled trial: N.G.M. Rossen (NL)
- Epigenetics of IBD: Jack Satsangi (UK)

Scientific session 2: Pharmacokinetics in clinical practice: Does it matter? 15:00–17:00
Geert D’Haens (NL) and Eugeni Domènech (ES)
- Influence of the inflammatory burden on pharmacokinetics of biologicals: Diane Mould, (US)
- Best abstract: Adalimumab and infliximab levels in neonates (ERA study): Mette Jølsgaard (DK)
- Understanding pharmacokinetics and immunogenicity of anti-TNFs: Ann Gils (BE)
- Best abstract: Infliximab trough level thresholds vary depending on the efficacy criterion chosen in IBD patients: Xavier Roblin (FR)
- Best abstract: Disease burden outweighs the impact of drug concentrations and antibodies to infliximab in primary non-response to infliximab in Crohn’s Disease patients: Thomas Billiet (BE)
- Applying pharmacokinetics in the daily care of patients: from combination therapy to therapeutic drug monitoring: Barrett Levesque (US)
- Best abstract: Deep remission in Crohn’s Disease does not prevent disease relapse after withdrawal of anti-TNF a therapy: Martin Bortlik (CZ)
- Applying the lessons learnt from anti-TNF strategies to novel biologics: Yehuda Chowers (IL)

Friday, February 20, 2015

Scientific session 3: Optimal use of resources 08:30–09:30
Anna Kohn (IT) and John Mansfield (UK)
- The true cost of IBD care: Keith Bodger (UK)
- Best abstract: The first prospective Australian population-based study of newly diagnosed IBD identifies frequent use of immunomodulators, low surgery rates and high cost from medications and investigations: Olga Niewiadomski (AUS)
Scientific session 4: The gut barrier under attack: Therapeutic implications 09:30-10:30
Silvio Danese (IT) and Philippe Marteau (FR)
- Mechanisms of damage and repair: Gijs van den Brink (NL)
- Best abstract: Medication-induced microscopic colitis: do recency and duration of use matter? Bas P.M. Verhaegh (NL)
- Best abstract: Budesonide MMX® 9 mg for inducing remission in patients with Mild-to-Moderate Ulcerative Colitis Not Adequately Controlled with Oral 5-ASAs: David T. Rubin (US)
- The microbiome in the pathogenesis and therapy of IBD: Ailsa Hart (UK)

Scientific session 5: Delivering quality to the patients 11:00-12:00
Simon Travis (UK) and Philippe Marteau (FR)
- The central role of the IBD nurse in the multidisciplinary management: Marian O’Connor (UK)
- Best abstract: Information needs and concerns of patients with Inflammatory Bowel Disease: What can we learn from participants of a national clinical cohort? Valérie Pittet (CH)
- Measuring the quality performance of your centre: Xavier Calvet Calvo (ES)
- Best abstract: Patient-relevant Endpoints in Inflammatory Bowel Diseases - Have Changes Occurred in Germany over the Past Twelve Years? Andreas Stallmach (DE)
- Panel discussion: Simon Travis (UK) and Ronan O’Connell (IE) and Zuzana Zelinkova (SK) and Hankje Escher (NL) and Marian O’Connor (UK)

Scientific session 6: Anti-TNF: Originators & Biosimilars 13:30-15:00
Gerassimos Mantzaris (GR) and Gronata Fiorino (IT)
- The science behind biosimilars: Gonzalo Calvo (ES)
- Best abstract: Use of anti-TNF-α agents in relation to first-time surgery for ulcerative colitis and Crohn’s disease during childhood: Michael Due Larsen (DK)
- Experience with biosimilars from rheumatology: Ulf Müller-Ladner (DE)
- Best abstract: Multicentre clinical trial with topical administration of the Toll-Like receptor 9 agonist DIMS0150 shows evidence for efficacy in moderate to severe Ulcerative Colitis: Raja Atreya (DE)
- Best abstract: Treatment strategy during the first year after diagnosis in patients with inflammatory bowel diseases from the 2011 ECCO-EpiCom inception cohort: Zsuzsanna Vegh (HU)
- Unanswered questions on biosimilars in IBD: Stefan Schreiber (DE)

Scientific session 7: ECCO Fellowships & Grants 15:30-16:10
Edouard Louis (BE) and Pieter Hindryckx (BE)
- Outcomes from the 2013-14 Fellowships: The effect of vitamin D on the intestinal microbiome in patients with Ulcerative Colitis: Mayur Garg (AUS)
- Outcomes from the 2013-14 Fellowships: Mechanisms of primary non response to anti-TNFα therapy in Inflammatory Bowel Disease: Konstantinos Papamichael (GR)
- Announcement of ECCO Fellowships and Grants 2015: Edouard Louis (BE)
Scientific Programme
10th Congress of ECCO - Barcelona

• Best abstract: Long-term outcomes in a cohort of patients with acute severe ulcerative colitis refractory to intravenous steroids treated with cyclosporine or infliximab: David Laharie (FR)
• Best abstract: Prolonged Deep Remission of Ileocolonic Crohn’s Disease following Autologous Haemopoietic Stem Cell Transplantation, presented on behalf of all the ASTIC Trialists: Chris Hawkey (UK)

Scientific session 8: Challenging Cases
16:10-17:10
Edouard Louis (BE) and Pierre Michetti (CH) and Frank Rueemmele (FR)
• Case 1: Risk of cancer in chronic perianal disease: Stephan Vavricka (CH)
• Case 2: Risk of infection occurring under biological treatment: Thomas Billet (BE)
• Case 3: Loss of response to anti-TNF in paediatrics: Maigorzata Sladek (PL)

Scientific session 9: What’s new on the Guidelines front?
17:10-17:50
Vito Annesi (IT) and Tiago Nunes (DE/BR)
• Malignancy: Rami Elakim (IL)
• Best abstract: Forty-Year Analysis of Colonoscopic Surveillance for Ulcerative Colitis Reveals Decreasing Risk of Interval and Advanced Cancer and Reducing Colectomy Rate for Dysplasia: Chang Ho Ryan Choi (UK)
• Best abstract: Patients with Inflammatory Bowel Disease and a history of cancer: The risk of cancer following exposure to immunosuppression: Jordan Axelrad (US)
• Extra-intestinal manifestations: Franck Carbonnel (FR) & Marcus Harbord (UK)

Saturday, February 21, 2015

Scientific session 10: New therapies and strategies
08:30-10:20
Laurent Peyrin-Biroulet (FR) and Krisztina Gece (HU)
• New algorithms for treating IBD: Gert van Assche (BE)
• Best abstract: TURANDOT: a randomized, multicenter double-blind, placebo-controlled study of the safety and efficacy of Anti-MAdCAM Antibody PF-00547659 (PF) in patients with moderate to severe Ulcerative Colitis (UC): Séverine Vermeire (BE)
• Best abstract: Anti-MAdCAM-1 Antibody (PF-00547659) for Active Refractory Crohn’s Disease: Results of the OPERA study: Geert D’Haens (NL)
• Best abstract: Methotrexate for corticosteroid-dependent ulcerative colitis: results of a placebo randomized controlled trial: Franck Carbonnel (FR)
• Positioning of the new molecules in practice: Brian Feagan (CA)
• Best abstract: A randomized, double-blind, placebo-controlled induction trial of an oral S1P receptor modulator (RPC1063) in moderate to severe Ulcerative Colitis: Results of the TOUCHSTONE study: William Sandborn (US)
• Best abstract: A randomized, double-blind placebo-controlled phase 2a induction study of MEDI2070 (anti-p19 antibody) in patients with active Crohn’s disease who have failed anti-TNF antibody therapy: Bruce E. Sands (US)
• New surgical techniques: Willem Bemelman (NL)

Scientific session 11: Managing the manageable: Chronic pain and fatigue
10:50-12:20
Eduard Cabré (ES) and Igor Khalil (RU)
• Joint pain: arthritis and arthralgias: Juan Jesús Gómez Reinó (ES)
• Algorithm for abdominal pain management: Andreas Sturm (DE)
• Algorithm for the management of fatigue: Janneke van der Woude (NL)
• Best abstract: Post-operative use of anti-TNFα agents in patients with Crohn’s disease and risk of re-operation - a nationwide cohort study: Jens Kjeldsen (DK)
• Best abstract: Oral delivery of a new class of non-antibody protein scaffold Nanofitins targeting TNF-alpha shows a strong preventive and curative anti-inflammatory effect in models of inflammatory bowel disease. Mathieu Clinier (FR)

Scientific session 12: ECCO Lecture

Séverine Vermeire (BE) and Julián Panés (ES)
• The science which will impact our IBD clinic. Maria Abreu (US)
• Awards and closing remarks: Séverine Vermeire (BE)
• The ECCO Film 2015
“The causes, consequences and quality of care for IBD”

February 20-22, 2014, Copenhagen, Denmark

Thursday, February 20, 2014

Top tips for chairs (closed session): 10:45 – 11:15
Geert D’Haens (NL)

Opening & welcome: 12:45 – 13:00
Simon Travis (UK) and Ole Hamberg (DK)

Scientific session 1: Neglected cells as potential target 13:00 – 14:30
Eduard Stange (DE) and James Lee (UK)
- Lymphatic endothelial cells as mediators and targets: Silvio Danese (IT)
- Best abstract: Innate lymphoid cells accumulate in IBD: Geremia, A. (UK)
- Mast cells at the leading edge: Guy Boeckxstaens (BE)
- Best abstract: The GCN2/eIF2alpha/ATF4 signaling pathway is necessary for autophagy response to infection with Crohn’s Disease-associated adherentive Escherichia coli: Nguyen, H. (FR)
- Best abstract: Circadian clock function maintains mucosal architecture and protects against intestinal inflammation in mice: Sina, C. (DE)
- Stromal cells: Innocent bystanders or regulators? Ben Owens (UK)

Scientific session 2: Optimisation of therapy 15:00 – 17:00
Jean-Frédéric Colombel (US) and Dirk van Assendelft (NL)
- Defining quality: Gil Melmed (US)
- Best abstract: Early combined immunosuppression for the management of Crohn’s Disease: A community-based cluster randomized trial: Feagan, B.G. (CA)
- Maintaining quality when choice is limited: Vineet Ahuja (IN)
- Best abstract: Is elderly-onset Ulcerative Colitis a different entity? Natural disease course and treatment response compared to adult-onset disease in the population-based IBDSL cohort: Jeuring, S. (NL)
- Best abstract: Personalised thiopurine dosing based on TPMT genotyping reduces leucopenia occurrence and results in cost-savings in IBD patients; Results from a randomized trial in the Netherlands: Coenen, M. (NL)
- Biologic drug levels in practice: Shomron Ben-Horin (IL)
- Best abstract: Anti-MAdCAM monoclonal antibody PF-00547659 does not affect immune surveillance in the central nervous system of anti-TNF and immunosuppressant experienced Crohn’s Disease patients who are anti-TNF inadequate responders: Results from the TOSCA study: D’Haens, G. (NL)
- Travel with IBD: Climb high, dive deep: Stephan Vavricka (CH)
Friday, February 21, 2014

Scientific session 3: Cost of therapy, burden of care  
08:30 – 09:30

Pia Munkholm (DK) and Irl Monstad (NO)
- Biosimilars – straight ahead or off at a tangent? Pierre Michetti (CH)
- Best abstract: The cost of investigations and medical treatment including biological therapy in a European inception cohort from the biological era – An ECCO-EpiCom study: Burisch, J. (DK)
- Best abstract: Long-term safety and efficacy of golimumab in patients with moderately to severely active Ulcerative Colitis: Results from the PURSUIT-SC maintenance study extension: Reinisch, W. (CA)
- Exit strategies: James Lindsay (UK)

Scientific session 4: Tomorrow’s therapy  
09:30 – 10:30

Herbert Tilg (AT) and Pär Myrelid (SE)
- It’s decision time: Anti-TNF vs anti-integrin therapy: Julian Panés (ES)
- Best abstract: Alpha-I integrin expression as a predictive biomarker for induction of clinical remission by etorilizumab: Analysis of a phase II trial in moderately-severely active Ulcerative Colitis: Keir, M. (US)
- Best abstract: Tralokinumab (CAT-354), an interleukin 13 antibody, in moderate to severe Ulcerative Colitis: A phase 2 randomized placebo-controlled study: Berner Hansen, M. (SE)
- Tomorrow’s surgery: Antonio Spinelli (IT)

Scientific session 5: Fibrosis as a complication  
11:00 – 12:20

Gerhard Rogler (CH) and Tim Raine (UK)
- ECCO-DigestScience Research funding 2014 – Award ceremony
- Intestinal fibrogenesis: Claudio Fiocchi (US)
- Best abstract: Epigenetic control of colonic inflammation via the methyl-binding protein MBD2: Jones, G. –R. (UK)
- Imaging: inflammation vs. Fibrosis: Andrea Laghi (IT)
- Best abstract: Status of ER stress and autophagy in Crohn’s Disease: From genetics to functional readouts: Nys, K. (BE)
- Tandem Talk: Strictureysis: potential and practice: Iris Dotan (IL) and Willem Bemelman (NL)

Scientific session 6: Intestinal failure  
13:30 – 14:50

Laurence Egan (IRE) and Aurelien Amiot (FR)
- Physiology and consequences of short bowel syndrome: Palle Jeppesen (DK)
- Best abstract: Early endoscopic, laboratory and clinical predictors of poor disease course in paediatric Ulcerative Colitis (UC): Turner, D. (IL)
- Surgical quality: timing of decision-making: Iain Anderson (UK)
- Best abstract: Gut homing markers in perianal Crohn’s fistulae: Yassin, N.A. (UK)
- Intestinal transplantation: Just the end, or the end of the beginning? Peter Friend (UK)
Scientific session 7: ECCO Fellowships and Grants

Michael Kamm (AUS) and Pierre Michetti (CH)
- Outcomes from 2012 – 13 Fellowships: Nathalie Aoun (LEB) and Markus Tschurtschenthaler (AT)
- Announcement of ECCO Fellowships and Grants 2014: Edouard Louis (BE)
- Best abstract: Transethnic association study of IBD identifies 14 new disease loci and demonstrates pervasive sharing of genetic risk factors and phenotypic features between five seronegative autoimmune disease: Weersma, R.K. (NL)
- Best abstract: Cross-disease study determines extent of sharing of associated loci between five seronegative autoimmune disease: Ellinghaus, D. (DE)
- Best abstract: Optimising the use of faecal calprotectin for early diagnosis of IBD in primary care: R. P. H. Logan (UK)

Scientific session 8: Challenging Cases

Michael Kamm (AUS) and Pierre Michetti (CH) and Yves Panis (FR)
- Case 1: Ileal Crohn’s disease (is therapeutic choice making decisions more complex?): Marc Ferrante (BE)
- Case 2: Acute severe colitis (the stakes are high!): Maria Nachury (FR)
- Case 3: Dealing active Crohn’s in pregnancy: Jaqueline Paterson (UK)

Scientific session 9: What’s new on the guideline front

Axel Dignass (DE) and Rami Eliakim (IL)
- ECCO Guidelines: Reproduction and IBD: Janneke van der Woude (NL)
- ECCO Guidelines: P-ECO/ESGPHAN Guidelines in Paediatric CD: Frank Rummele (FR)
- ECCO Guidelines: The Crohn’s Disease Consensus: Axel Dignass (DE)

Saturday, February 22, 2014

Scientific session 10: Colitis under the microscope

Gerassimos Mantzaris (GR) and Signe Wildt (DK)
- Is microscopic colitis IBD? Cord Langner (AT)
- Best abstract: Identification of an anti-inflammatory protein from Faecalibacterium prausnitzii, a deficient commensal bacteria implicated in Crohn’s Disease: Seksik, P. (FR)
- Best abstract: Hypoxia responsive elements methylation status governs adherent-invasive Escherichia coli-receptor CEACAM6 expression in Crohn’s Disease: Barnich, N. (FR)
- Best abstract: 16S rRNA gene pyrosequencing indicate that siblings of Crohn’s Disease patients exhibit a biologically relevant dysbiosis in the mucosal microbiota communities: Hedlin, C. (UK)
- Treatment-refractory microscopic colitis: Andreas Munch (SE)
- ECCO Guidelines on Anaemia in IBD: Konstantinos Katsanos (GR)
- Best abstract: Steroid-free remission in adalimumab-treated paediatric patients with moderately to severely active Crohn’s Disease in the IMAGINE 1 trial: Griffiths, A. (CA)
- ECCO Guidelines on Surgery in Ulcerative Colitis: André D’Hoore (BE)
Scientific session 11: Challenging current practice: Value-based healthcare for IBD

10:50 – 12:20

Zuzana Serclova (CZ) and Marilia Cravo (PT)
- What triggers relapse? Charles Bernstein (CA)
- Best abstract: Low microbial gene diversity and depletion of Akkermansia muciniphila is associated with a relapsing course of Ulcerative Colitis: Casellas, F (ES)
- Post-operative prevention - offence or defence? Paul Rutgeerts (BE)
- Best abstract: Optimising post-operative Crohn’s Disease management: Best drug therapy alone versus endoscopic monitoring, disease evolution, and faecal calprotectin monitoring. The POCER study: Kamm, M.A. (AU)
- Best abstract: Agreement among central readers in the evaluation of endoscopic disease activity in Crohn’s Disease: Khanna, R. (CA)
- Challenging conventional pathways of care: Daan Hommes (US)

Scientific session 12: ECCO Lecture

12:20 – 12:50

Séverine Vermeire (BE) and Simon Travis (UK)
- The causes of Crohn’s Disease? Tony Segal FRS (UK)
- Awards and closing remarks: Séverine Vermeire (BE)
- The ECCO Film 2014
“New concepts and current challenges in IBD”

February 14-16, 2013, Vienna, Austria

Thursday, February 14, 2013

Top tips for chairs (closed session): Geert D’Haens (NL) 10:15 – 10:45

Join the fight against IBD 2013: “Crohn’s and Colitis in Europe: The burden of disease in young people:

Helmut Brand (NL) 12:15 – 12:45

Opening & welcome:
Simon Travis (UK) and Wolfgang Petritsch (AT) 12:45 – 13:00

Scientific session 1: Early stage IBD Oliver Brain (UK) and 13:00 – 14:30
Silvio Danese (IT)
- Does the pathogenesis change over the course of the disease?: Matthieu Allez (FR)
- Best abstract: Functional consequences of a novel IL-10 receptor alpha mutation on innate and adaptive immunity in early-onset Inflammatory Bowel Disease: J. N. Samsom (NL)
- Is there a therapeutic window of opportunity?: Gert van Assche (BE)
- Best abstract: A novel FOXO3-driven pathway determines prognosis in Crohn’s Disease, rheumatoid arthritis and malaria: J. Lee (UK)
- Best abstract: Anti-TNF in patients with an early course of Crohn’s Disease - a prospective observational study in Germany: B. Bokemeyer (GER)

Scientific session 2: Preventing progression in IBD 15:00 – 17:00
Arthur Kaser (UK) and Alexander Moschen (AT)
- Fat and inflammation: Britta Sieg mund (GER)
- Best abstract: Caspase 8 maintains epithelial cell adhesion and intestinal homeostasis in vivo through regulation of clathrin-dependent endocytosis and autophagy: G. Pinetón de Chambrun (FR)
- Inflammation in IBD: Tissue repair or despair: Florian Rieder (US)
- Best abstract: Prep 1: A new player in the development of IBD-associated fibrosis: S. D’Alesion (IT)
- Best abstract: Development of the Crohn’s Disease (CD) digestive damage score: The Lé mann score: B. Pariente (FR)
- Best abstract: ER stress transcription factor Xbp1 suppresses intestinal tumourigenesis: L. Niederreiter (UK)
- Preventing cancer: Ian Lawrance (AU)
- ECCO: ESP Histopathology Guidelines in IBD: Arzu Ensari (TR) and Fernando Magro (PT)
Scientific session 3: What is on the horizon?  
08:30 – 09:30
Siew Ng (CN) and Herbert Tilg (AT)
- Genomics in IBD: Who gets what and when? Stefan Schreiber (GER)
- Best abstract: Characterization of the ~40,000 patient cohort of the International Inflammatory Bowel Disease Genetics Consortium (IIBDGC): C. W. Lees (UK)
- Best abstract: Clinical and endoscopic improvement following haemopoetic stem cell transplantation in the ASTIC trial: C. Hawkey (UK)
- Therapeutic targets to hit or miss: Jean-Frédéric Colombel (US)

Scientific session 4: Clinical trials in Ulcerative Colitis  
09:30 – 10:30
Franck Carbonnel (FR) and Alexander Eser (AT)
- Pitfalls in design and practice: Brian Feagan (CA)
- Best abstract: Indigenous Australians (IA) have a distinctive gut microbial profile compared to patients with Inflammatory Bowel Disease (IBD) and non Indigenous control: G. Iyngkar (AU)
- Best abstract: Videlizumab induction therapy for patients with Crohn’s Disease and prior anti-tumour necrosis factor antagonist failure: A randomised, placebo-controlled, double-blind, multicentre trial: P. Rutgeerts (BE)
- Long-term outcomes: Sandro Ardizzone (IT)

Scientific session 5: Reproduction and IBD  
11:00 – 12:20
Monica Cesarini (IT) and Sanja Kolacek (HR)
- Pharmacokinetics in pregnancy and location: Implications for drug efficacy & safety: Zuzana Zelinkova (SK)
- Best abstract: Pre-existing IgG antibodies to the Fab region of infliximab predict efficacy and safety in IBD patients naïve to anti-TNF agents: C. Steenholt (DK)
- Care from conception to delivery: Janneke van der Woude (NL)
- Best abstract: Prevalence of anemia in patients with Inflammatory Bowel Disease during the first ten years from diagnosis-results from a population-based inception cohort, the IBSEN Study: M. L. Holvik (NO)
- Neonatal safety: Saskia de Wildt (NL)

Scientific session 6: Adolescents with IBD  
13:30 – 14:50
Kajsa-Leena Kolho (FI) and Frank Ruemmele (FR)
- The adolescent phenotype: Gabor Veres (HU)
- Best abstract: Incidence and phenotype at diagnosis in paediatric IBD patients –An ECCO-EpiCom study: J. Bursch (DK)
- Organising care: Hankje Escher (NL)
- Best abstract: Serious infections and associated risk factors in patients receiving infliximab and immunotherapies for children with Inflammatory Bowel Disease: DEVELOP registry data: J. Escher (NL)
- Therapeutic strategies: Richard Russell (UK)

Scientific session 7: ECCO Fellowships and Grants  
15:20 – 16:05
Marie Joossens (BE) and Andreas Sturm (GER)
- Outcomes from 2011/12 Fellowships: Timon Erik Adolph (AT) and Jessica Claire Wilson (IE)
- Announcement of ECCO Fellowships and Grants 2013: Andreas Sturm (GER)
- Best abstract: Relationships between clinical remission, C-reactive protein normalization and mucosal healing in Crohn’s Disease: Analyses from the SONIC trial: L. Peyrin-Biroulet (FR)
- Best abstract: Optimising the use of faecal calprotectin for early diagnosis of IBD in primary care: P. H. Logan (UK)
Saturday, February 16, 2013

Scientific session 9: Course and treatment of IBD in the elderly

08:30 – 10:30

Mircea Diculescu (RO) and Konstantinos Papadakis (GR)

- The natural history of IBD in the elderly: Corinne Gower-Rousseau (FR)
- Best abstract: The quality of care for inpatients with Inflammatory Bowel Disease in the UK over a six year period: L. Alrubayy (UK)
- Medical management of IBD in the elderly: David Binion (US)
- Best abstract: Tumour necrosis factor-alpha antagonists and cardiovascular disease in Inflammatory Bowel Disease: N. Nyboe Andersen (DK)
- Best abstract: Mortality and causes of death in Ulcerative Colitis: Results from a Norwegian population based study during a twenty years period of follow-up (the IBSEN study): I. L. K. Monstad (NO)
- Minimising damage: Single incision surgery and enhanced recovery: Tonia Young-Fadok (US)
- First N-ECCO Consensus on caring for patients with IBD: Marian O’Connor (UK)
- Opportunistic Infection Guidelines: The update: Jean-François Rahier (BE)

Scientific session 10: Treating IBD in patients with past or current malignancy

11:00 – 12:20

Dino Tarabar (RS) and Ricardo Veloso (PT)

- The risk of extra-intestinal cancer in IBD: Tine Jess (DK)
- Best abstract: Risk of cervical dysplasia and cancer in patients with Inflammatory Bowel Disease: C. Rungø (DK)
- Lessons from rheumatology: Georg Schett (GER)
- Best abstract: When to stop therapy in Crohn’s Disease? Results of the EPACT-2 Update panel: V. Pittet (SH)
- Practical management of IBD with past or current malignancy: David Laharie (FR) and Jean-Frédéric Blanc (FR)

Scientific session 11: ECCO Lecture

12:20 – 12:50

Simon Travis (UK) and Séverine Vermeire (BE)

- Where it all started and where it’s going to: Biological therapy for IBD: Sander van Deventer (NL)

Closing remarks

12:50 – 13:00

Organising Committee Members and Simon Travis (UK)
“Breaking down barriers in IBD”

February 16-18, 2012, Barcelona, Spain

Thursday, February 16, 2012

Top tips for chairs (closed session): Geert D’Haens (NL) 10:45 – 11:15

Opening & welcome:
Miquel Gassull (ES) and Daniel Hommes (US) 12:45 – 13:00

Scientific session 1: Common ground across inflammatory disorders 13:00 – 14:20
Miquel Sans (ES) and Jan Wehkamp (GER)
- Tandem talk: Shared pathways in inflammation: Maria Abreu (US) and Fiona Powrie (UK)
- Best abstract: Card9 is a crucial adapter protein for gastro-intestinal immune response. Harry Sokol (FR)
- Best abstract: Identification of Glycoprotein 2 as an immunomodulator of innate and adaptive immune responses: Lael Werner (GER)
- Best abstract: Induction of autophagy upon DC-T cell contact is mediated by LKB1-AMPK-mTOR signaling: Manon Wildenberg (NL)
- Inflammatory side-effects of biological therapy: François Aubin (FR)

Scientific session 2: Measuring success and failure in IBD Dana Duricova (CZ) 14:50 – 16:10
and Pierre Michetti (CH)
- Predicting disease outcome: Siew Ng (HK)
- Best abstract: Mortality and cancer in pediatric Inflammatory Bowel Disease: A population-based study: Guillaume Savoye (FR)
- Tandem talk: Scoring disease damage and disability: Benjamin Pariente (FR) and Laurent Peyrin-Biroulet (FR)
- Best abstract: Development of three practical indices for mucosal healing among patients with moderate to severe Crohn’s Disease: Edouard Louis (BE)
- Assessing endoscopic and disease activity in practice: Gert van Assche (BE)

Scientific session 3: Preliminary results from the 3rd Scientific Workshop 16:10 – 16:30
Dana Duricova (CZ) and Pierre Michetti (CH)
- Malignancy in IBD: Laurent Beaumerie (FR), Silvio Danese (IT) and Laurence Egan (IRE)

Mini-session 3: ECCO-ESPGHAN Paediatric Guidelines on UC Dan Turner (IL) 16:30 – 17:00

84
Friday, February 17, 2012

Scientific session 4: Imaging in IBD

08.30 – 09.30
Simon Jackson (UK), André D’Hoore (BE) and Janneke van der Woude (NL)
- Medical or surgical therapy for obstruction: Is imaging the key? Casper Gijbert Noomen (NL)
- IBDU facing surgery - Are you sure the small bowel is normal? Alisa Hart (UK)
- ECCO-ESGAR Imaging Guidelines: Julián Panés (ES)
- Case resolution
- Best abstract: Endocytoscopy allows accurate in vivo differentiation of mucosal inflammatory cells in IBD - A pilot study: Helmut Neumann (GER)
- Best abstract: Use of fecal calprotectin as marker of disease activity in patients under maintenance treatment with infliximab for ulcerative colitis: Martine De Vos (BE)

Scientific session 5: Complications carousel: Management tips and tricks

09.30 – 10.30
Simon Jackson (UK), André D’Hoore (BE) and Janneke van der Woude (NL)
- Anaemia: Christoph Gasche (AT)
- Osteoporosis: Ad Van Bodegraven (NL)
- Renal: Satish Keshav (UK)
- Ocular: Luis Pablo (ES)
- Pulmonary: Franck Carbonnel (FR)
- Thromboembolism: Gerassimos Mantzaris (GR)
- Discussion

Scientific session 6: Impact of IBD on daily life

11.00 – 12.20
Fermin Meán (ES) and Fernando Magro (PT)
- Debate: IBD and IBS – Marriage or divorce? Giovanni Barbara (IT) and Michael Kamm (AUS)
- Best abstract: SPARC modifies colonic tissue healing and inflammation by regulating collagen and MMP expression: Ian Lawrance (AUS)
- Best abstract: Anti TNF- alpha Therapy is a major cost driver in Inflammatory Bowel Disease: Results from the COIN study: Mirthe Van der Valk (NL)
- The patient perspective: Ben Wilson (UK)

Guided poster session
Poster award ceremony

Scientific session 7: Organising care in IBD Mircea

13.30 – 14.30
Diculescu (RO) and Francesca Casellas (PT)
- E-Health and home-testing: Ready for prime time? Pia Munkholm (DK)
- Best abstract: Importance of trough levels and antibodies on the long-term efficacy of Infliximab therapy in Ulcerative Colitis: María Teresa Arias Santander (ES)
- Best abstract: Individualised infliximab treatment using therapeutic drug monitoring: A prospective controlled trough level adapted infliximab treatment (TAXIT) trial: Niels Vande Casteele (BE)
- The IBD care pathway: Daniel Hommes (US)
Scientific session 8: ECCO Fellowships and Grants

15:00 – 15:50

Andreas Sturm (GER)
- Fellowship 1: Bénédicte Brouais-Le Royer (CH)
- Fellowship 2: Lael Werner (GER)
- Announcement of ECCO Fellowships and Grants 2012: Andreas Sturm (GER)
- The role of proteases in IBD: Daniel Lottaz (CH)
- Best abstract: Multiple functional variants at the 3p21 locus contribute to ulcerative colitis. Results from a European consortium: Isabelle Cleynen (BE)
- Best abstract: TLR4 signaling activates the WNT pathway in a mouse model of colitis-associated neoplasia: Rebeca Santana Silva (US)

Scientific session 9: Challenging Cases

15:50-17:25 Jürgen

Schölerich (GER), Peter Irving (UK), Manuel Barreiro (ES) and Antonino Spinelli (IT)
- Life-threatening restrictive TBC – Pericarditis affecting a Crohn’s patient while on treatment with an anti-TNF 42: Xavier Aldegueur (ES)
- The troubled journey of a young colitis patient: Shaji Sebastian (UK)
- Crohn's Disease, Anti-TNF & surgery: Paulo Kotze (BRA)
- Best abstract: Adenomas in patients with Inflammatory Bowel Disease: Increased risk of advanced neoplasia: Fiona van Schaik (NLD)
- Best abstract: Immunosuppressive co-treatment with adalimumab (ADA) may be more effective than ADA monotherapy for maintaining remission in Crohn's disease (CD): Catherine Reenaers (BE)
- How I manage abnormal LFTs in IBD: Maria Esteve (ES)

Saturday, February 18, 2012

Scientific session 10: Surgery in IBD

08:30 – 10:00

Daniel Hommes (US) and Bjorn Moun (NOR)
- Perianal CD: Bruce George (UK)
- Best abstract: Adding ciprofloxacin to adalimumab results in a higher fistula closure rate in perianal fistulizing Crohn’s disease: Peter Dewint (NLD)
- Tandem talk: Find the best timing for surgery: Sandro Ardizzone (IT) and Antonino Spinelli (IT)
- Best abstract: Risk of colectomy in patients with ulcerative colitis under thiopurine treatment: Study of prevalence and predictive factors: ENEIDA project: Alex Cañas-Ventura (ES)
- Best abstract: Long-term outcome after first intestinal resection in paediatric-onset Crohn's disease: A population-based study: Medina Bouait (FR)
- Managing complications: Emmanuel Tret (FR)

Scientific session 11: Where are we heading?

10:30 – 11:50

Antonio Lopez San Roman (ES) and Simon Travis (UK)
- Are gene hunting days over? Miles Parkes (UK)
- Best abstract: Genetic and functional evidence for a role for CYLD in Crohn’s disease: Results from a European consortium: Isabelle Cleynen (BE)
- Are stem cells ready for clinical practice? Gijs van den Brink (NL)
- Best abstract: TNF and MDP induce epithelial-to-mesenchymal transition in human intestinal cells: Implications for the pathogenesis of Crohn's disease-associated fistulae and the use of anti-TNF antibodies: Michael Scharl (CH)
- Are we ready to manage the microbiome? Arlette Darfeuille-Michaud (FR)
Scientific session 12: ECCO Lecture 11:50 – 12:20
Antonio Lopez San Roman (ES) and Simon Travis (UK)
- Translating evidence from clinical trials into personalised medicine: Stephen Hanauer (US)

Closing remarks: 12:20 – 12:30
Simon Travis (UK)
February 24-26, 2011, Dublin, Ireland

Thursday, February 24, 2011

Top tips for chairs (closed session): Geert D’Haens (NL) 10:45 – 11:15

Opening & welcome: Daniel Hommes (NL) and Colm O’Morain 12:45 – 13:00

Scientific session 1: Where are we heading?
Jean-Frédéric Colombel (FR) and Laurence Egan (IRE)
- Concept and importance of mucosa-associated bacteria: Arlette Darfeuille-Michaud (FR)
- Best abstract: Autophagy contributes to immune regulation through destabilization of the immunological synapse: Manon Wildenberg (NL)
- Metabolic functions as sensor for the microbiome: Dirk Haller (GER)
- Best abstract: Gene expression profiling in CD8 T cells predicts disease course in Crohn’s Disease and Ulcerative Colitis: James Lee (UK)
- Stressed out! Arthur Kaser (AT)
- Best abstract: Crohn’s Disease-associated dysbiosis as a predictive factor of clinical relapse: A microbiological substudy of the GETAID-STORI cohort: Sylvie Rajca (FR)
- Microbial manipulation for IBD in practice: Eamonn Quigley (IRE)

Scientific session 2: Intestinal Healing: 2nd ECCO Pathogenesis Workshop
Florian Rieder (US) and Gigi Veereman (BE)
- Overview: Andreas Sturm (GER)
- Mechanisms of intestinal healing: Miquel Sans (ES)
- Measures and markers for monitoring intestinal healing: Marco Daperno (IT)
- Impact of intestinal healing on the course of IBD: Laurent Peyrin-Biroulet (FR)
- Therapeutic strategies to enhance intestinal healing: Geert D’Haens (NL)
- Best abstract: Pro-fibrogenic action of Toll-like receptor and NOD-like receptor ligands on human intestinal myofibroblasts: Florian Rieder
- Best abstract: Depth of remission may not predict outcome of UC over 2 year: Daniel Burger (UK)

Mini-session 2: ECCO Guidelines 1: The ECCO Consensus process and future prospects
Gert van Assche (BE) 16:40 – 17:00

Friday, February 25, 2011

Scientific session 3: The age of innocence: IBD in children
Sanja Kolacek (CRO) and Tom Øresland (NO)
- IBD in the very young - insights into pathogenesis: Frank Ruemmele (FR) 08:30 – 10:00
• Best abstract: Paediatric modification of the Montréal Classification for Inflammatory Bowel Disease - the Paris classification: Arie Levine (IL)
• IBD Surgery in children: indications and outcome: Paolo Lionetti (IT)
• Best abstract: Induction and maintenance Adalimumab therapy for the treatment of Moderate to Severe Crohn’s Disease in children: Anne Griffiths (CAN)
• Best abstract: Bronchopulmonary manifestations in Inflammatory Bowel Diseases: a retrospective study from the GETAID: Matthieu Allez (FR)
• Management of IBD in adolescence: Robert Heuschkel (UK)

Mini-session 3: ECCO Guidelines 2: Paediatric acute severe colitis

Dan Turner (IL)

10:00 – 10:20

Scientific session 4: Targets in IBD: Lost and Found

Silvio Danese (IT) and Charlie Lees (UK)

• TLRs as therapeutic targets: Luke O’Neill (IRE)
• Best abstract: Phase III safety, immunogenicity and clinical results of TNFα-kinoid immunotherapeutic immunization in Crohn’s Disease patients: Pierre Vandepapellere (FR)
• Past and future of T cell-directed therapies: Yehuda Chowers (IL)
• Best abstract: Inhibition of IL17A by Secukinumab is ineffective for Crohn’s Disease (CD): Simon Travis (UK)
• Best abstract: NKG2D activation drives Th17 response in Crohn’s Disease: Benjamin Patiente (FR)
• Therapeutic implications of autophagy and apoptosis: Stefan Schreiber (GER)

Guided poster session
Poster award ceremony

Scientific session 5: Optimising surgical outcomes in IBD

Johan D. Soderholm Linkoping (SWE) and Antonino Spinelli (IT)

• Nutrition and medication preparation for surgery: John Hyland
• Best abstract: Cyclosporin versus Infliximab in acute severe ulcerative colitis refractory to intravenous steroids: A randomized study: David Laharie
• Tandem Talk: Treating ileocaecal Crohn’s disease: resect or medicate? Julian Panes (ES) and André D’Hoore (BE)
• Best abstract: Infliximab, Azathioprine, or Infliximab + Azathioprine for treatment of Moderate to Severe Ulcerative Colitis: the UC SUCCESS trial: Remo Panaccione (CANC)
• Best abstract: Infliximab for Severe IV steroid-refractory Ulcerative Colitis: Can Infliximab trough levels guide our management? Marc Ferrante (BE)
• Improving outcomes of pouch surgery: raising the bar: John Nicholls (UK)

Scientific session 6: Daily challenges in IBD

Hülya Özer-Hamzaoglu (TR), Martine De Vos (BE)

• Report of the ECCO Consensus on reproduction and IBD37: Janineke van der Woude (NL)
• Best abstract: Risk of squamous and basal cell carcinomas in patients with Inflammatory Bowel Disorders exposed to thiopurines: The Cesarine National Cohort Study: Laurent Peyrin-Biroulet (FR)
• Optimising conventional therapies for IBD: Peter Irving (UK)
• Best abstract: 52-week clinical efficacy with Adalimumab in patients with Moderately to Severely Active Ulcerative Colitis who failed corticosteroids and/or immunosuppressants: Walter Reinisch (AT)
• Best abstract: Long term evolution and impact of immunomodulator co-treatment and withdrawal on Infliximab on trough levels in 223 patients with Crohn’s Disease: David Drobne (BE)
• Tailoring anti-TNF therapy in CD: Edouard Louis (BE)

Mini-session 6:  
Hülya Över-Hamzaoglu (TR)  
17.00 – 17.20

• Imaging in IBD: Simon Jackson (UK)

Saturday, February 26, 2012

Scientific Session 7: Challenging Cases  
Bemelman (NL), Eugene Domenech (ES), Michael Kamm (AT), Joseph Keane (IE), Siew Ng (CN)  
08:30 – 10:00 Willem

• Challenging Case 1: Tuberculosis: Séverine Vermeire (BE)  
• Challenging Case 2: Transplantation: Elena Ricart (ES)  
• Challenging Case 3: Hermann Schulze (DE)

Scientific Session 8: Cancer and IBD  
Dino Tarabar  
10:30 – 12:00

(RS), Gijs van den Brink (NL)  
• Inflammation and Cancer: Partners in crime: Florian Greten (DE)  
• Best abstract: Junctional adhesion molecule-a is a new key regulator in Colitis associated colon cancer: Stefania Vetrano (IT)  
• Needle in a haystack: strategies to detect cancer: Ralf Klessich (DE)  
• Best abstract: Incidence of dysplasia and colorectal cancer in patients with Ulcerative Colitis included in the Spanish ENEIDA registry: Jordi Gordillo (ES)  
• Best abstract: Risk factors for Inflammatory Bowel Disease associated colorectal carcinoma: Maurice Lutgens (NL)  
• Extraintestinal cancer in IBD: Corey Siegel (USA)

Scientific Session 9: ECCO Lecture  
Daan  
12:00 – 13:10

Hommes (NL), Simon Travis (UK)  
• ECCO Fellowships 2010: Presentation 1: Emanuela Sala (IT)  
• ECCO Fellowships 2010: Presentation 2: Caterina Strisciuglio (IT)  
• Announcement of ECCO Fellowships & Grants 2011: Matthieu Allez (FR)  
• Marc Lémann Lecture: Understanding clinical trials in IBD: Jean-Frédéric Colombel (FR)

Closing remarks  
Daan  
13:00 – 13:10

Hommes (NL)
“Cause and consequence in IBD”

February 25-27, 2010, Prague, Czech Republic

Thursday, February 25, 2010

Opening and welcome

13:00 – 13:10

Petr Dite (CZ), Jean-Fred Colombel (FR)

Scientific Session 1: Fibrogenesis and its consequences

13:00 – 14:40

Franco Scaldaferr (IT)

- Mechanisms of intestinal fibrogenesis: Miquel Sans (ES)
- Best abstract: Smad7 expression in T cells protects from colitis-associated colorectal cancer: Massimo Fantini (IT)
- Markers of fibrosis in practice: Is this stricture inflammatory?: Gerhard Rogler (CH)
- Best abstract: IRF-4 drives experimental colitis through direct activation of IL-17 promoter: Jonas Mudt (DE)
- Best abstract: Oxygen sensor inhibition attenuates TNF-α-induced intestinal epithelial damage by hypoxia-inducible factor (HIF)-1-dependent repression of fas-associated death domain protein (FADD): Pieter Hindryckx (BE)
- Therapeutic opportunities for modifying fibrosis: lessons from the liver: Massimo Pinzani (IT)

Scientific Session 2: Extraintestinal manifestations

15:10 – 16:50

Martin Bortlik (CZ), Republic Gerard Dijkstra (NL)

- Communication between the gut and liver: Pierre Desreumaux (FR)
- Best abstract: Modulation of gut immune homeostasis via the Toll-interacting protein: Michel H Mailard (CH)
- PSC and prognosis: Roger Chapman (UK)
- Best abstract: Genetic variants that predispose to early complications in Crohn's disease identified by re-analysing genome-wide association study data from 3 consortia: James Lee (UK)
- Best abstract: Decreased expression of ATG 16L1 and IRGM results in pro-inflammatory dendritic cells: Manon Wildenberg (NL)
- Best abstract: Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: Walter Reinisch (AT)
- When the skin causes problems in IBD: Emmanuel Lafitte (CH)

Scientific Session 3: Therapeutic opportunity: Leukocyte Trafficking

08:30 – 10:00

Maria Papp (HU), Andreas Sturm (DE)

- Mechanisms in intestinal inflammation: Jesús Rivera Nieves (USA)
- Best abstract: Phase I results of intravenous autologous bone marrow derived mesenchymal stromal cell treatment in refractory Crohn's disease: Marjolijn Duijvestein (NL)
- Policing the traffic - safety first?: Brian Feagan (CA)
Scientific Session 4: Endpoints and outcomes of therapy

10:30 – 12:00

Milan Lukas (CZ), Gottfried Novacek (AT)
- Predicting the course of disease: Andreas Stallmach (DE)
- Best abstract: Predictors of poor outcome in paediatric Crohn’s disease: Guillaume Savoye (FR)
- Mucosal healing and its relevance: Gert van Assche (BE)
- Best abstract: Mucosal healing in Crohn’s disease is associated with high infliximab trough levels: Wouter Van Moerkercke (BE)
- Future perfect-endpoints and damage scores: Laurent Peyrin-Biroulet (FR)

Guided poster session
Award ceremony

Scientific Session 5: It’s not always IBD

13:30 – 15:00

Andrea Cassinotti (IT), Denis Franchimont (BE)
- Chronic granulomatous disease: Edward Loftus (USA)
- Best abstract: Clinical and biological efficacy to anti-TNF therapy relates to reciprocally modulating blood and intestinal mucosa Foxp3 expression: Zhe Li (BE)
- TB or not TB? Gerassimos Mantzaris (GR)
- Best abstract: Endoscopic response to placebo therapy in Crohn’s disease: Marc Ferrante (BE)
- Best abstract: Deep remission for adalimumab-treated patients with moderate to severe ileocolonic Crohn’s disease: Results from EXTEND: Jean-Frédéric Colombel (FR)
- Intestinal Behçet’s disease: Aykut Ferhat Celik (TR)

Scientific Session 6: Safety in IBD therapy

15:30 – 17:00

Iris Dotan (IL), Zusana Zelinkova (SK)
- Immunomodulation and lymphomas: Laurent Beaugerie (FR)
- Best abstract: Liver histology of IBD patients who are treated with 6-thioguanine due to failure of conventional thiopurines: Dirk van Asseldonk (NL)
- Pregnancy: Janneke van der Woude (NL)
- Best abstract: Severe auto-immune driven arthralgia as a new side effect in anti-TNFα treated IBD patients? Wouter Van Moerkercke (BE)
- Best abstract: Long-term outcome of treatment with infliximab in paediatric Crohn’s disease: a population-based study: Jean-Frédéric Colombel (FR)
- Travelling with IBD: Shomron Ben-Horin (IL)
Saturday, February 27, 2010

Scientific Session 7: Intestinal failure  
08:30 – 10:00

Ana-Maria Catuneanu (RO), Miquel Gassull (ES)
- Physiology of short bowel syndrome: Palle Bekker Jeppesen (DK)
- Best abstract: Animal protein intake and risk of inflammatory bowel disease: The E3N prospective study: Prevost Jantchou (FR)
- Managing high output stomas and enterocutaneous fistulae: Simon Gabe (UK)
- Best abstract: Effects of dietary and systemic iron on chronic ileitis targeting endoplasmic reticulum stress responses and apoptosis in the epithelium: Stefan Wagner (DE)
- Best abstract: Predictors of intestinal failure in inflammatory bowel disease: Richard Gearry (NZ)
- Intestinal transplantation: Olivier Goulet (FR)

Scientific Session 8: Challenging Cases  
10:00 – 11:00

Francisco (PT), Grazyna Rydzewska (PL), Severine Vermeire (BE), Alastair Windsor (UK)
- Case 1: Hide and seek - CMV in IBD: Johannes Meier (DE)
- Case 2: An unusual mediastinal complication during anti-TNF treatment: Harald Peeters (BE)
- Case 3: Severe hypoalbuminemia in a patient with long duration Crohn’s disease treated with Infliximab: Catarina Andrade Fidalgo (PT)

Scientific Session 9:  
Pathogenesis Workshop: Loss of response to anti-TNF monoclonal antibodies  
11:30 – 12:15

Mathieu Allez (FR), Yehuda Chowers (IL)

Scientific Session 10: ECCO Lecture  
12:15 – 13:00

Jean-Frederic Colombel (FR), Daan Hommes (NL)
- ECCO Fellowship 2009: The impact of anti-TNF therapy of the faecal microbiota in inflammatory bowel disease: Francesca Fava (IT)
- Announcement of ECCO Fellowships & Grants 2010: Matthieu Allez (FR)
- Science at the bench - what will impact on clinical practice? Claudio Fiocchi (USA)
- ECCO’s road 2010-2012: Daan Hommes (NL)
"Unmet therapeutic needs in IBD"

February 5-7, 2009, Hamburg, Germany

Thursday, February 5, 2009

Scientific Session 1

Axel Dignass (DE), Tibor Hlavaty (SK)

- Welcome: Jean – Frederic Colombel (FR)
- IBD: An inflammatory barrier disease? (Tandem talk part 1): Pierre Michetti (CH)
- IBD: An inflammatory barrier disease? (Tandem talk part 2): Stefan Schreiber (DE)
- Best Abstract: Colonic mucosal expression of barrier genes in patients with inflammatory bowel disease before and after first infliximab treatment: Ingrid Arijis (BE)
- Best abstract: targeting gut T cell Ca2+ release-activated Ca2+ channels inhibits Th1 cytokine production and T-bet in inflammatory bowel disease: Antonio Di Sabatino (IT)
- The unmet therapeutic need in IBD: the Japanese perspective: Toshifumi Hibi (JP)

Scientific Session 2

15:00 – 17:00

Charlie Lees (UK), Giovanni Monteleone (IT)

- How do anti-inflammatory therapies work? – Back from the bedside to the bench (Tandem Talk part 1: Clinical): Julian Panes (ES)
- Best abstract: Azathioprine modulates human monocyte function via the p2-2 signalling pathway: Lu Zhou (NL)
- Best Abstract: The lymphatic system controls intestinal inflammation and inflammation-associated colon cancer through the chemokine decoy receptor D6: Stefania Vettrano (IT)
- Changing gut flora: aetiological & therapeutic implications (Tandem talk part1): Patricia Lepage (AT)
- Changing gut flora: aetiological & therapeutic implications (Tandem talk part2): Herbert Tilg (AT)
- Best abstract: neutrophil accumulation and bacterial clearance are delayed in patients with crohn’s disease: Buhussain Hayee (UK)
- Best abstract: Temporal stability of faecal microbiota by inter spacer rDNA bacterial profiling (IS-pro): Mathijs Grasmann (NL)
Friday, February 6, 2009

Scientific Session 3  
08:30 – 10:30
Laurence Egan (IE), marc Lemann (FR), Markus Neurath (DE), Tom Øresland (NO), Stefan Schreiber (DE)

- Live Endoscopy: Live Demonstration via Satellite from Kiel to Hamburg: Marco Deparno (IT), Stephan Hellmig (DE), Tanja Kühbacher (DE), Susanna Nikolau (DE), Marcus Seeger (DE), Andrea Sturm (DE)

Scientific Session 4  
11:00 – 14:00
Jean-Frederic Colombel (FR), Andre van Gossum (BE)

- OMEG-ECCO consensus report: small bowel endoscopy in IBD (Part 1): Arnaud Bourreille (FR)
- OMEG-ECCO consensus report: small bowel endoscopy in IBD (Part 2): Ana Ingjatovic (UK), Chairs: Matthieu Allez (FR), Willem Bemelman (NL), Lloyd Mayer (USA), Simon Travis (UK)
- Difficult cases in IBD: Yehuda Chowers (IL)
- State of the art lecture (endoscopy): Optimal endoscopic techniques in 2009: Ralf Kiesslich (DE)

Guided poster Session

Scientific Session 5  
14:00 – 15:20
Elena Beloussova (RU), Konstantinos Papadakis (GR)

- Immunomodulators in IBD: is there a price to pay?: Gert van Assche (BE)
- Best abstract: Thiopurine therapy is associated with a three-fold decrease in the incidence of advanced colorectal neoplasia in IBD patients with longstanding extensive colitis: The sesame prospective data: Laurent Beaugerie (FR)
- Best abstract: Aza-thioprine/biological therapy does prevent surgery but not recurrence in smokers with crohn’s disease: Tamas Szamosi (HU)
- Stress in IBD: the overlooked villain: David Rampton (UK)
- Best abstract: Geographic distribution of inflammatory bowel disease (IBD) in France is influenced by sunlight exposure: V. Nenich (FR)
- Best abstract: Patterns and predictors of dosage increase in patients treated with adalimumab for crohn’s disease in the United States: Jingdong Chao (USA)

Scientific Session 6  
15:50 – 17:00
Simon Travis (UK)

- ECCO Fellowship 2008: Alessia R. Grillo (IT)
- Announcement of ECCO Fellowship & Grants 2009: Simon Travis (UK), Chairs: Jens Dahlerup (DK), Laurent Payrin-Biroulet (FR)
- The right use of diagnostics: How not to harm patient: Edouard Louis (BE)
• Best Abstract: Lack of usefulness of systematic determination of azathioprine (AZA) metabolites during follow-up of inflammatory bowel disease (IBD) patients under thiopurinic therapy: Final results of the meta-study. Y. Gonzalez Lama (ES)

• Best abstract: Immunosuppressive (IS) therapy impacts the results of interferon® and tuberculine skin in routine screening for latent tuberculosis (LTB) in patients with inflammatory bowel disease (IBD), Palov Papay (AT)

Saturday, February 7, 2009

Scientific Session 7

Michael Kamn (AU), Miquel Sans (ES)

• Crohn’s disease: Where it all started and where it’s all going. Lloyd Mayer (USA)
• The unmet therapeutic need in IBD: a European regulatory view. Sif Ormsdottir (IS)
• Best abstract: Welcome: A randomized, double-blind, controlled trial comparing certolizumab pegol 400 mg every 2 weeks with every 4 weeks for maintenance of response and remission in patients with moderate-to-severe Crohn’s disease with secondary failure to infliximab: Paul Rutgeerts (BE)
• Best abstract: Clinical course and cost of care in ulcerative colitis. Markov chain analysis of a European prospective population-based cohort. Selwyn Odes (DK)

Scientific Session 8

Beaupere (FR), Geert D’Heans (BE), Sanja Kolacek (HR), Alastair Windsor (UK), Oded Zmora (IL)

• Optimizing IBD management: Case-based discussion: Limited ileocecal crohn’s disease with a simple perianal fistula at presentation: Gianluca Sambierto (IT)
• Optimizing IBD management: Case-based discussion: Fistulising CD: Dario Sorrentino (IT)
• Optimizing IBD management: Case-based discussion: Acute severe UC in 16 yr old female: Franck Carbonnel (FR)
• Best abstract: Laparoscopic-assisted versus open ileocolic resection for crohn’s disease: Long term results of a prospective randomized trial: E. J. Eshuis (NL)

Scientific Session 9

Jean-Frederic Colombel (FR), Eduard Stange (DE)

• CD Consensus update presentation (Part 1): Alex Dignass (DE)
• CD Consensus update presentation (Part 2): Gert van Assche (BE)
• CD Consensus update presentation (Part 3): James Lindsay (UK)
• ECCO lecture: The unmet therapeutic need in IBD: Michael Kamn (AU)
• Concluding remarks. Jean-Frederic Colombel (FR)
3rd Congress of ECCO

February 28 – March 1, 2008, Lyon, France

Thursday, February 28, 2008

Welcome
Miquel Gassull (ES), Jean-Frédéric Colombel (FR)

Scientific Session 1: Pathogenesis of IBD: What's New and What's the Relevance to Clinical Practice?

Stefan Schreiber (DE), Christian Mottet (CH)
- New Discoveries in IBD Genetics and insights into Therapeutic Development: Miles Parkes (UK), Severine Vermeire (BE)
- Of Mice and Men: Relevance of Animal Studies to Human Research: Fabio Cominelli (USA), Silvio Danese (IT)
- Best Abstract: Selective Influence of Tcf-4 Mediated Wnt Signaling on Intestinal In innate and Adaptive Immunity of Ileal Crohn’s Disease: Maureen Koslowski (DE)
- Best Abstract: Evidence for Dysbiosis in Pouchitis Using 16s rRNA Sequencing: Simon D. McLaughlin (UK)
- Defensins: What's their role in Crohn's Disease? Eduard Stange (DE)

Scientific Session 1 continued: Pathogenesis of IBD: What's New and What's the Relevance to Clinical Practice?

Daan Hommes (NL), Shomron Ben-Horin (IL)
- T-Cell Co-stimulation and Therapeutic Implications: Markus Neurath (DE)
- Best Abstract: Lymphoneogenesis: A New Component In Inflammatory Bowel Disease Pathogenesis: Silvio Danese (IT)
- Best Abstract: Probiotic E. Coli (SymbioFlor® 2) Treatment Mediates Antimicrobial β-Defensin (hBD-2) Synthesis and Fecal Excretion in Humans: Jan Wehkamp (DE)

Friday, February 29, 2008

Scientific Session 2: Live Endoscopy

Guido Tytgat (NL), Geert D’Haens (BE), Jean-Fredéric Colombel (FR), Gert de Hertogh (BE)
- Live Demonstrations via Satellite from Lille to Lyon (1): Brian Saunders (UK) Markus Neurath (DE), Gert Van Assche (BE), Jean-Marie Reimund (FR), Bernard Dudois (FR), Yoram Bouhnik (FR), Philippe Marteau (FR), Philippe Bullois, Jeanne Boitard, Vincent Maunoury
- Live Demonstrations via Satellite from Lille to Lyon (2)

Current Concepts on Cancer in Ulcerative Colitis

12:00-12:30
Scientific Session 3 - Panel Discussion: Pathology, Radiology and Surgery in Adult and Paediatric IBD: What the Gastroenterologist Needs to Know

Marc Lemann (FR)
- Panel: Robert Lofber (SE)
- Panel: Gert de Hertogh (BE)
- Panel: Andre D’Hoore (BE)
- Panel: Andreas Schreyer (DE)
- Panel: Robert Heuschkel (UK)
- Case presentation 1: Longstanding UC with Dysplasia: Stephan Vavricka (CH)
- Case presentation 2: Refractory Pouchitis: Marc Ferrante (BE)
- Case presentation 3: Extensive Small Bowel in Crohn’s Disease in an Adolescent: Laurent Peyrin-Biroulet (FR)
- Talk: Europe-wide perspectives, improving the lives of people with IBD: Rod Mitchell (UK)
- ECCO Fellowships & Grants: Miquel Gassull (ES), Simon Travis (UK)
- ECCO Fellowships 2007: Kostas Karmiris (GR)
- Announcement of ECCO Fellowships and Grants 2008:
- Historical Perspectives of the Management of Severe Colitis: Renzo Caprilli (IT), Miquel Gassull (ES), Simon Travis (UK)

Saturday, March 1, 2008

Scientific Session 4: Risks Associated with IBD

Boris Vucelic (HR), Martin Bortlik (CZ)
- Malignancy and Lymphoma in IBD: Larry Egan (UK)
- Best Abstract: Colonoscopic Surveillance in Inflammatory Bowel Disease improves Survival after Colorectal Cancer Diagnosis: Maurice Lutgens (NL)
- Best Abstract: Inflammatory Bowel Disease and Pregnancy: Preliminary Results of an European Multicenter Prospective Case-Control Study: Aurora Bortoli (IT)
- Opportunistic Infections in IBD, Diagnosis and Prevention (or if ready title should be changed into: ECCO consensus on opportunistic infections): Jean-Frédéric Colombel (FR), Jean-Francois Rahier (FR)
- Best Abstract: Long-term Efficacy of Infliximab and Colectomy-free Survival in Outpatients with Refractory Ulcerative Colitis: Marc Ferrante (BE)
- Best Abstract: Maintenance Therapy with Azathioprine (aza)/6-mercaptopurine (6-mp) in Crohn’s Disease (cd) reduces the Risk of Re-operation particularly in Smokers: Pavol Papay (AT)

Scientific Session 5: Management of IBD

Pierre Michetti (CH), Walter Reinisch (AT)
- Complex Fistulizing Crohn’s Disease: Marijana Protic (RS)
- The Evaluation of Fistulizing Perianal Crohn’s Disease: André D’Hoore (BE)
- The Combined Management of Fistulizing Perianal Crohn’s Disease: Remo Panaccione (CA)
- Best Abstract: Assessment of Certolizumab Pegol in the Treatment of Crohn’s Disease in Patients for Whom Infliximab Treatment was not Successful: Open-Label Induction Preliminary Results from the WELCOME Study: Séverine Vermeire (BE)
- Best Abstract: Long Term Outcome and Quality of Life after Restorative Proctocolectomy in a Cohort of 955 Canadian Patients: Marco Scarpa (IT)
- Flexible Therapy in IBD: Is It Possible?: Paul Rutgeerts (BE)

- Concluding Remarks: Jean-Frédéric Colombel (FR)